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1RÉSUMÉ 
Regulation of Osteoclast Activation and Autophagy through Altered Protein Kinase 
Pathways in Paget’s Disease of Bone 
 
Par 
Stephen Robert McManus 
Programme d’Immunologie 
 
Thèse présentée à la Faculté de médecine et des sciences de la santé en vue de l’obtention 
du diplôme de philosophiae doctor (Ph.D.) en Immunologie, Faculté de médecine et des 
sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
La maladie osseuse de Paget (MP) est un désordre squelettique caractérisé par une 
augmentation focale et désorganisée du remodelage osseux. Les ostéoclastes (OCs) de MP 
sont plus larges, actifs et nombreux, en plus d’être résistants à l’apoptose. Même si la 
cause précise de la MP demeure inconnue, des mutations du gène SQSTM1, codant pour la 
protéine p62, ont été décrites dans une proportion importante de patients avec MP. Parmi ces 
mutations, la substitution P392L est la plus fréquente, et la surexpression de p62P392L dans 
les OCs génère un phénotype pagétique partiel. La protéine p62 est impliquée dans de 
multiples processus, allant du contrôle de la signalisation NF-κB à l’autophagie. Dans les 
OCs humains, un complexe multiprotéique composé de p62 et des kinases PKCζ et PDK1 
est formé en réponse à une stimulation par Receptor Activator of Nuclear factor Kappa-B 
Ligand (RANKL), principale cytokine impliquée dans la formation et l'activation des OCs. 
Nous avons démontré que PKCζ est impliquée dans l’activation de NF-κB induite par 
RANKL dans les OCs, et dans son activation constitutive en présence de p62P392L. Nous 
avons également observé une augmentation de phosphorylation de Ser536 de p65 par PKCζ, 
qui est indépendante d’IκB et qui pourrait représenter une voie alternative d'activation de 
NF-κB en présence de la mutation de p62. Nous avons démontré que les niveaux de 
phosphorylation des régulateurs de survie ERK et Akt sont augmentés dans les OCs MP, et 
réduits suite à l'inhibition de PDK1. La phosphorylation des substrats de mTOR, 4EBP1 et 
la protéine régulatrice Raptor, a été évaluée, et une augmentation des deux a été observée 
dans les OCs pagétiques, et est régulée par l'inhibition de PDK1. Également, l'augmentation 
des niveaux de base de LC3II (associée aux structures autophagiques) observée dans les OCs 
pagétiques a été associée à un défaut de dégradation des autophagosomes, indépendante de 
la mutation p62P392L. Il existe aussi une réduction de sensibilité à l’induction de l'autophagie 
dépendante de PDK1. De plus, l’inhibition de PDK1 induit l’apoptose autant dans les 
OCs contrôles que pagétiques, et mène à une réduction significative de la résorption osseuse. 
La signalisation PDK1/Akt pourrait donc représenter un point de contrôle important dans 
l’activation des OCs pagétiques. 
Ces résultats démontrent l’importance de plusieurs kinases associées à p62 dans la 
sur-activation des OCs pagétiques, dont la signalisation converge vers une augmentation de 
leur survie et de leur fonction de résorption, et affecte également le processus autophagique.  
Mots clés : Autophagie, Osteoclaste, Paget, Kinase, PDK1, p62 
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2SUMMARY 
Regulation of Osteoclast Activation and Autophagy through Altered Protein Kinase 
Pathways in Paget’s Disease of Bone 
 
By 
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Thesis presented at the Faculty of medicine and health sciences for the obtention of 
Doctorate degree diploma [philosophiae doctor (Ph.D.)] in Immunology, Faculty of 
medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada 
 
Paget’s disease of bone (PDB) is a skeletal disorder characterized by focal and 
disorganized increases in bone turnover. In PDB, osteoclasts are larger, more active, more 
numerous, and resistant to apoptotic stimuli. While no single root cause has been identified, 
mutations to the gene encoding the p62 protein, SQSTM1, have been described in a 
significant population of patients with PDB. Among these mutations, the P392L 
substitution is the most prevalent, and overexpression of p62P392L in osteoclasts generates at 
least a partial pagetic phenotype in vitro. Normally this protein mediates a number of cell 
functions, from control of NF-κB signaling to autophagy. In human osteoclasts, a 
multiprotein complex containing p62 and protein kinases PKCζ and PDK1 (the principal 
kinase of Akt), form in response to stimulation by receptor activator of nuclear factor 
kappa-B ligand (RANKL), the principal osteoclastogenic-signaling cytokine. We found that 
PKCζ is involved in RANKL-induced activation of NF-κB, and that it contributed to a 
basal activation of NF-κB observed in p62P392L mutants. This may be regulated in part by a 
PKCζ dependent increase in p65 phosphorylation at Ser536 which we characterized, 
independent of IκB. This could represent one alternative pathway by which mutant p62 
leads to increased NF-κB activation. 
 We observed increased basal phosphorylation of survival regulators ERK and Akt in 
PDB that was reduced upon PDK1 inhibition. The activity of 4EBP1 and Raptor, associated 
with mTOR activity, were also altered in pagetic osteoclasts and regulated by PDK1 
inhibition. We then identified autophagic defects common to pagetic osteoclasts; with 
higher basal levels of LC3II (associated with autophagic structures), regardless of p62 
mutation, and reduced sensitivity to autophagy induction in PDB. These results suggest an 
accumulation of non-degradative autophagosomes. Inhibition of PDK1 not only induced 
apoptosis in PDB and controls, but significantly reduced resorption in PDB, and with 
regards to autophagy, PDK1 inhibition was more potent in PDB than in controls. Therefore 
PDK1/Akt signaling represents an important checkpoint to PDB osteoclast activation. 
 In sum, these results demonstrate the importance of several p62-associated kinases 
in the over-activation of pagetic osteoclasts, through increased survival and altered 
signaling. As p62 mutations alone do not account for most cases of PDB, the 
characterization of these pathways may identify a common factor linking pagetic 
osteoclasts. Therefore these studies represent a novel approach to osteoclast apoptosis, 
activation, and autophagy associated with PDB. 
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1INTRODUCTION 
 
The Skeletal System 
The skeletal system, while appearing inert at first glance, is a dynamic organ 
responsible for a number of vital functions in the body; including but not limited to providing 
protection and support to other organ systems, as well as permitting movement through 
collaboration with the muscular system. At the cellular level, bone provides a reservoir of 
growth factors and cytokines, maintains the acid-base balance and mineral homeostasis, and 
is the site of hematopoiesis. Like other connective tissue, bone has both a cellular and an 
extracellular matrix component. The matrix is made up of collagen fibers and non-
collagenous proteins, with type I collagen accounting for ~90% of total protein, and the non-
collagenous osteocalcin, osteopontin, and bone sialoprotein, and others making up the other 
10%. In contrast with other connective tissue, the extracellular matrix of bone is mineralized 
physiologically, through the deposition of layers of carbonated hydroxyapatite. This mineral 
component, making up 50-70% of bone, provides bone's characteristic mechanical rigidity 
and strength (Clarke 2008). Elasticity and flexibility are due to the organic matrix, which 
makes up another 20-40%, lending bone incredible resilience without compromising its 
strength, and another 5-10% of bone is water. 
There are two major types of bone; trabecular (also called cancellous or spongy), and 
cortical (also called compact). Cortical bone is denser and hard, whereas trabecular bone is a 
honeycomb network that is more mesh-like. Depending on their intended function, ratios of 
one type to the other at skeletal sites throughout the body will vary. For example, trabecular 
bone will more frequently be found within ribs, the skull, or the ends of long bones, while 
the denser cortical bone makes up the outer shell (or cortex) of most bones of the skeleton. 
Both of these bone types are typically formed in a lamellar pattern, where there is a highly 
ordered deposition of collagen fibers, with each layer in alternating orientation. This pattern 
is vital to providing bone with its mechanical strength and integrity (Ankersen et al. 1994). 
In disease, this pattern can be lost, leading to compromised structure. 
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Bone remodeling is the mechanism of bone renewal in the skeleton. This process 
involves continuous removal of small packets of old bone, the filling of these areas with 
newly synthesized collagen-rich matrix, and finally with mineralization of this matrix to form 
new bone. Remodeling sites develop primarily in a random manner, but are targeted to areas 
requiring repair as well (Clarke 2008). In addition to remodeling, according to Wolffs Law, 
the skeleton undergoes constant modeling in response to changes in biomechanical forces 
(Wolff 1892; Wolff 2010). The skeletal system, like any other, is in a state of controlled 
balance, dependent on cooperation between the mechanisms responsible for formation and 
those responsible for its counterpart, resorption.  
The three major cell types forming the foundation of bone activity are the osteoclasts 
that break down bone, osteoblasts that build new bone, and osteocytes that maintain living 
bone. Bone remodeling relies on these activities to be carried out by the independent (yet 
ultimately synergistic) action of osteoblasts and osteoclasts in response to stimuli that can be 
biomechanical or strictly biological, depending on the circumstance.  
 
The Remodeling Cycle 
Bone replacement is initiated by osteoclastic resorption and immediately followed by 
osteoblastic formation. The remodeling cycle can be broken down into four sequential 
phases: resting/activation, followed by resorption/remodeling, then reversal and finally 
formation (Figure 1). Resorption and formation are closely linked within discrete temporary 
anatomic structures, described as "basic multicellular units," or BMUs, made up mainly of 
osteoclasts, osteoblasts, and bone-lining cells. A BMU is active in three dimensions; 
excavating and refilling a tunnel through cortical or compact bone, or a trench across the 
surface of cancellous or trabecular bone. At any given time it is estimated that there are 
approximately one million BMUs in action (Parfitt et al. 1996), and the lifetime of one of 
these units is estimated to be between six and nine months (Smith, Gardiner, and Dunstan 
2012). 
The activation of remodeling corresponds to a region of bone surface which converts 
from quiescence to remodeling activity, a process which requires recruitment of osteoclast 
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precursors from circulation, and changes in the lining cells that will close off the BMU 
(Parfitt 2002). The osteoclast precursors will develop, bind to the bone matrix, and eventually 
enact resorption as mature osteoclasts, as will be described in greater detail later. The 
characteristic resorbed areas left behind are referred to as Haversian canals on cortical bone, 
and Howship's lacunae on cancellous bone. This step is relatively short in the remodeling 
cycle, taking only two to four weeks. 
 
 
 
Figure 1: Bone Remodeling 
The process of remodeling is dynamic, but for one area to undergo all four stages of 
remodeling takes approximately four months. Following recruitment and activation of 
osteoclasts, they resorb the bone, then undergo apoptosis. The activity of the osteoclasts 
allows for the recruitment of mononuclear cells and preosteoblasts during the reversal phase. 
Finally, the rate limiting step of the process, bone formation takes place, carried out by the 
osteoblasts, followed by a number of them developing into osteocytes embedded in the bone, 
and the majority of the rest undergoing apoptosis. 
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stem cell
Osteoblast
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The reversal stage begins following completion of the resorption phase, with initiation 
of apoptosis of the osteoclasts (Reddy 2004). Cytokines and growth factors are produced by 
active osteoclasts or released from the bone matrix during the resorption of bone, serving as 
recruitment and other stimulatory signals for other cells in the microenvironment (Martin and 
Sims 2005). Among these are transforming growth factor-β (TGF-β), released from the bone 
matrix. TGF-β activates osteoblasts, decreases osteoclast resorption by inhibiting RANKL 
production by osteoblasts and stromal cells in the bone microenvironment, and can also 
directly induce apoptosis in osteoclasts (Houde et al. 2009). This reversal phase allows for 
transition from resorption to formation, halting osteoclast activity and recruiting the bone-
forming cells.  
At this point, osteoblast precursors will proliferate locally, differentiating into 
osteoblasts in response to signals. During the formative phase, these cells deposit initially 
unmineralized bone matrix called osteoid, filling the lacunae produced by the osteoclasts. 
Once embedded in osteoid, osteoblasts can mature into terminally differentiated osteocytes, 
which produce and maintain a canalicular network permitting them to connect to other 
osteocytes as well as surface lining cells (Parfitt 1994). Other osteoblasts lying on the bone 
surface become quiescent lining cells (Clarke 2008), and with the completion of bone 
formation, approximately 70% of osteoblasts will undergo apoptosis ( Cohen 2006). The 
osteoblast-like bone-lining cells regulate the flow of mineral ions to the bone extracellular 
fluid, forming the blood-bone barrier, and can also re-differentiate to osteoblasts if called for 
(Seeman 2009).  
In comparison with the relatively quick resorption phase, formation is a long process, 
taking 3 to 6 months to complete. This contrast provides an example to why precise 
regulation between these two phases is critical to balance in the skeletal system; different 
phases must succeed in maintaining homeostasis despite significant variation in the time 
required to complete their activities. During formation, osteoblasts synthesize new organic 
matrix, (which is primarily type-1 collagen), and regulate mineralization of that same matrix. 
The regulation of this mineralization step is carried out through the release of small 
membrane-bound vesicles containing concentrated calcium and phosphate, and 
enzymatically destroy inhibitors of mineralization like pyrophosphate or proteoglycans  
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(Anderson 2003). In a healthy system, these combined steps forming the process of bone 
remodeling help to preserve the mechanical strength of bone by replacing aged and 
microdamaged bone with healthier tissue; new bone that is more apt to maintain calcium and 
phosphate homeostasis, as well as a more stable supporting scaffold. 
Regulation of Bone Remodeling 
Hormones 
 Several hormones play important roles in maintenance of normal bone turnover. 
Calcium-regulating hormones 1,25-dihydroxy vitamin D and parathyroid hormone (PTH) 
lead to increases in osteoclast formation and resorptive activity (Teitelbaum 2000). One 
crucial systemic hormone whose presence varies drastically in more than half of the 
population is estrogen. Its function is complex and influences multiple cell lines and 
pathways still under study that inhibit bone resorption, as well as aid in bone formation 
(Weitzmann and Pacifici 2006). Studies in animal models have suggested that estrogen acts 
on both production and activity of local factors that regulate osteoblast and osteoclast 
precursors alike (Trivedi, Goswami, and Chattopadhyay 2010). Of the cytokines and 
growth factors with effects on bone cells that are released in response to estrogen, M-CSF, 
IL-1, -6, and -7 are included, as well as TNF, prostaglandins, and IGF-1 (Riggs, Khosla, 
and Melton 2002). While the majority of these are produced within the bone 
microenvironment, some, like IGF, can be produced elsewhere, demonstrating that 
estrogen-mediated bone regulation is para-, auto- and endocrine. This provides an example 
of the connectivity of the skeletal system that makes it a challenge to study in vivo. 
Remodeling can be regulated by intestinal microbiota, inhaled pollutants, diet and physical 
activity, and much more, leading to great potential for variance even among a “control” 
population (Satarug et al. 2010; Rizzoli 2014; Sjögren et al. 2012).  
The impact of hormones on remodeling are not limited to differentiation and 
activation of varying bone cells either. The pro-bone formation effect of estrogen is carried 
out in large part by regulation of programmed cell death, encouraging apoptosis in 
osteoclasts, but preventing it in the mesenchymal stem cell derived osteoblasts and 
osteocytes (Balasch 2003). The inhibition of apoptosis in osteoblasts by sex steroids as well 
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as bisphosphonates is carried out primarily through activation of ERK, which regulates this 
pathway on two levels; the first of which being kinase-dependent activation of transcription 
factors and ultimately gene transcription (Kousteni et al. 2003). The second of these 
mechanisms is dependent on the cytoplasmic ERK target p90RSK, which phosphorylates 
the pro-apoptotic protein BAD, as well as the CCAAT/enhancer binding protein (C/EBPβ) 
(Buck et al. 2001; Bellido and Plotkin 2011). The phosphorylation of C/EBPβ allows it to 
bind and inhibit pro-caspases, whereas the phosphorylation of BAD is directly inhibitory, 
rendering it inactive (Plotkin et al. 2005). Therefore apoptotic regulation by estrogen is 
carried out by pathways both dependent and independent of transcriptional activity. The 
exact mechanisms of increasing osteoclast sensitivity to apoptosis by hormones are still 
under investigation, but can act both directly on the osteoclasts in the form of interfering 
with receptor activator of nuclear factor kappa-B (RANK) signaling partners (Robinson et 
al. 2010), or indirectly through the induction of Fas ligand on osteoblasts (Krum et al. 
2008). 
Growth Factors 
 Bone is also the host of a great number of growth factors. Among the most abundant 
of these are the aforementioned IGFs, which are important modulators of local bone 
remodeling. A murine IGF-1 knockout model showed an increase in bone volume that was 
primarily attributed to reduced osteoclast number (Wang et al. 2006), but IGF1R knockouts 
have also been observed to have significantly lowered bone formation rates (Yakar, 
Courtland, and Clemmons 2010). Overexpression of IGF-1 in collagen-1 secreting cells 
(including but not necessarily limited to osteoblasts), led to increased bone width and 
length, indicating that IGF1is important to activity of both major cell types in the 
remodeling process (Jiang et al. 2006).  
Transforming growth factor β (TGF-β) and its related family of bone morphogenic 
proteins (BMPs) are present and highly involved in the skeleton, functioning both in 
skeletal development and remodeling. TGF-β is an important player in bone biology, 
directly and indirectly inducing effects in both osteoclasts and osteoblasts; from inducing 
osteoclast formation (Nakamura et al. 2015), to the upregulation of Bim and eventual 
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osteoclast apoptosis in vitro (Houde et al. 2009), and by the coupling of resorption to 
formation by stimulating Wnt1 production (Weivoda et al. 2015). BMPs, as their name 
implies, are a group of signaling molecules originally characterized for their ability to 
induce bone formation (Wu, Shi, and Cao 2007). Many members of this family were first 
described in osteogenesis, but have recently been subjects of interest in the context of bone 
resorption as well. Most of the known BMPs are expressed in skeletal tissue, with a number 
detectable in osteoblasts (Anderson et al. 2000). The majority are recognized as promoters 
of bone formation, but there are exceptions like BMP-3; a negative regulator of this process 
(Daluiski et al. 2001). BMP-2 and -7 have been used following orthopedic surgery to 
improve bone repair in spinal fusion, for example (Senta et al. 2009). The potently 
osteogenic BMP-9 also directs osteoclast activity and survival, as the addition of BMP-9 to 
mature osteoclasts in vitro significantly increased bone resorption while decreasing the 
rates of apoptosis in these cells (Fong et al. 2013). In this in vitro study, BMP-9 osteoclast 
activation involved phosphorylation of Smad-1/5/8 and ERK1, pathways common with 
TGF-β stimulation (Chen, Deng, and Li 2012). 
Cytokines 
In addition to the numerous hormones and growth factors influencing bone cell 
functions, there are also a number of cytokines of great importance to bone formation, 
balance, and remodeling. It has been established that the vast majority of all of these factors 
that influence bone resorption either play a role in or depend on a common final pathway 
involving the RANK and its ligand, RANKL. RANKL is the main stimulator of osteoclast 
differentiation and activation (Boyle, Simonet, and Lacey 2003). It is a TNF family 
member expressed by osteoblasts and stromal cells (as well as other tissues, including 
muscle, thymus, and intestinal cells) (Wada et al. 2006). In vivo as well as in vitro studies 
have demonstrated that by binding to the membrane-bound receptor RANK, RANKL is 
crucial to myriad pathways necessary for the formation, survival, and bone-resorbing 
capabilities of osteoclasts (Burgess et al. 1999; Hsu et al. 1999; Ikeda and Takeshita 2015). 
(Figure 2). Given its virtual omnipresence, the associated pathways of RANK will be 
further expanded in later sections.  
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Figure 2 : RANKL/RANK Signaling in the Osteoclast 
RANKL is the principal cytokine in osteoclast differentiation, activation, and survival. It 
activates the TNF-related receptor RANK in a trimeric symmetric complex, recruiting 
TRAF6. Downstream signaling includes activation of Src, PI3K, MKK, TAK1 and others, 
leading to stimulation of numerous pathways including p38, MAPK, ERK, and JNK. 
Activation of the MAP kinases also leads to activation of the transcription factors c-Fos, c-
Jun, and NFATc1. Among other cytoprotective effects, activation of Akt following PI3K 
activity results in the phosphorylation and inhibition of the pro-apoptotic protein BAD. 
 
It is important to note in the context of the skeleton that there is a third partner in 
the RANKL/RANK axis, known as osteoprotegerin (OPG); another member of the TNF 
receptor family. OPG has no transmembrane domain, and is a secreted decoy receptor 
competing with RANK to bind with RANKL, thus inhibiting osteoclast differentiation and 
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bone-resorbing function (Simonet et al. 1997). This decoy activity is essential in the fine-
tuning of bone resorption (Abrahamsen and Teng 2005; Wensel, Iranikhah, and Wilborn 
2011).  
Bone-resorbing factors like PTH, 1,25(OH)2D3, and TNF-α act principally through 
increasing the RANKL/OPG ratio in the bone microenvironment. Where the factors named 
all can act directly on the osteoclast as soluble factors in vitro, this effect is typically carried 
out by the osteoblast/stromal cells in vivo. Logically, inhibitors of bone resorption often 
function by lowering the RANKL/OPG ratio, or through other methods of blocking RANK 
signaling (Kong and Penninger 2000). The two sides of the coin in this model were 
demonstrated decisively by Blair et al in 2005 when severe osteoporosis was shown in 
OPG knockout mice, as well as osteopetrosis in their RANKL knockout counterparts(Blair 
et al. 2006).  
 
The Osteoblast 
Development 
 The first major event in the bone microenvironment that must take place giving way 
to osteogenesis is the development of mesenchymal stem cells into differentiating and 
bone-forming osteoblasts. Their lineage separates the osteoblasts from their counterpart, the 
resorbing osteoclast, which arises from hematopoietic stem cells. While osteoclasts are thus 
more closely related to other myeloid-derived cells like the dendritic cell, osteoblasts are 
members of the same family tree that gives rise to bone, cartilage, fat, and fibrous 
connective tissue. Unlike the osteoclast, the osteoblast can dedifferentiate, and even re-
differentiate into these other types under the right stimuli (Blum and Begemann 2015). 
However, this is uncommon and the vast majority of osteoblasts will either give rise to 
bone-lining cells and osteocytes, or die through apoptosis, depending on cytokine and 
biomechanical signals. 
There are three major stages of osteoblastogenesis: proliferation, matrix maturation, 
and mineralization, with each stage determining the function of the osteoblast at that time. 
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Osteoblast differentiation is dependent on many factors and signaling pathways, including 
ATF4, transcription factor Runx2, and FGF, but the two best characterized pathways are 
those of the Wnt and BMP signaling families (Yamaguchi et al. 2008; Kobayashi et al. 
2016). 
 The Wnt signaling pathway plays a particularly critical role in bone formation. The 
Wnt proteins bind to a receptor complex composed of a frizzled receptor coupled to a G 
protein and of the co-receptor LRP5/6. Activation of the Wnt-pathway induces a cascade of 
intracellular events that stabilize -catenin, which can then be more easily transferred to the 
nucleus, where it binds to transcription factors and modulates the expression of genes that 
promote osteoblast expansion and function (Baron and Kneissel 2013). Naturally occurring 
Wnt antagonists include Dickkopf (DKK1), secreted frizzled-related proteins (sFRP1/2) and 
sclerostin. These antagonists interfere with the activation of the complex, thereby inhibiting 
bone formation (Winkler et al. 2005).  
 The Wnt receptor LRP5 has been well characterized in osteoblasts, as human studies 
have shown that patients with loss-of-function mutations to LRP5 have low bone mass (Gong 
et al. 2001), and those with a mutation rendering LRP5 insensitive to inhibitors like DKK1 
and Sclerostin were identified as having high bone mass (Little et al. 2002; Balemans et al. 
2008). Conditional deletion of the gene coding β-catenin in osteoblasts or osteocytes resulted 
in severely low bone mass, and similarly, expression of a non-degradable form of β-catenin 
led to bone mass increase (Kramer et al. 2010). Both of these works demonstrated a 
dysregulation of the OPG/RANKL signaling axis, as OPG is a direct transcriptional target of 
β-catenin (Glass et al. 2005). Mice lacking Frizzled 9 have reduced bone mass resulting from 
altered β-catenin-independent Wnt signaling (Heilmann et al. 2013), and non-canonical Wnt 
signaling through PKCδ promotes bone formation as well (Tu et al. 2007).  
Other cytokines and growth factors involved in modulating differentiation are 
numerous, including TGF-β and several BMPs and their respective inhibitors, like noggin, 
chordin, and others (Huang et al. 2007). Additionally, the function of osteoblasts is 
regulated by a number of hormones as previously mentioned. Many of these cytokines, 
hormones, and growth factors have contrary effects on osteoblasts and osteoclasts, and 
often the effects of one stimulatory factor will indirectly regulate the other cell type through 
the first. Crosstalk among these bone cells and others in the microenvironment must thus 
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remain a consideration with any in vivo study, and likewise its absence under in vitro 
conditions (Sims and Walsh 2012). In the case of Wnt signaling, stabilized beta-catenin 
induces OPG expression, resulting in high bone mass by regulating osteoclast function 
(Glass et al. 2005). It has also been known to be involved in crosstalk with TGF-β, an 
osteoclast activity modulator (Mbalaviele et al. 2005).  
Function 
Excluding the contributions of resorption, bone mass is first determined by the 
number of mature osteoblasts as well as their bone-forming capability and activity. There 
are three bone-specific roles by which we can separate osteoblast function. The first of 
these is bone formation; the synthesis and subsequent secretion of proteins that make up the 
extracellular matrix (ECM) of bone. Continuing bone formation, following ECM synthesis, 
the osteoblast must express the genes responsible for the induction of mineralization of the 
ECM; this process will endow the bone its rigidity and hardness. The remainder of bone is 
an unmineralized, organic portion of the bone matrix referred to as osteoid, and it 
eventually accounts for around 2% of bone volume. Osteoid is composed primarily of type 
1 collagen, but also includes osteocalcin (OCN), chondroitin sulfate, matrix gla protein 
(MGP), bone sialoprotein (BSP), and growth factors like the aforementioned BMPs and 
TGF-B (Huang et al. 2007). As a regulatory mechanism, osteoblasts will only deposit 
osteoid on pre-existing mineralized matrix. While none of these molecules involved are 
unique to the osteoblast, it is the only cell type in the body found to co-express their genes, 
making it a unique and vital bone-depositing cell.  Although less abundant, non collagenous 
proteins have crucial roles, particularly in bone mineralisation or cell attachment. 
The second function of the mature osteoblast is to regulate stem cell population, 
involving hematopoietic stem cell (HSC) expansion in the bone marrow (Calvi et al. 2003). 
And the third of these functions is the role played by osteoblasts in the differentiation of 
osteoclasts, which will be further elaborated in the osteoclastogenesis section. Briefly, the 
two main cytokines necessary to trigger osteoclastogenic signaling pathways, M-CSF and 
RANKL, are expressed in and on osteoblasts, particularly active osteoblasts (Capulli, 
Paone, and Rucci 2014). Other factors affecting expression of these cytokines include the 
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surrounding environment as well as the maturity of the osteoblast. Likewise, expression of 
chemoattractants like those of the chemokine (c-c motif) ligand (CCL) family, many of 
which are osteoclast precursor recruiters, are modulated by calcineurin/NFAT signaling in 
osteoblasts (Winslow et al. 2006). In a healthy system, the osteoblast and osteoclast 
preserve a delicate balance, each helping to regulate the presence and activity of the other 
in order to maintain bone homeostasis, coupling bone formation and bone resorption.  
 
The Osteoclast 
 The osteoclast is generally derived from hematopoietic cells of monocyte-
macrophage lineage. Excluding a near negligible contribution from osteocytes, this 
multinuclear cell is uniquely responsible for the resorption of bone (Teitelbaum 2000). As 
large cells that are the product of fusion of monocytes, they are typically between 20-100 
μm in diameter, with an average of 3-10 nuclei, though under certain pathologies they can 
grow much larger, and have been observed with up to 100 nuclei (Galson and Roodman 
2014). Differentiation and eventual function of the osteoclast rely on a host of signals, both 
systemic and local, with the bone microenvironment alone generating possible 
contributions from marrow stromal cells, T and B lymphocytes, osteoblasts, and osteocytes. 
In addition, as osteoclasts are secretory cells, they are responsible in part for their own 
stimulation or inhibition through feedback (Yavropoulou and Yovos 2008). 
Osteoclastogenesis, the production and maturation of these cells, involves a complex 
development process that can be split into four steps; commitment, differentiation, 
multinucleation, and finally activation of immature osteoclasts.  
Commitment 
 Excluding totipotent cells, the first cell type in the line giving way to osteoclast 
development is the pluripotent hematopoietic stem cell. This stem cell is still hardly limited 
in terms of variety, able to further differentiate into granulocytes, megakaryocytes, 
monocytes, dendritic cells, and of course, the osteoclast (Figure 3). The earliest identifiable 
precursors with osteoclast-forming potential are granulocyte-macrophage colony forming 
units (GFU-GM) (Menaa, Kurihara, and Roodman 2000). The cytokines GM-CSF and later 
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M-CSF are required to stimulate proliferation and prevent apoptosis of the early osteoclast 
precursors. The principal transcription factors involved in these earliest stages of 
development are PU.1, micropthalmia-associated transcription factor (MITF), and c-Fos. 
PU.1 is a member of the Ets family of transcription factors, more specifically the SP1 
subfamily, which is involved in myeloid and b-lymphoid cell development. Ets factors can 
act as transcription activators, repressors, or both, depending on context and co-factors 
(Sharrocks 2001). As PU.1 is responsible for the earliest events in osteoclastogenesis, PU.1 
null mice lack not only osteoclasts, but also macrophages, though they can still produce 
monocytic cells (Tondravi et al. 1997). Importantly, PU.1 regulates the transcription of the 
RANK gene in myeloid precursors, allowing for RANK ligand signaling (Kwon et al. 
2005). As will be discussed in greater detail throughout this section, RANKL is the 
preeminent osteoclastogenic cytokine, and thus this ability of precursors to respond to it is 
crucial. 
MITF is a leucine zipper transcription factor that is implicated in the differentiation 
and survival of many cell types, including those of non-myeloid origin (Cheli et al. 2010). 
Like PU.1, MITF is expressed in macrophages and osteoclasts, as well as their precursors. 
Interaction with PU.1 allows MITF to regulate target genes such as cathepsin K, acid 
phosphatase, TRAP, and osteoclast-associated receptor (OSCAR) in early osteoclast 
differentiation (Hu et al. 2007). Other target genes include chloride channel 7 (Clcn7), 
necessary for bone-resorbing activity through acidification, and Ostm1, a membrane 
protein necessary for chloride channel stability in osteoclasts, whose knockout induces 
severe osteopetrosis in a murine model (Meadows et al. 2007; Pata, Héraud, and Vacher 
2008).  
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Figure 3 : Osteoclast Development and Lineage 
The hematopoietic stem cell, in response to M-CSF stimulation, gives rise to the myeloid 
stem cell. Depending on activation signals, this cell can further differentiate into 
megakaryocytes, granulocytes, monocytes/macrophages, and osteoclasts, to name a few. It 
is through RANKL signaling that these myeloid precursors become preosteoclasts, which 
undergo fusion and form another multinucleated precursor. Further RANKL stimulation 
allows for continued differentiation and eventual activation of the mature osteoclast, 
capable of resorbing bone.  
 
c-Fos is another key mediator of lineage commitment between osteoclasts and 
dendritic cells; another cell type derived from monocyte progenitors sensitive to GM-CSF, 
specifically MDPs (Monocyte and Dendritic cell Precursors) (Miyamoto et al. 2001; Liu 
and Nussenzweig 2010). However, differentiation is mediated by GM-CSF and M-CSF at 
the early phases of osteoclastogenesis. While RANKL and M-CSF are osteoclastogenic, 
RANKL in combination with GM-CSF becomes an activating factor of dendritic cells (Lee 
et al. 2009). However, after c-Fos expression following M-CSF signal transduction, these 
precursors are no longer competent to respond to GM-CSF, ensuring their path as 
preosteoclasts (Miyamoto et al. 2001). Across cell types (and including osteoclasts), c-Fos 
is most heavily associated with proliferation, differentiation, and survival, and is necessary 
for NFATc1 transcription (Boyce et al. 2015). The murine c-Fos knockout results in an 
osteopetrotic phenotype (Matsuo et al. 2000). 
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M-CSF, required for proliferation and osteoclast formation, has one receptor, 
transcribed by the macrophage c-FMS gene (Ross 2006), an activity that also depends on 
PU.1 (Tondravi et al. 1997). M-CSF can induce further expression of c-FMS by forming an 
autocrine loop to amplify M-CSF-mediated signals, and through stimulation of PU.1 (Yao 
et al. 2006). Loss of function of the M-CSF gene in mice led to decreases in macrophage 
numbers and an absence of osteoclasts, again producing an osteopetrotic phenotype (Dai et 
al. 2002). In cells deprived of M-CSF, the transcription factor MITF is sequestered to the 
cytoplasm through 14-3-3 protein interactions, thus inhibiting the translation of its 
numerous target genes required for osteoclastogenesis (Bronisz et al. 2006). Production of 
this growth factor in the bone microenvironment is carried out constitutively by T-
lymphocytes, stromal cells, and osteoblasts. This production can be induced by elevated 
PTH levels, or inflammatory molecules like TNF-α or IL-10 (Agbanoma et al. 2012). TNF-
α can also induce c-FMS expression (Yao et al. 2006).  
RANKL/M-CSF signaling activates expression of osteoclastogenic genes via two 
mechanisms; the first being down-regulation at mRNA and protein levels of the DNA-
binding protein Eos, a transcriptional repressor of the Ikaros family. This leads to a 
disassociation of co-repressors from PU.1 and MITF. The second is through 
phosphorylation and activation of MITF through the ERK and p38 MAPK pathways, 
allowing for recruitment of co-activators (Mansky et al. 2002). These co-activators (BRG1 
and CBP/p300) unwind chromatin, and recruit transcriptional machinery like RNA 
polymerase II, respectively, in addition to acting as adaptor molecules (Bronisz et al. 2014; 
Asai, Funaba, and Murakami 2014). Downstream signaling from PI3K, p42/p44 ERK, and 
proto-oncogene c-Cbl are the key signal transducing mechanisms of M-CSF (Ross 2006). 
The PI3K/Akt cascades regulate (among other pathways) proliferation of osteoclast 
precursors through GSK3β and FoxO regulation. By phosphorylating these inhibitory 
factors, their ability to inhibit cell cycle entry is suppressed, allowing the cells to respond to 
proliferative stimuli (Manning and Cantley 2007).  
Given that the majority of these transcription factors and associated cytokines are 
ubiquitous, regulating multiple cell lineages, none of these early osteoclastogenic pathways 
have been considered for therapeutic intervention. To block one or more of PU.1 or MITF, 
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for example, would have catastrophic side effects beyond regulation of osteoclastic 
selection. However, the further into osteoclast-specific pathways we venture, the more 
practical the consideration of particular targets becomes. 
Differentiation 
The aforementioned RANKL, member of the TNF superfamily, is produced by 
osteoblasts in the periosteum and stromal cells in the bone marrow under normal 
physiological conditions. In the case of skeletal inflammation, such as the conditions 
produced under rheumatoid arthritis, RANKL is also produced in large quantities by T-
lymphocytes (Kong et al. 1999). In some situations, RANKL can be cleaved from the 
membrane of the cell and function as a soluble ligand (Kanamaru et al. 2004). Deletion of 
either RANKL or its receptor results in a complete absence of osteoclasts, arresting 
osteoclastogenesis immediately following M-CSF-induced expansion of osteoclast 
progenitor cells.  
In addition to RANK, RANKL also has a soluble decoy receptor, osteoprotegerin 
(OPG), which is produced by osteoblasts and competitively binds RANKL so as to prevent 
RANK signaling (Yasuda et al. 1998). Deletion of the gene coding for OPG (TNFRSF11B) 
has been shown to increase osteoclast activity and numbers (Buckley and Fraser 2002). The 
expression of RANK is regulated by a variety of hormones including PTH, forskolin, and 
PGE2, all of which act on the cyclic AMP/PKA pathway, as well as vitamin D, which acts 
through its own pathway referred to as VDR-mediated (Takahashi et al. 2014). Upon 
binding RANKL, the receptor trimerizes, permitting its activation. One of the earliest steps 
of this activation is the recruitment of and interaction with the signal transducer TRAF6 
(TNF receptor associated factor 6). The recruitment of TRAF6 is essential to 
osteoclastogenesis, as TRAF6 deficient mice develop severe osteopetrosis stemming from 
an impairment of osteoclast differentiation, preventing eventual resorptive activity (T. 
Kobayashi et al. 2003). Likewise, osteoclast-related TRAF6 is RANKL-dependent, despite 
its association and signaling cascade participation with other receptors like CD40 and TLR 
family members (Ye et al. 2002). While the exact reasons for this unique RANKL/TRAF6 
axis are not fully explained, some hypotheses include differing downstream MAPK 
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activation due to involvement of other RANKL signaling partners, and a higher recruitment 
of TRAF6 to the surface receptor (Kadono et al. 2005). Among these other downstream 
intracellular signaling pathways are activation of IκB kinases (IKK) α and β, MAP kinases 
p38 and ERK, and atypical PKCs. (Figure 2) Once TRAF6 activates the TAK1 kinase, 
TAK1 can phosphorylate IKKβ, which in turn phosphorylates the inhibitory protein IκB 
(Chen, Bhoj, and Seth 2006; Walsh et al. 2008). While IκB is ordinarily bound to the 
inactive form of NF-κB in the cytoplasm, this phosphorylation leads to the dissociation of 
the complex, and the shuttling off of IκB for degradation (May and Ghosh 1997). The 
release of NF-κB from IκB permits the former to translocate to the nucleus, where it binds 
DNA and induces transcription of a variety of genes necessary for osteoclast differentiation 
and survival. Studies have shown that mice lacking NF-κB subunits are osteopetrotic and 
missing osteoclasts in a similar manner to those lacking TRAF6 or RANKL (Iotsova et al. 
1997), indeed without NF-κB there can be no transcription of a vast number of osteoclast-
related genes, and thus no osteoclasts or resorption to follow (Boyce et al. 2015).  
Another critical signaling pathway downstream of RANKL/TRAF6 is PI3K (Arron et 
al. 2001). This pathway is triggered by M-CSF to aid in cell proliferation, but it's also 
known for its cytoprotective effects. Briefly, PI3K activation leads to PDK1 activation, 
which subsequently phosphorylates Akt, which goes on to inactivate the pro-apoptotic 
BAD via phosphorylation (Toker and Cantley 1997). Overexpression studies of RANK 
demonstrated increases in intracellular Ca2+, regulated by PLC. This accelerated NF-κB 
translocation as well as the activation of JNK signaling (Komarova et al. 2003). The role of 
JNK in osteoclastogenesis is complicated, as complete blockade of its activity inhibits 
differentiation, but its activation is also accompanied by an increase in apoptotic cell death 
(Vaira et al. 2008). Generally, the activation of MAP kinases by RANKL leads to the 
activation and translocation of many transcription factors besides those already detailed, 
including ATF2, c-Jun, and members of the NFAT family, which is another factor leading 
to gene transcription vital to osteoclast differentiation and activation (Matsumoto et al. 
2000; Sitara and Aliprantis 2010).  
The NFAT family is necessary as a transcription regulator downstream of NF-κB; 
responsible for a number of genes crucial to osteoclast formation. There are five known 
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members, the most active of which being NFATc1, with in vitro studies demonstrating that 
induction of NFATc1 expression is sufficient for differentiation even in the absence of 
RANKL (Takayanagi et al. 2002). Correspondingly, deletion of the NFATc1 gene resulted 
in the cessation of osteoclast formation following RANKL stimulation. Nuclear 
localization, and thus transcription of target genes by NFATc1 is regulated by intracellular 
calcium levels, and knockout of Ca2+-signaling modulator Inositol polyphosphate 4-
phosphatase type IIa (Inpp4bα) resulted in non-RANKL-dependent NFATc1 nuclear 
localization and transcriptional activation (Ferron et al. 2011). In the early stages of 
osteoclastogenesis, NFATc2 is also recruited to the NFATc1 promoter, but it alone is not 
sufficient to activate the promoter. It is through cooperation with NF-κB that NFATc1 is 
induced, followed by an auto-amplification phase (Asagiri et al. 2005). Of the osteoclast-
specific genes regulated by NFATc1 (and by extension, NF-κB), we observe cathepsin K, 
TRAP, CTR, OSCAR, and others (Matsumoto et al. 2004; Kim et al. 2005). To optimize 
transcription it can form complexes with the aforementioned PU.1, MITF, and c-FOS; 
however, these complexes are not required for osteoclastogenesis (Crotti et al. 2008). In 
addition to these effects, NFAT also negatively regulates osteoblast differentiation through 
the regulation of Fos-related protein (FRA)-2 (Zayzafoon 2005); the production of Fra-2 is 
a positive regulator of bone and matrix formation (Bozec et al. 2010). It has also been 
demonstrated that cell-cell contact between preosteoclasts and osteoblasts or stromal cells 
is important to RANK signaling (Garcia-Palacios et al. 2007). The importance of cell 
contact for osteoclastogenesis will be elaborated in greater detail in the following section. 
Multinucleation 
One of the most visibly characteristic activities of the developing osteoclast is cell 
fusion and resulting multinucleation. Despite there being other types of cell fusion in the 
body, the process that takes place during osteoclastogenesis is easily distinguishable (Ishii 
and Saeki 2008). The most obvious effect of multinucleation is the increase in cell size. 
This, along with a spreading of the cytoplasm, allows for a much larger surface area in 
contact with the bone, allowing for greater overall resorptive effect. This contact is vital, as 
unlike macrophages, osteoclasts do not primarily degrade their targets in lysosomes within 
the cell, but must create a seal at the bone surface, forming an “extracellular lysosome” 
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(Teitelbaum and Ross 2003). While the area of a cross-section of several non-fused cells 
and a fused multikaryon from these same cells is identical, the volume increases, as 
explained by their respective volume equations:   
2
3
𝜋𝑟3 × 4 versus 
2
3
𝜋(2𝑟)3. Volume, in 
turn, is a limiting factor for determining resorbing capacity, dictating how far the osteoclast 
can spread. In addition, multinucleation has the positive effect of transferring the RANKL 
signaling cascade and its effects to the additional nuclei included in the cell, effectively 
multiplying the signal. Without this step of multinucleation, resorption is significantly 
reduced, as studies have proven mononuclear osteoclasts to be poor resorbers of bone 
(Vignery 2005).  
In addition to the cascades already mentioned, RANKL stimulation also initiates 
gene expression of chemokines MCP-1 and RANTES, both of which are chemotactic 
signals for monocytes (Kim, Day, and Morrison 2005). Simultaneously, it induces MCP-1 
receptors CCR2 and CCR4, which when activated stimulate the PI3K pathway (Hayashida 
et al. 2001). In addition to these monocyte-targeting chemoattractants, NFATc1 induces 
expression of cell fusion molecules such as vacuolar ATPase Vo domain d2 isoform, and 
the dendritic cell-specific transmembrane protein (DC-STAMP), by directly binding their 
promoter regions and initiating transcription (Kim et al. 2008). Murine models lacking 
functional v-ATPase Vod2 or DC-STAMP have been observed with impaired osteoclast 
fusion, and significantly reduced resorption (Lee et al. 2006).  
RANKL has also been demonstrated to induce the translocation of membrane-
bound CD9 from non-lipid raft microdomains to raft domains (Ishii et al. 2006). CD9 has 
been proposed to interact with other membrane-associated molecules responsible for cell 
fusion in osteoclastogenesis, bringing them to lipid raft microdomains (Claas, Stipp, and 
Hemler 2001). Once activated, CD9 also regulates osteoclast development through p42/p44 
ERK (Yi et al. 2006). Additionally, CD9 expression is elevated in bone tissue in 
osteoporosis, suggesting its dysregulation can be linked to bone resorptive disease (Iwai et 
al. 2008). The expression of the lipid raft component flotillin is markedly increased during 
osteoclast differentiation (Ha et al. 2003), as well as caveolin-1, a lipid raft stabilizer (Lee 
et al. 2015). Knockdown of Cav-1 reduces osteoclast formation and NFATc1 activation in 
response to RANKL. As the lipid composition of the plasma membrane plays a large role 
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in membrane fusion, the induction of a change in membrane composition is important 
(Chernomordik and Kozlov 2003). Disruption of lipid rafts has been shown to block 
RANK/TRAF6 interaction (Ha et al. 2003), as well as impairing v-ATPase activity in 
osteoclasts (Ryu et al. 2010). In short, the fusion mechanism is vital to healthy osteoclast 
function, enabling them to act as efficient remodelers of bone despite their relatively small 
numbers in the bone cell population. 
Maturation and Actin Ring Formation 
 One of the final steps undertaken by an osteoclast on the way to becoming a mature, 
multinucleated, bone-resorbing cell is the polarization of the cell membrane. This is 
necessary for the generation of resorptive pits (Saltel et al. 2004). The osteoclasts must 
therefore produce two structures; a villous organelle covering the bone surface referred to 
as the ruffled membrane, and an actin ring surrounding this contact area, forming the 
“sealing zone”, which isolates the resorptive microenvironment from the exterior. Without 
polarization and cytoskeletal re-organization resulting in the extracellular lysosome 
formation, resorptive function is lost (Novack and Teitelbaum 2008). While all of the 
precise mechanisms necessary for this are not fully detailed, several key pathways and 
molecules of import have been identified (Ma et al. 2010). 
Prior to polarization, the osteoclast must receive confirmation that it is in contact 
with the bone surface. The integrin ανβ3 is the principal integrin expressed by osteoclasts, 
responsible for the recognition of mineralized matrix (Zou et al. 2007). (Figure 4) It does so 
by targeting the RGD sequence conserved in osteopontin and bone sialoprotein (Sharp et al. 
1999). Integrins can transduce a variety of intracellular signaling pathways once activated; 
either directly mediated by the ligand itself, or through signaling downstream of growth 
factor receptors (Haas and Plow 1994). Deletion of the j83 integrin subunit was shown to 
induce osteopetrosis in mice (Cheng et al. 2000), and it has been shown to be necessary for 
motility, bone matrix adhesion, and polarization of the osteoclast (Novack and Teitelbaum 
2008).  
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Figure 4 : Resorption Mechanisms in the Mature Osteoclast 
Following αvβ3-integrin-mediated attachment of the cell to the surface of bone, the 
characteristic ruffled border of the osteoclast is formed by the transport of vesicles 
containing H+ATPase to the laminal membrane. Carbonic anhydrase generates H+ and 
HCO3 ions, acidifying the environment. This acidification is necessary for the activity of 
enzymes like Cathepsin K, an acid protease that degrades type 1 collagen, the primary 
component of organic bone matrix. H+ is transported out of the cell and into the resorption 
lacuna by electrogenic proton pumps (the aforementioned H+ATPase), and intracellular pH 
is maintained by a Cl-/HCO3 exchanger at the antiresorptive surface. Likewise, 
electroneutrality is maintained by chloride channel activity (CLC7), which transports Cl- 
into the resorption lacuna. Finally, calcium balance within the cell is maintained by 
transporters both at the antiresorptive surface and the ruffled border (shown in green).  
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The mechanism of integrin contact is unique when compared with most other cells. 
Ordinarily, integrins mediate matrix contact through focal adhesions, containing signaling 
and cytoskeletal molecules, leading to the formation of stress fibers (contractile actin 
bundles providing force). With regards to the bone surface, however, the osteoclast 
organizes its fibrillar actin into sealing zones rather than forming stress fibers, and forms 
podosomes; ring structures of integrin receptors with an actin-rich core, rather than focal 
adhesions, which are made up of denser plaques of actin (Faccio et al. 2003). While 
somewhat tangential to the results later presented in this manuscript, and thus not further 
explained here, for interested parties a complete review summarizing the differences 
between different matrix contact structures and their roles in health and disease can be 
found in the Journal of Signal Transduction (Eleniste and Bruzzaniti 2012). 
An effective resorbing osteoclast is constantly in motion, and thus in these motile 
cells the sealing zone is frequently being disassembled, and other, non-podosomal integrins 
move to lamellipodia (extensions of the membrane) at the leading edge of the cell. To 
efficiently resorb bone, the osteoclast must be able to detach, migrate, and re-attach in order 
to re-form the sealing zone. It is because of this movement that resorptive pits more 
frequently resemble a chain of overlapping circular indentations, rather than single isolated 
holes, and the integrins, particularly ανβ3, are necessary for this process. c-Src, one of the 
best identified associated signaling molecules in osteoclastogenesis, was first studied in 
1991 in a murine model, where c-Src -/- mice were severely osteopetrotic, yet expressed 
large numbers of osteoclast-like cells (Boyce et al. 1992). The problem developed by these 
mice was that their “osteoclasts” lacked ruffled membranes and actin rings. c-Src is known 
to regulate osteoclasts both through its role as a kinase and an adaptor molecule (Miyazaki 
et al. 2004), and it has since been established that one function of c-Src, as a re-organizer of 
the cytoskeleton, is to link ανβ3 to the cytoskeleton following RANKL stimulation (Izawa 
et al. 2012). Another notable interaction of the ανβ3 integrin is with the M-CSF/c-Fms 
pathways. Upon binding M-CSF, c-Fms activates the integrin by targeting its cytoplasmic 
domain, which alters the conformation of its extracellular, ligand binding region (Faccio et 
al. 2003). This conformational change can partially emulate ανβ3 activation. 
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Mechanisms of Resorption 
The penultimate step of polarization and establishment of the sealing zone allows 
for the defining step of osteoclast activity to take place: the secretion of acid and acidic 
hydrolases onto the bone surface to degrade the extracellular matrix. The high amount of 
acid secreted by the osteoclast is necessary in order to dissolve the hydroxyapatite making 
up the bulk of the bone structure. This low pH is also necessary for the acidic hydrolases, 
notably cathepsin K, to be active, and degrade the remaining organic matrix (Teitelbaum 
and Ross 2003). Deletion of cathepsin K leads to decreased bone resorption coupled with 
an increase in formation (Saftig et al. 1998), driven by osteoclast-specific signaling 
(Lotinun et al. 2013). Similar to lysosomes, the engine driving acid secretion across the 
ruffled membrane are the v-type H+-ATPases. Their continued action would be impossible 
if the cytoplasm became alkalinized, however, so the protons and chloride ions being 
transported through the channels must be replenished. For this process, the osteoclast 
depends on the concerted activity of carbonic anhydrase, which is responsible for the 
conversion of CO2 to bicarbonate and protons, and an anion exchanger, such as anion 
exchange protein 2 (AE2) (Josephsen et al. 2009).  
The resorbing osteoclast must also have mechanisms for the transportation of 
breakdown products that accumulate in the sealing zone. The acid and proteases it secretes 
solubilize large amounts of calcium (up to 40 mM) and phosphate, which will eventually be 
released to the bloodstream, as well as other organic breakdown products (Silver, Murrills, 
and Etherington 1988). While the majority of these products are moved via transcytosis via 
the osteoclast out through the other side of the cell, it is impossible to fully prevent some 
calcium and phosphate ions from entering the osteoclast (Salo et al. 1997). To maintain 
homeostasis, the osteoclast employs several calcium-transporting transmembrane proteins 
(Figure 4). Among these are included the voltage operated (opening at depolarized 
membrane potentials) and ligand-gated Ca2+ channels, Na+-Ca2+ exchangers, and 
ryanodine receptor Ca2+ channels (Datta and Horrocks 2003). The development and 
utilization of ion channels and transporters is a hallmark of the adult osteoclast, the final 
manifestation of weeks of development in response to diverse signaling pathways. 
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The acidification process permitting dissolution of bone material is initiated by 
carbonic anhydrase (CA) activity (Riihonen et al. 2007). The protons generated by this 
activity are transported into the resorptive microenvironment by the electrogenic proton 
pump (H+ATPase) mentioned earlier. It is the incorporation of the acidified vesicles 
containing H+ATPase into the plasma membrane that causes the formation of the 
phenotypically characteristic “ruffles” (Schlesinger, Mattsson, and Blair 1994), and the HCl 
generated by these pumps is responsible for the acidification of the microenvironment. 
Once mineral degradation is under way, degradation of the bone organic matrix (primarily 
type 1 collagen) can take place. This function has a number of effectors, including acid 
phosphatases like TRAP, matrix metalloproteinases (MMPs), and cathepsin K. Like the ion 
channels necessary for activation, during polarization they relocalize to the ruffled 
membrane after osteoclast attachment to bone, in order to be at the site of action (Mulari, 
Vääräniemi, and Väänänen 2003). 
Regulation of Resorption 
An array of disorders are associated with bone resorptive imbalance. They can be 
related to excess osteoclast activity, as seen in postmenopausal osteoporosis, chronic 
inflammatory bone diseases, and Paget's disease of bone, but also in the case of limited 
osteoclastic activity, as with osteopetrosis. While other cell types like the osteoblast often 
play contributory roles, the osteoclast is more frequently targeted in treatment by drugs 
referred to as “anti-resorptive”, given that formation is by far the time-limiting step in 
remodeling. Treatment with estrogen, raloxifene (a selective estrogen receptor modulator), 
and bisphosphonates has been shown to increase osteoclast apoptosis, and thus inhibit 
bone-resorbing activity (Iñiguez-Ariza and Clarke 2015). However, since the formation of 
bone is tightly linked to post-resorption signals regulated by osteoclast activity, complete 
termination of such activity still leads to reduced bone formation and a net loss of bone 
mass. In some cases, this is still preferential to leaving the osteoclasts unchecked, but this 
treatment paradigm does leave room for improvement.  
One recent therapy rising in popularity is the RANKL-binding antibody denosumab, 
which has proven effective at reducing osteoclast activity by preventing osteoclastogenesis 
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(Schwarz and Ritchlin 2007). Alternatives allowing such a reduction without completely 
halting osteoclast activity provide a promising target without threatening to overly disrupt 
bone formation. Thus, further knowledge of signaling pathways and their regulatory 
mechanisms in osteoclastogenesis, and even osteoblast activating signaling controlled by 
osteoclasts is necessary. Studies have shown that inhibition of c-Src, v-ATPase, or CLC-7 
in osteoclasts, while reducing resorption, does not interfere with subsequent bone formation 
(Boyce et al. 2006). A field with potential for growth is Wnt signaling; while Wnt/β-catenin 
signaling has seen a large surge in interest in recent years, the effect of Wnt proteins on 
osteoclast lineage cells is a few years behind that of their partner cells. For example, it was 
shown in 2006 that Wnt3a regulates osteoclast differentiation through the down-regulation 
of RANKL induction and expression in osteoblasts, unbalancing the RANKL/OPG axis 
(Spencer et al. 2006). A 2015 study found that canonical Wnt receptors are expressed on 
myeloid cells, and that Wnt3a reduced osteoclastogenesis by suppressing early NFATc1 
transcription, through both non-canonical (PKA) and canonical (β-catenin) pathways 
(Weivoda et al. 2015). These results indicate that while targeting osteoclasts for apoptosis 
may still be a popular and practical choice in treating disease, evolving knowledge about 
the activation of these complex cells may provide more elegant tools in the near future. 
 
Signaling Pathways in Osteoclast Activation and Survival 
NF-κB 
Precursors of osteoclasts are drawn to future resorption sites on the bone surface in 
response to signals at these sites, most often RANKL. In conditions such as osteoporosis 
related to sex-hormone deficiency or in bone disease secondary to pro-inflammatory 
cytokines, an increased expression of RANKL leads to increased osteoclastogenesis and 
osteoclast activity (Boyce et al. 2015). The interaction of RANKL with its receptor RANK 
activates NF-κB signaling in osteoclast precursors as well as in osteoclasts. Most aspects of 
differentiation and activation of osteoclasts are regulated by NF-κB signaling. 
NF-κB consists of a family of transcription factors that positively regulate the 
expression of a multitude of genes involved in inflammation, immunity, differentiation, 
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proliferation, and survival (Oeckinghaus and Ghosh 2009; Courtois and Gilmore 2006). 
Although NF-κB activity is inducible in most cells, NF-κB can also be detected as a 
constitutively active, nuclear protein in certain cell types. The NF-κB family includes RelA 
(p65), p50, p52, RelB, and c-Rel. p50 and p52 are cleavage products of larger precursor 
proteins p105 and p100, respectively, which are encoded by NFKB1 and NFKB2 (Liptay et 
al. 1992; Fan and Maniatis 1991). In fact, proteasomal processing of p105 occurs 
constitutively in non-stimulated cells, excising their C-terminal portion in order to generate 
p50 (Palombella et al. 1994). All of the aforementioned family members have a Rel 
homology domain located in their N-terminus, allowing them to form homo- and 
heterodimers, as well as to bind specific DNA sequences on gene promoters. However, 
DNA binding also requires a C-terminal transcription activation domain, which p50 and 
p52 do not possess, and thus rely on the other three family members to positively regulate 
gene transcription (Vallabhapurapu and Karin 2009). Of these, RelA/p50 contribute the 
bulk of critical signaling in the canonical pathway, occurring soon after initiation of 
activation. Typically, (unless otherwise noted), NF-κB activity refers to this canonical 
RelA/p50-mediated signaling. In osteoclasts, this occurs in response to cytokines including 
RANKL, TNF, and others, and is transient (Boyce and Xing 2007). However, in 
osteoclasts, a non-canonical NF-κB is also activated in response to RANKL but not TNF, 
several hours after initiation of canonical signaling (Novack et al. 2003). This is begun by 
translocation of RelB/p52 heterodimers to the nucleus and is sustained over several hours. 
(Figure 5)  
Regulation of NF-κB 
There are a number of activation steps that make up NF-κB signaling requiring 
ubiquitination and proteasomal degradation, or processing of inhibitory proteins. These 
inhibitory NF-κB proteins are called IκBs. In most cells under non-stimulated conditions, 
NF-κB dimers interact with IκB proteins, and are thus retained in an inactive form in the 
cytosol. It is the phosphorylation of these inhibitors by the IκB kinase (IKK) that leads to 
their subsequent degradation, permitting nuclear translocation of NF-κB followed by 
transcription of target genes. Known IκBs include IκBα, IκBβ, and IκBε (Hayden and 
Ghosh 2008), which each contain multiple ankyrin repeats allowing them to bind NF-κB 
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dimers, blocking the function of their nuclear localization signals. The most common 
RelA/p50 heterodimers are typically kept inactive in the cytoplasm via interaction with 
IκBα, but can also be found bound to IκBβ (Vallabhapurapu and Karin 2009). Additionally, 
the C-terminal portions of p105 and p100 possess multiple ankyrin repeats, allowing them 
IκB-like functions within the cell (Dobrzanski, Ryseck, and Bravo 1995; Liou et al. 1992).  
Under stimulatory conditions, such as ligand binding at RANK or other TNF 
receptors, p105 is phosphorylated, targeted to the proteasome, and rapidly degraded 
without release of p50. IκBα, the RelA/p50 regulator, undergoes the same process, allowing 
existing NF-κB heterodimers to translocate to the nucleus. Contrary to p105, p100 is 
typically not processed in unstimulated cells, functioning as an inhibitory protein bound to 
RelB. The non-canonical signaling pathway for NF-κB involves ubiquitination of p100, 
which leads to processing to p52 rather than proteasomal degradation, and resulting in 
RelB-p52 heterodimers translocating to the nucleus (Madge and May 2011).  
Canonical NF-κB 
Canonical NF-κB signaling is activated by the trimeric IKK complex, consisting of 
two catalytic subunits (IKKα and IKKβ), as well as a regulatory subunit IKKγ, which is 
also known by the name NF-κB essential modulator (NEMO) (Shibata et al. 2007). (Figure 
5) When activated, the IKK complex phosphorylates IκBα, leading to polyubiquitination, 
and followed by rapid degradation by the 26s proteasome. This liberates the RelA-p50 
heterodimer to go to the nucleus (Vallabhapurapu and Karin 2009). Most IKK activity in 
the canonical pathway of cells, including RANKL signaling in osteoclasts and their 
precursors, is mediated by IKKβ (Boyce et al. 2015). This makes phosphorylation levels of 
IKKβ and nuclear levels of p50 attractive targets for measuring NF-κB signaling in these 
cells. Two other important inhibitory effects of IKK signaling to note are the upregulation 
of early expression of IκBα, and later expression of p100 (Novack et al. 2003; Bonizzi and 
Karin 2004). The former initiates a negative feedback loop, limiting RelA-p50 
translocation, while the latter limits non-canonical NF-κB pathway signaling. 
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Non-Canonical NF-κB 
Non-canonical signaling is set in motion by IKKα following its phosphorylation by 
NF-κB-Inducing Kinase (NIK). Under non-stimulated conditions, NIK is found 
constitutively ubiquitinated on receptors like CD40, by TNF receptor-associated factor 3 
(TRAF3). Under these same conditions, TRAF2 and the inhibitor of apoptosis (IAP) 
proteins cellular IAP1 (cIAP1) and IAP2 are bound to the same complex (Zarnegar et al. 
2008). Following ligand stimulation, cIAP1/2 ubiquitinate TRAF3, leading to its 
degradation and the release of NIK from the receptor complex. NIK is then free to 
phosphorylate IKKα, resulting in the proteasomal processing of p100 to p52, and 
subsequent formation of RelB/p52 heterodimers (Figure 5) (Senftleben et al. 2001).  
NF-κB Signaling in Osteoclastogenesis 
NF-κB1/2 double knockout mice were originally generated to investigate the role of 
NF-κB in immunity, but in addition to immune deficiency (severe B- and T-cell 
differentiation defects), they also demonstrated osteopetrosis because they failed to develop 
osteoclasts (Franzoso et al. 1997; Iotsova et al. 1997). Both the immune deficiencies and 
osteopetrotic phenotype were reversed in mice via transplantation of hematopoietic cells 
from wild-type mice, suggesting that the defects observed were of hematopoietic and not 
mesenchymal origin; further, that the bone phenotype in these dKO mice was osteoclast 
and not osteoblast-driven (Franzoso et al. 1997). TNF, IL-1, RANKL, and other cytokines 
were not sufficient to rescue the defect in osteoclast differentiation, suggesting that NF-κB 
is essential to cytokine-induced osteoclast formation (Xing et al. 2003). A near identical 
murine phenotype was observed in RANKL and RANK knockout mice, confirming the 
necessity of RANK and downstream NF-κB signaling for osteoclast formation (Boyce and 
Xing 2007). 
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Figure 5 : Activation Pathways of NF-κB 
RANKL and TNF induce canonical signaling through recruitment of TRAF6 or TRAF2/5, 
respectively, to their receptors, allowing for activation of a complex consisting of IKKα, 
IKKβ, and IKKγ or NEMO. This, in turn, induces phosphorylation and degradation of 
IκBα, and the release of p65/p50 heterodimers, which translocate to the nucleus, initiating 
transcription and activation of c-Fos, NFATc1, and others necessary for osteoclast 
differentiation. RANKL can also activate non-canonical pathways leading to NF-κB 
transcription, through the ubiquitination leading to lysosomal degradation of TRAF3 via 
cIAP1/2, releasing NF-κB inducing kinase (NIK), which in turn directly phosphorylates 
IKKα. IKKα phosphorylates p100, leading to its ubiquitination and proteasomal processing 
to p52, allowing RelB/p52 heterodimers to translocate to the nucleus, again initiating 
transcription. 
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While RANKL and NF-κB KO mice do not form mature osteoclasts, they do 
present increased numbers of RANK-positive, osteoclast precursors in their spleens that are 
negative for a number of osteoclastic markers including TRAP and calcitonin receptor 
(Xing et al. 2002). This indicates that RANKL and NF-κB signaling are not required for 
early differentiation of myeloid precursors to osteoclast precursors, but are for the 
formation of mature bone-resorbing osteoclasts. The expression of RANK in osteoclast 
precursors and other myeloid precursors is induced by M-CSF, which is also necessary for 
osteoclast formation, regulating a number of maturation and survival pathways (Fuller et al. 
1993; Yoshida et al. 1990; Tanaka et al. 1993).  
RANKL-Activation of NF-B and NFAT 
The NF-κB activation in response to RANKL in osteoclasts is rapid. Within an hour 
of receptor/ligand interaction, there is a transient increase in mRNA levels of RelA and p50 
(Asagiri et al. 2005). During this time, RelA and p50 are recruited to the promoter of 
nuclear factor of activated T cells 1 (NFATc1), inducing transient amplification of NFATc1 
expression (Takayanagi et al. 2002). NFATc1 is required for osteoclast formation, but in 
early stages of osteoclastogenesis, its role is focused more on down-regulation of 
constitutively active repressors of RANK signaling rather than inducing expression of 
osteoclastogenic genes, which will come later (Zhao and Ivashkiv 2011). In fact, 
osteoclastogenesis is dependent on negative regulation of some signaling pathways 
activated in response to “pro-osteoclastic” factors. For example, during osteoclast 
formation, the major role of RelA upon RANKL stimulation is to prevent apoptosis 
mediated by JNK, Bid, and caspase 3, all triggered in response to RANKL (Vaira et al. 
2008; Otero et al. 2008). Following the initial increase in NFATc1 expression described 
above, c-Fos and p52 levels increase in osteoclast precursors roughly two hours following 
RANKL stimulation, and maintain these levels throughout osteoclast differentiation 
(Yamashita et al. 2007). It is 72-96 hours after initial RANKL treatment that NFATc1 
expression levels rise again, and expression of several genes involved in resorption are 
induced. These include but are not limited to DC-STAMP, cathepsin K, and TRAP, as 
mentioned in the section detailing osteoclastogenesis.  
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Like other members of the TNF receptor superfamily, RANK lacks a kinase domain 
that would permit it to directly mediate downstream signaling (Darnay et al. 2007). 
However, RANK is very effective at recruiting a variety of interaction partners, including 
kinases like TGFB-activated kinase-1 (TAK1) (Figure 2). Once recruited, TAK1 induces 
activation and phosphorylation of the aforementioned IKKβ, which phosphorylates IκB, 
necessary for osteoclast formation via NF-κB as shown in mice (Ruocco et al. 2005). IKK 
supports osteoclastogenesis via NF-κB-mediated prevention of apoptosis, and IKKβ-null 
mice exhibit defects in osteoclast generation, this defect having been shown as due to an 
increase in JNK activation (Otero et al. 2008). Inhibition of JNK restored the 
osteoclastogenic capabilities of these murine precursors, highlighting the anti-apoptotic 
importance of IKK. As detailed further in a later section, RANK also recruits other kinases,  
adaptor molecules, and signal transducers such as TRAFs 1, 2, 3, and 5 in addition to 
TRAF6, as well as p62 (described later), which play major roles both in osteoclastogenesis 
and the pathology of several bone diseases. 
Regulation Via PKCs 
The structure of all PKCs includes a catalytic domain and a regulatory domain, 
attached by a hinge region. The catalytic domain is highly conserved between the different 
isoforms, while the regulatory region differs. PKCs are thus grouped into four classes; 
conventional or classical (cPKCs), novel (nPKCs), atypical (aPKCs), and PKNs. cPKCs 
have a binding pocket for diacylglycerol and phospholipids, as well as a C2 domain 
granting sensitivity to calcium (Castagna et al. 1982). nPKCs are similar, activated by DAG 
and phospholipids, but do not share dependence on calcium, despite sensitivity to the ion. 
The PKN subfamily members are characterized by three leucine-zipper-like heptapeptide 
repeat 1 (HR1) domains in their regulatory region, allowing them to bind Rho-GTP and 
regulate phosphorylation by PDK1 (Flynn et al. 2000). Their function is not yet established 
in bone, but small GTPases of the Ras superfamily are key regulators of osteoclast 
function, from development to activity (Itzstein, Coxon, and Rogers 2011). aPKCs include 
PKCζ and PKCι, and are insensitive to both DAG and calcium, lacking the DAG-binding 
region as well as the C2 domain (Diaz-Meco and Moscat 2012). However, they instead 
  
32 
32 
include a structural domain that allows for interaction with a variety of regulatory proteins, 
permitting their activation. 
When inactive, PKCs are thought to be auto-inhibited by the pseudosubstrate (PS) 
domain (an isoform-specific sequence in the regulatory domain); the conformation of the 
protein blocking the substrate-binding pocket in its kinase domain (Pears et al. 1990). In 
order to free themselves of the PS domain, aPKCs must be phosphorylated on a Ser and Thr 
site in their kinase domain, stabilizing the active conformation. This process requires the 
participation of two upstream activators. The first of these is phosphoinositide-dependent 
protein kinase 1 (PDK1), which phosphorylates the activation loop in the kinase domain 
(Le Good et al. 1998). The second is mammalian target of rapamycin 2 complex 
(mTORC2), which phosphorylates the turn motif in the C-terminal tail of PKCs (Ikenoue et 
al. 2008). While classical PKCs require a third phosphorylation in their hydrophobic motif, 
PKCζ contains an acid phosphomimetic Asp rather than a phosphorylatable Ser. This 
residue binds to the PDK-1-interacting fragment (PIF) pocket of PDK1, achieving the same 
effect (Balendran et al. 2000). There are likely as-yet unidentified regulatory or scaffolding 
components which permit access to the PIF, possibly modified in disease. In total, these 
activation steps take place in response to the binding of lipid second messengers, allosteric 
effectors, or both to specific domains in the regulatory region (Diaz-Meco and Moscat 
2012). 
The two atypical protein kinases share approximately 70% homology, and their 
activity is similar. The atypical PKCs are present in a range of cell types, from endothelial, 
to immune, to osteoclasts (Hirai and Chida 2003; Reyland 2009). PKCζ is involved in the 
regulation of several vital pathways, particularly cell survival, but also proliferation, 
differentiation, and polarization of the cell. Despite not requiring DAG activation, PKCζ 
has been proven to be sensitive to other lipids like phosphatidylinositols (PIs) (Limatola et 
al. 1994), arachidonic acid (Müller et al. 1995), and several others. Additionally, interaction 
with specific binding partners is a likely mechanism by which aPKC activation is 
modulated, conferring specificity to the kinases. Interaction with the zinc-finger in the C1 
domain of PKCζ allows the regulatory protein Par-4 to block enzymatic activity (Díaz-
Meco et al. 1996). The other known site for modulation by adapters is PB1, but in this case 
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the domain is best characterized as affecting localization rather than direct enzymatic 
activity (Moscat and Diaz-Meco 2000). 
PB1 protein-protein interaction is unique to the aPKCs among the PKC superfamily. 
This domain is a modular scaffold domain, named after the first such domains discovered 
in Phox and Bem1p, mediating homo- and heterodimeric interactions (Moscat and Diaz-
Meco 2000). PB1s are found outside of the aPKCs as well, in scaffold proteins like p62 and 
NBR1, as well as members of the MAPK family including MEKK3 and MEK5α. However, 
the type of PB1 domain (I/II) in which aPKCs are classed include only p62 and the 
relatively novel TFG (Sumimoto, Kamakura, and Ito 2007). Type I PB1 contains an OPCA 
motif allowing it to interact with a conserved lysine residue of the type II domain, and thus 
heterodimers can form between type I and II, and dimers of multiple varieties for type I/II 
containing PB1 domains. (Figure 6). However, homodimer formation has only been 
demonstrated by p62 to date (Wilson et al. 2003).  
Par-6 and p62 are selective adapters for the aPKCs, with Par-6 having been 
demonstrated as vital to the control of cell polarity, regulating the role of the aPKCs in this 
process through its PB1 domain (Macara 2004). The p62 signaling platform has been 
shown to play a critical role in NF-κB activation, interacting with PKCζ (Moscat and Diaz-
Meco 2009). However, p62 is not a substrate, nor does it appear to affect the intrinsic 
kinase activity of PKCζ (Sanchez et al. 1998). Given that p62 is host to a number of 
domains allowing it to function as a scaffold, it is possible that its role with respect to PKCζ 
involves localization and proximity to other proteins with which it may be associated, 
establishing a signaling network (Moscat, Diaz-Meco, and Wooten 2009). To date, the 
determining conditions for the different PKCζ complexes is not fully clear. 
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Figure 6 : Interaction Motifs and Domains of p62, PKCζ, PDK1 and Akt 
The cytosolic p62 is a scaffolding protein that interacts with the RANK/TRAF6 signaling 
complex, and is one of the functional links reported between RANKL and TRAF6-
mediated NF-κB activation. Its activity is made possible by a number of interaction motifs, 
enabling recruitment of specific proteins and regulation of multiple downstream pathways. 
TRAF6 interacts with the TF6-b sequence, RIP binds the ZZ domain, and a number of 
kinases including ERK and the aPKCs all interact with the PB1 domain. The UBA domain 
binds polyubiquitin chains, and is important for the ubiquitination of TRAF6.The aPKC PS 
domain inhibits its activity prior to phosphorylation, which can be carried out by PDK1, 
which autophosophorylates in its kinase domain, permitting activity. The PH motif of 
PDK1 permits interaction with numerous other proteins, including Akt, which it 
phosphorylates on Thr308, activating the kinase. Akt activity can be further activated by 
phosphorylation of its regulatory domain at the Ser473 residue. PB1, PB1 dimerization 
domain; ZZ ZNF, ZZ-type zinc-finger; TF6-b, TRAF6 binding sequence; PEST, (P, 
Proline; E, Glutamate; S, Serine; T, Threonine) rich sequence; UBA, ubiquitin-associated; 
PS, pseudosubstrate region; MATH, meprin and TRAF homology 
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In NF-κB signaling, PKCζ has been reported to be upstream of IκB kinase (IKK), 
able to bind IKKβ in order to modulate its activation (Lallena et al. 1999). PKCζ controls 
the function of NFAT in T-lymphocytes through phosphorylation of glutathione S-
transferase-NFAT1 (NFATc2), and PKCζ co-precipitates with NFAT1 and/or NFAT2 
(San-Antonio, Iñiguez, and Fresno 2002). However, results in gene-deficient murine 
models have shown that there is a tissue-specific variation of PKCζ involvement in NF-κB 
signaling. Specifically, PKCζ was shown to be required for IKK activation in the lung in 
response to TNF-α, but not in fibroblasts, where instead its main function appears to be 
phosphorylation of RelA in order to regulate NF-κB transcriptional activity (Leitges et al. 
1996; Duran, Diaz-Meco, and Moscat 2003). The control of NF-κB via alternative 
mechanisms of activation allows for tighter control of some of the thousands of genes 
whose expression is regulated by this transcription factor (Perkins 2006). Studies have 
shown that phosphorylation of RelA versus the classical activation pathway is one means of 
doing so (Zhong, Voll, and Ghosh 1998). 
PI3K and PDK1 Signaling 
The phosphoinositide-3-kinase (PI3K) enzymes have been established as major 
signaling molecules in a variety of cellular functions, from glucose metabolism (Okada et 
al. 1994), to cellular proliferation, survival (Cantley 2002), inflammation (Hawkins and 
Stephens 2014), angiogenesis, and more. Mutations to members of the PI3K family are 
frequently observed in cancer, and by some estimates, abnormal PI3K signaling may occur 
in as much as 50% of all malignancies (Fyffe, Buus, and Falasca 2013). There are eight 
mammalian isoforms within the PI3K family, consisting of a catalytic subunit and varying 
regulatory subunits, depending on class grouping. Their common activity is to catalyze the 
phosphorylation of position 3 of the inositol group of phosphoinositides, the best 
characterized product of which is phosphatidylinositol-3,4,5-triphosphate (PtdIns[3,4,5]P3 
or PIP3), which is derived from phosphorylation of PtdIns[4,5]P2 (Fyffe, Buus, and Falasca 
2013). The PIP3 synthesis by PI3K is carried out in response either to receptor tyrosine 
kinases or G-protein-coupled receptor activation, and PIP3 subsequently acts as a second 
messenger by inducing translocation of target proteins to the membrane through their PH 
domains. This pathway is negatively regulated by the phosphatase and tensin homolog 
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(PTEN), which directly dephosphorylates PIP3 at the 3' position, effectively “resetting” the 
PI3K signal (Song, Salmena, and Pandolfi 2012). 
PDK1 
PDK1 is a member of the cAMP-dependent protein kinase A/protein kinase G/protein 
kinase C (AGC) kinase family which all share sequence homology in their catalytic domain 
to cAMP-dependent protein kinase 1 and protein kinase C (PKC) (Pearce, Komander, and 
Alessi 2010). PDK1 was first discovered as the kinase responsible for phosphorylation of 
the Akt activation loop at its Thr308 residue. This phosphorylation is also dependent on 
PtdIns(3,4,5)P3 concentration in vitro, which associates PDK1 to upstream PI3K 
activation. It possesses an N-terminal catalytic domain, a C-terminal PH domain, a PIF 
pocket, and a nuclear export sequence (Figure 6) (Fyffe and Falasca 2013). This export 
sequence is essential for the export of PDK1 from the nucleus to the cytoplasm through the 
nuclear pore complex (Scheid, Parsons, and Woodgett 2005). PDK1 is found constitutively 
in a homodimeric complex via PH domain interaction, a dimerization that appears to be 
necessary in the regulation of its activity (Masters et al. 2010). 
One common characteristic of many AGC kinases are two phosphorylation sites that 
regulate their activation. The first of these is in the activation loop located in the kinase 
domain, and the second in the hydrophobic motif, adjacent to the catalytic domain (Alessi 
et al. 1997), and the phosphorylation of these sites permits kinase activity. Like other AGC 
kinases, PDK1 can be phosphorylated within its activation loop on Ser241 (Wick et al. 
2003). As this is an autophosphorylation reaction, PDK1 kinase is considered constitutively 
active, and its regulation involves several different mechanisms. The first of these involves 
its localization. PDK1 localizes at the plasma membrane through interaction of its PH 
domain with the phosphoinositides PtdIns(3,4,5)P3 and PtdIns(3,4)P2 (Currie et al. 1999). 
Though its membrane localization has been heavily investigated, and the affinity of the PH 
domain for PI3K products suggests a PI3K-dependent membrane translocation, the 
chronology of its localization remains controversial. PDK1 may translocate to the plasma 
membrane following growth factor stimulation, or it may be constitutively localized there 
(Fyffe and Falasca 2013). Regardless, this localization is critical for Akt phosphorylation. 
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PDK1 is considered a master kinase, regulating gene expression, the cell cycle, 
survival, and other pathways through a plethora of downstream kinases and their associated 
signaling cascades (Kikani, Dong, and Liu 2005). Although PDK1 is best known for its 
central role in Akt function, it also has activity unrelated to Akt; phosphorylating and 
activating other AGC protein kinases without first binding PIP3, such as include serum 
glucocorticoid-dependent kinase (SGK), p70 and p90 ribosomal protein S6 kinases (S6K 
and RSK, respectively), and atypical PKC family members like PKCζ through activation 
loop phosphorylation (Mora et al. 2004; Finlay and Cantrell 2011). The mechanism of 
action of these kinases differs from that of Akt. The PIF, a hydrophobic pocket whose full 
name is the PDK1 interacting fragment pocket, is essential to PDK1 interaction with the 
hydrophobic motif of these protein kinases (Biondi et al. 2001), and mutations to the PIF 
pocket prevent their binding and subsequent phosphorylation.  
Given the vast number of targets and varied pathways of PDK1, deletion in 
drosophila and mice has been shown to be lethal (Han et al. 2015), and demonstrate that 
PDK1 is required for normal embryonic development (Lawlor et al. 2002). In a murine 
model, the PDK1-/- genotype lacked branchial arches, had defects in neural crest 
specification and forebrain development, and also several failures in circulatory system 
development, leading to death before embryonic day ten (Lawlor et al. 2002). Therefore, in 
order to study PDK1 knockdown, hypomorphic mice for PDK1 were generated, with 
expression of the gene reduced by 80-90% across all tissues. Interestingly, cells from these 
mice showed no significant differences in the activation of its AGC targets, whose activity 
was induced by insulin. The mice presented a decrease in body size of 40-60% compared 
with wild-type, but this difference was finally attributed to a decrease in individual cell size 
rather than cell numbers (Bayascas et al. 2005).  
Akt 
The serine threonine kinase Akt, also referred to as protein kinase B, is a central 
kinase in many cellular pathways, particularly survival. It belongs to the AGC superfamily 
of protein kinases that all share a similar mechanism of activation, as well as structural 
homology within their catalytic domain (Song et al. 2005). Dysregulation of AGC kinases 
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is often associated with dysfunction and diseases, including cancer, diabetes, and various 
inherited diseases (Pearce, Komander, and Alessi 2010). In mammals, three Akt genes have 
been identified, but while Akt1 is ubiquitously expressed, Akt2 and -3 are primarily 
expressed in insulin-responsive tissues and the brain, respectively (Hers, Vincent, and 
Tavaré 2011). 
All three isoforms share a conserved domain structure consisting of an amino 
terminal pleckstrin homology (PH) domain, a central kinase domain, and a carboxyl-
terminal regulatory domain containing a hydrophobic motif (Masure et al. 1999). (Figure 
6). The name of the PH domain is derived from the protein in which it was originally 
identified; pleckstrin, which is a PKC substrate found in platelets (Tyers et al. 1988). This 
domain in Akt is similar to those found in other signaling molecules that bind 3-
phosphoinositides (Lietzke et al. 2000), and will interact with membrane lipid products like 
PIP3, produced by phosphatidylinositol 3-kinase (PI3-kinase). The catalytic kinase domain 
in the central region of the molecule has been shown to be very similar with that of other 
AGC kinases such as PKC, p70S6K, and p90RSK (Peterson and Schreiber 1999). One 
feature of this region is a threonine residue (Thr308) whose phosphorylation can partially 
activate Akt, and is required for complete activation (Alessi et al. 1996; Vincent et al. 
2011). The aforementioned hydrophobic motif in the C-terminal contains a serine residue 
whose phosphorylation is required for full activation of the kinase, as with all members of 
the AGC family (Andjelković et al. 1997). Unlike with Thr308, phosphorylation at Ser473 
alone is insufficient to initiate kinase activity. 
Regulation of Akt 
Activation of Akt by growth factors requires a PI3K and PH domain-dependent 
membrane translocation step, following which Akt can be phosphorylated at its two key 
regulatory sites (Thr308 and Ser473) by one of its kinases. PI3K activity, in turn, is 
mediated by tyrosine kinase or G-protein-coupled receptors, depending on class (Wymann, 
Zvelebil, and Laffargue 2003). Following its recruitment to these receptors, it is activated, 
and PIP2 on the 3-hydroxyl group generates the second messenger molecule PIP3. PIP3 
levels are balanced by tight regulation from phosphatases like PTEN (Simpson and Parsons 
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2001). While PIP3 does not activate Akt directly, it is through interaction with the PH 
domain that it recruits Akt to the plasma membrane, allowing phosphorylation by PDK1 at 
Thr308 (Stephens et al. 1998). The concurrent phosphorylation of Akt at Ser473 is believed 
to be carried out primarily by mTORC2, as Rictor knockout in vitro ablates Ser473 activity 
(Sarbassov et al. 2005a), but there is also evidence that this site can be autophosphorylated, 
or targeted by other serine kinases (Jiang and Qiu 2003). 
The recruitment of PDK1 to the membrane is similar to that of Akt, as PDK1 is a 
serine/threonine kinase possessing a C-terminal PH domain with a high binding affinity for 
3-phosphoinositides. Interestingly, phosphorylation of Akt by PDK1 requires PIP3, but not 
in Akt mutants lacking the PH domain (Biondi et al. 2000). This suggests that this domain 
may be masking the S308 residue when not bound to PIP3. While deletion of PDK1 does 
not change Ser473 phosphorylation, overexpression of PDK1 in vitro leads to a 
phosphorylation increase (Hill et al. 2001), suggesting that it may contribute indirectly to 
this process. 
The majority of proteins reported to interact with Akt are substrates, and do not 
affect its kinase activity (Brazil, Park, and Hemmings 2002). However, several proteins 
besides the kinases previously identified have been demonstrated as capable of regulating 
Akt activity in a transient manner. Proteins like carboxyl-terminal modulator protein 
(CTMP) interacts with the C-terminal of Akt, reversing Ser473 phosphorylation, and this 
activity was shown to reverse Akt-dependent cancer cell growth in nude mice (Maira et al. 
2001). Trb3 is the mammalian homolog of the Drosophila protein tribbles, which 
negatively regulates Akt activation by binding the central region of its kinase domain, 
reducing phosphorylation (Du et al. 2003). Another negative regulator, Keratin K10, does 
not directly prevent phosphorylation, but rather sequesters Akt to the cytoskeleton, 
inhibiting its intracellular translocation and thus activation in epithelial cells (Paramio et al. 
2001).  
However, there are also a great number of known positive regulators of Akt. Among 
them are several members of the Hsp family; molecular chaperones that promote refolding 
and stabilization in response to cellular stress. Hsp27, for example, binds Akt isoforms 
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following stress treatments, leading to activation of Akt and apoptosis reduction in 
neutrophils (Rane et al. 2003). The aptly named Akt-interacting protein (also known as 
AKTIP or Ft1) interacts directly with Akt and enhances phosphorylation of both regulatory 
sites, in part through promoting its interaction with PDK1 (Remy and Michnick 2004). 
Confirming its physiological relevance, blocking Ft1 activity was demonstrated to increase 
susceptibility of T-lymphocytes to apoptosis. 
Akt and Cell Survival 
The Akt pathway is recognized as critical to cell survival, and activation of the Akt 
pathway allows cells increased resistance in the face of apoptotic stimuli (Yao and Cooper 
1995). It has been shown to be elevated and important to survival in several cancers 
(Wendel et al. 2004). The pro-survival signaling initiated by Akt can directly affect the 
apoptosis pathway, in the case of targeting the pro-apoptotic Bcl-2 related protein, BAD. It 
can also affect the transcriptional response to apoptotic stimuli, by affecting activity of the 
p53 family and Forkhead factors. In addition, metabolic regulation by Akt feeds back into 
survival pathways, another means of reducing cell death.  
Apoptosis as previously described here typically involves release of cytochrome c 
from mitochondria, activation of Apaf-1, and cleavage of caspase-9 leading to the caspase 
cascade (Thornberry and Lazebnik 1998). Members of the Bcl-2 family are critical 
regulators of this pathway, including anti-apoptotic effectors like Bcl-2, and Bcl-xL, but 
also the pro-apoptotic BAD of the BH3 subfamily, as well as Bax and Bak of the Bax 
subfamily (Czabotar et al. 2014). The activity of BAD is carried out through the binding of 
the protein to Bcl-2 or Bcl-X, inhibiting their anti-apoptotic activity. The phosphorylation 
of BAD on Ser136 by Akt eliminates the apoptotic effect exerted by BAD, promoting cell 
survival (Datta et al. 1997). Once phosphorylated, it is released from a Bcl-2/Bcl-X 
complex on the mitochondrial membrane, and goes on to form complexes with 14-3-3 
proteins in the cytosol, allowing the anti-apoptotic function of Bcl-2 proteins (Czabotar et 
al. 2014). Caspase-9, normally an initiator and effector of apoptosis, has also been shown to 
be phosphorylated by Akt, on its Ser196, reducing its activity (Cardone et al. 1998).  
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Another mechanism regulated by Akt is the stress-activated protein kinase (SAPK) 
pathway, which consists of JNK and p38 MAPK pathways; regulating cellular responses to 
stress or cytokines (Johnson and Lapadat 2002). Akt has been shown to phosphorylate at 
least three kinases upstream of SAPK responses. Apoptosis signal-regulating kinase 1 
(ASK1) is the first of these MAP kinase kinase kinases (MKKKs) to act as a substrate of 
Akt, phosphorylated on Ser83, promoting inhibition of apoptosis (Zhang et al. 2005). 
However, studies have also shown that Akt/MAPK pathways (including ASK1/p38) can 
promote apoptosis (Pan et al. 2010). As the roles of MKKKs and the SAPK pathway are 
diverse, the response mediated by Akt can be both stimuli and cell dependent. Mixed 
lineage kinase 3 (MLK3) is the second MKKK regulated by Akt, phosphorylated on 
Ser674, leading to its inactivation (Barthwal et al. 2003). In neuronal cells, nerve growth 
factor withdrawal has been shown to activate MLK3-JNK signaling, inducing expression of 
FasL and BH3 members of the Bcl-2 family, and prevention of these processes is the likely 
means by which Akt phosphorylation of MLK3 encourages increased cell survival (Chadee 
2013). In a manner consistent with the phenomenon described for ASK1, knockdown of 
MLK3 in tumor cells lead to apoptosis (Cronan et al. 2012). Similar to the other MKKKs, 
SAPK/ERK kinase (SEK1), also known as MKKK4 or Jun kinase kinase (JNKK), can be 
phosphorylated on Ser80 by Akt, thus inactivating SEK1 and reducing susceptibility to 
UV-induced apoptosis (Park et al. 2002). 
The regulation of cell survival by Akt via transcriptional factors includes 
modulation of both pro- and anti-apoptotic genes. The aforementioned Forkhead (FH or 
FoxO) family has four known isoforms, all of which can be directly phosphorylated by Akt 
(Zhang et al. 2011). These phosphorylated FoxO proteins regulate cell survival by inducing 
expression of their target genes, a number of which are anti-survival, and phosphorylation 
by Akt inhibits these transcriptional functions, contributing to cell survival, growth, and 
proliferation. Target genes for the FoxO family include death receptors ligands like Fas 
ligand and TRAIL, intracellular components for apoptosis such as members of the Bcl-2 
family, and various cyclin-dependent kinase inhibitors (CDKIs) (Liu, Kao, and Huang 
2008). 
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Anti-apoptosis genes regulated by Akt include cyclic AMP-response element binding 
protein (CREB), phosphorylated on Ser133, increasing its transcriptional activity as well as 
its affinity for its co-activator CRB (Du and Montminy 1998). This mediates expression of 
bcl-2 family genes. Yes-associated protein (YAP) is phosphorylated by Akt in a PI3K-
dependent manner, suppressing apoptosis via reduction of co-transcriptional activity with 
the p53-like p73 (Conforti et al. 2012; Basu et al. 2003). Finally, the key regulator of the 
immune response, and of osteoclast development and activity, NF-κB, is a target of Akt. As 
activation of NF-κB is typically dependent on phosphorylation of the IKK complex, Akt 
regulates NF-κB translocation by affecting IKK activity both directly and indirectly 
(Vallabhapurapu and Karin 2009). This allows, among many other genes, for the 
transcription of pro-survival Bcl-xL, caspase inhibitors, and c-Myb (Lauder, Castellanos, 
and Weston 2001). The degradation of the IκB protein is enhanced in Akt-transformed 
cells, and loss of NF-κB activity interferes with PI3K and Akt-induced oncogenic 
transformation of chicken embryo fibroblast (CEF) cells (Bai, Ueno, and Vogt 2009). Akt 
phosphorylates IKKα on Thr23, an event which is prerequisite for Ser534 phosphorylation 
of the p65 NF-κB subunit. This suggests that Akt regulation of NF-κB signaling may be 
dependent on p65 Ser534 phosphorylation. Studies have also shown that the 
serine/threonine protein kinase Cot/Tpl2 is phosphorylated by Akt, and that this permits 
Cot induction of NF-κB transcription following IKK stimulation (Kane et al. 2002). 
ERK Signaling 
 Alterations to the MAPK/ERK1/2 cascade have been associated with several 
diseases affecting bone, suggesting a role for ERK1 and 2 in human skeletal development 
(Stevenson et al. 2011). In addition, RANKL also activates the MEK/ERK pathway 
contributing to osteoclast differentiation and survival (Ang et al. 2011), and the p62 UBA 
domain plays an important role not just in the activation of NF-κB and NFAT, but also in 
ERK phosphorylation (Yip et al. 2006). Furthermore, the RAS/MAPK pathway has already 
been shown to be imbalanced in PDB (Yip et al. 2006). The ERKs are serine/threonine 
kinases with 84% shared homology (Lefloch, Pouysségur, and Lenormand 2008). Upon 
extracellular stimulation, the Ras-Raf-MEK cascade phosphorylates ERK, thereby 
activating it, at which point ERK1 and 2 phosphorylate cytoplasmic as well as nuclear 
  
43 
43 
factors affecting a host of functions in the cell, from gene expression, to migration, 
apoptosis, and more (Fiil et al. 2009; Subramaniam and Unsicker 2010; Bates et al. 2010). 
In a skeletal context, in vivo dual ERK disruption in osteoblast lineages led to reduced 
RANKL production, and thus reduced osteoclastogenesis (Matsushita et al. 2009). Studies 
using pharmacologic kinase inhibitors on osteoclasts in vitro have also indicated the 
importance of ERK signaling to osteoclast formation and function (Bradley and Oursler 
2008; Kim et al. 2003). The first genetic study examining the direct regulation of osteoclast 
physiology by ERK was published in 2011, describing the consequences of ERK1 and 
ERK2 disruption to differentiation, migration, and bone resorptive activity, both in vivo 
and in vitro (He et al. 2011). This study demonstrated that ERK1 plays a significant role in 
the modulation of osteoclast differentiation and migration, affects bone resorption, and 
ultimately bone mineral density in a murine model.   
The p62 Scaffold: the functional link between RANKL and TRAF6-mediated signals 
The universal signal for targeting proteins for degradation, be it via autophagy or 
proteasome pathways, is ubiquitination. In both of these processes, p62 plays a major role 
through the binding of ubiquitinated protein as well as trafficking. These activities are 
made possible by the varied domains of the scaffold (Figure 6). p62 is involved in the 
formation of multimeric protein complexes through PB1 domain interactions, and also 
plays a role in protein turnover thanks to its UBA domain at its C-terminus, as this domain 
binds non-covalently to polyubiquitin chains, preferentially those of the K63 variety 
(Seibenhener et al. 2004; McManus and Roux 2012). At the other end, the N-terminus 
domain permits association with the proteasome, specifically 26S and S5a subunits 
(Nakamura et al. 2010). In between are 7 known structural motifs with protein-interaction 
domains, including two PEST sequences (associated with proteasomal degradation), an 
LC3-interacting region (LIR), a binding site for the RING-finger protein TRAF6, a p38-
binding domain, and a ZZ finger that interacts with RIP (a serine/threonine kinase involved 
in survival regulation). In a neuronal model, p62 has been demonstrated to direct the 
trafficking of protein complexes containing TRAF6, PKCζ, and the neutrophin receptors, 
showing it to be an essential player in signaling protein degradation and recycling (Wooten 
et al. 2006). 
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With so many interaction motifs, p62 serves as a scaffold for multiple pathways; in 
the context of the osteoclast, its most important role is perhaps as a switchboard from 
which several cascades are regulated following RANKL-activation. In both mature 
osteoclasts and their precursors, the interaction between RANK and its ligand results in 
multiple cascades that ultimately activate transcription factors, most notably NF-κB and 
NFATc1 (Shinohara and Takayanagi 2007). The initiation of these sequences requires the 
recruitment of TNFR associated factor 6 (TRAF6) to the receptor complex, a change that is 
responsible for most of the downstream events leading to osteoclast differentiation and 
activation (Wada et al. 2006). The reliance on TRAF6 for signal transduction can be 
attributed to the fact that RANK, like other members of the TNFR family, lacks the 
intracellular motifs necessary for intrinsic enzymatic activity (Ye et al. 2002). The 
cytoplasmic domain of RANK is able to directly interact with five of the six TRAF proteins 
via different binding sites, with that of TRAF6 being most proximal to the membrane 
(Gohda et al. 2005). Three TRAF-binding motifs of RANK have been shown to be 
involved in osteoclast differentiation and activation, involving NF-κB activation as well as 
MAP kinases JNK, ERK, and p38 (Liu et al. 2004). Activated TRAF6 stimulates NF-κB 
activity through the activation of the IκB kinase (IKK) complex, either via aPKC or TAK1-
dependent phosphorylation (Walsh et al. 2008) (Figure 2). Through interaction with aPKC 
proteins, the p62-TRAF6 complex allows the formation of a multimeric protein complex 
that regulates NF-κB activation via phosphorylation of IκB kinase B (IKKΒ) (Moscat and 
Diaz-Meco 2000). p62 also binds the scaffolding receptor interacting protein (RIP), and 
phosphoinositide-dependent kinase 1 (PDK1), recruiting aPKCs to TNFR signaling 
complexes (Sanz et al. 1999). In the second pathway identified, without the aid of p62, 
TRAF6 also forms complexes with TGF-activated kinase 1 (TAK1), and adaptor proteins 
TGF-β activated kinase 1 (TAB1) and TAB2 (Mizukami et al. 2002). Once activated, in 
addition to its phosphorylation of IKKβ, TAK1 can also phosphorylate NF-κB-inducing 
kinase (NIK), which in turn can also activate the IKK complex, leading to NF-κB pathway 
activation. With regards to the MAP kinases, TAK1 also activates the JNK pathway, while 
TAB1 recruits and binds p38, leading to its activation (Ge et al. 2002). Finally, RANKL-
induced TRAF6 signaling also activates the Akt/PKB pathway through a signaling complex 
involving c-Src and its family members (Wong et al. 1999). All of the aforementioned 
  
45 
45 
signaling molecules are significant contributors to osteoclast differentiation, survival, and 
activity. As a scaffold, p62 is extremely important to RANK-induced signaling, both 
through the recruitment and formation of these signaling complexes, as well as its ability to 
bind and activate TRAF6. As a consequence, genetic inactivation of SQSTM1 has been 
demonstrated to inhibit IKK and NF-κB activation induced by RANKL, as well as NFATc1 
synthesis, and ultimately impairs osteoclastogenesis in a murine model (Durán et al. 2004). 
In this murine in vitro model, stimulation of osteoclasts with RANKL has been shown to 
induce formation of a ternary complex containing TRAF6, p62, and aPKCs. It has been 
demonstrated in a human osteoclast model as well that following RANKL stimulation of 
human osteoclasts, P-PKCζ and P-PDK1 can be immunoprecipitated with the TRAF6/p62 
complex (Chamoux et al. 2009). This is consistent with the fact that PKCζ, like other 
aPKCs, is a substrate of PDK1, and suggests that there is a role for PDK1 in p62-aPKC 
signaling. Given established role of PDK1, a serine/threonine kinase, as a master protein 
kinase in the regulation of many cell signaling pathways, it may also play a role in other 
TRAF6-p62 associated cascades. However, the role and importance of PDK1 in osteoclast 
p62 signaling has yet to be examined in any great detail. 
p62 and Other NF-κB Activation Pathways 
The IKK complex is central to NF-κB activation, and can be composed of 3 subunits 
depending on canonical or non-canonical signaling. Of these, two are catalytic; IKKα and 
IKKβ, and the third, IKKγ or NEMO, is regulatory. Outside of osteoclasts, p62 has been 
shown to regulate IKK activation through its ability to bind atypical PKCs, who favor 
phosphorylation and thus activation of IKKβ (Duran et al. 2008). In a cell line derived from 
a rat adrenal medulla tumor (PC-12), IKKβ is recruited to a multiprotein complex including 
p62, TRAF6, and aPKC (Wooten et al. 2005). Disrupting p62-TRAF6 interaction prevented 
the TRAF6 polyubiquitination necessary for the recruitment of subsequent subunits, and 
led to failure to activate NF-κB though IKKβ. 
p62 and Regulation of TRAF6 Through De-ubiquitinase Activity 
As a molecular adaptor, interactions between p62 and TRAF6 stimulate K63-linked 
autoubiquitination and E3 ligase activity, regulating the synthesis of K63 chains on target 
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substrates. In addition to its UBA domain, the PB1 domain of p62 is required for TRAF6 
polyubiquitination (Moscat, Diaz-Meco, and Wooten 2007). This modification of TRAF6 is 
an important mechanism mediating its signaling functions (Lamothe, Besse, et al. 2007). 
While it has been demonstrated that K63-linked ubiquitination is not an absolute 
requirement for its E3 ligase activity in mediating downstream activity, it remains a 
significant marker of activation (Walsh et al. 2008).  
The role of p62 as a regulator of TRAF6 activity and ubiquitination is not limited to 
its direct interaction with the TRAF, but also though association with the de-ubiquitinase 
CYLD (Wooten et al. 2008). A de-ubiquitinating enzyme (DUB) with specificity for Lys63 
chains, it interacts with TRAF6, reversing the process of protein ubiquitination. Decrease in 
CYLD activity leads to the accumulation of K63-ubiquitinated substrates in a neuronal 
model, and conversely, CYLD activity negatively regulates NF-κB activity via reduction of 
TRAF6 activity (Kovalenko et al. 2003). This is observed in part though decreased 
activation of IKK and JNK, and as part of a negative signaling loop, CYLD expression is 
significantly upregulated under conditions of RANKL-induced osteoclastogenesis (W. Jin 
et al. 2008a). p62 interacts with CYLD, promoting the latter's binding to TRAF6, a process 
requiring a functional c-terminal domain of p62 (Figure 2). The CYLD-deficient mice 
present with severe osteoporosis arising from abnormal osteoclast differentiation, with 
larger and more numerous osteoclasts that are hyper-responsive to RANKL. Therefore 
CYLD is a crucial down-regulator of RANK signaling in osteoclasts, mediated in part by 
p62 function.  
Osteoclast-specific Transcriptional Regulation by p62 
RANKL is a specific and strong inducer of nuclear factor of activated T cells 
(NFAT), the master transcriptional regulator of osteoclast differentiation (I. Song et al. 
2009). NFATc1 specifically autoregulates its own promoter, in particular during RANKL-
induced osteoclastogenesis (Shinohara and Takayanagi 2007). Kinases may contribute to 
the nuclear shuttling of this factor, as PKCζ has been shown to interact with NFATc1, and 
this interaction may modulate NFAT-mediated transcription by increasing activity of its N-
terminal transactivation domain (San-Antonio, Iñiguez, and Fresno 2002). In 
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osteoclastogenesis, NFATc1 induction is dependent on p62-TRAF6/NF-κB activation and 
calcium signaling, as well as c-Fos pathways. Over the past decade, the importance of the 
role of c-Fos and related family members has been expanded in the osteoclast. This is due 
in no small part to their activity as transcriptional co-factors with NFATc1 (Yang et al. 
2005). Despite its crucial role as a transcription factor, NFATc1, like other NFAT family 
members, is only weakly able to bind DNA, and is dependent on association with other 
nuclear resident transcription factors (Macian 2005). Recent studies have further confirmed 
that CYLD knockdown significantly increased c-Fos expression in cells transduced to 
express both wild-type and mutant p62, without necessitating RANKL stimulation 
(Sundaram et al. 2011). The inhibition of PI3K by LY294002 reduces osteoclast formation 
and NFATc1 expression, but does not affect c-Fos, However, overexpression of Akt in 
bone-marrow-derived macrophages leads to the opposite effect; increasing 
osteoclastogenesis, NFATc1 expression, and c-Fos activity (Moon et al. 2012).  
Regulation of Survival in Osteoclasts 
Apoptosis, or programmed cell death, is regulated by a specifically ordered series of 
biochemical events that eventually lead to cell destruction, and is characterized by distinct 
morphological changes. These changes are defined by several major characteristics; 
shrinkage of the cell, condensation and fragmentation of the nuclear chromatin, and 
changes to the plasma membrane that result in recognition and phagocytosis of the 
apoptotic cell (Poon et al. 2014). The biochemical events have been split into two phases 
which are distinct only by categorization, as there is a great deal of overlap between the 
two. The first of these is the initial commitment phase, in which the apoptotic signal is 
received and first propagated, while the second is the execution phase, during which the 
aforementioned characteristic morphological changes take place, and leads to the cell's 
passing the “point of no return” in the apoptotic process (Chipuk, Bouchier-Hayes, and 
Green 2006). Both healthy and dysfunctional cells must constantly maintain a balance 
between pro- and anti-apoptotic gene expression and activity. The signal initiating the death 
of the cell, whether its origin be external (extrinsic) or internal (intrinsic), requires the 
cooperation of a cascade of downstream signaling events before the execution phase can 
take place. Apoptosis is a tightly controlled process with an ever growing pool of 
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regulators; a process to which the organism would not want cells committing to 
extraneously, leading to waste. Conversely, it is also extremely important that cells be able 
to enter apoptosis when necessary, removing those that are in excess, malfunctioning, 
invading, or otherwise potentially dangerous. In short, this molecular program linked to 
most major processes allows the organism to control cell types and numbers, helping foster 
a healthy, properly functioning environment. In order to provide context for a number of 
cellular processes to be described that directly or indirectly influence apoptosis, a brief 
summary of the basic mechanisms will be provided here. 
Caspases 
 The prime effectors in apoptosis are a group of cysteine proteases homologous to 
one another, making up the protein family known as the caspases (Thornberry and 
Lazebnik 1998). The elimination of caspase activity has been demonstrated to significantly 
slow or altogether stop the apoptotic process (McIlwain, Berger, and Mak 2013). The 
common element between all caspases is an active-site cysteine, allowing it to cleave 
aspartic acid peptide bonds within proteins. The specificity of each caspase is determined 
by the four amino acid residues terminal to this cysteine aspartate cleavage site (Chang and 
Yang 2000). The activation of caspases is not, however, the direct source of degradation of 
cellular proteins, acting mostly on a specific set of target proteins (Hengartner 2000). While 
in many cases this leads to inactivation of the protein in question, caspases can also activate 
proteins (most notably other caspases), either indirectly by cleaving off a regulatory 
subunit, or directly by removal of a negative regulatory domain. With hundreds of 
associated mechanisms, we can attribute most of the characteristic features of apoptosis to 
caspase activity, from the cleavage of nuclear lamins necessary for nuclear shrinking, to the 
loss of cell shape caused by cleavage of cytoskeletal proteins, to the activation of the DNA 
ladder nuclease (Enari et al. 1998; Taylor, Cullen, and Martin 2008).  
The Extrinsic Pathway 
 The death receptor associated (extrinsic) pathway is first activated upon the binding 
of a member of the death receptor superfamily; in the bone microenvironment (specifically 
the osteoclast), one might observe binding of CD95 ligand (FasL) to the CD95 (Fas) 
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receptor, or TRAIL to TRAIL-R1 or -R2 (Roux et al. 2005). Binding of the receptor leads 
to a clustering (typically a trimerization), and the subsequent formation of a death inducing 
signal complex (DISC), whose recruitment is made possible by uniting the intracellular 
death domains of the individual receptor subunits (Curtin and Cotter 2003). Continuing the 
example of Fas, via the adaptor molecule Fas-associated death domain protein (FADD), the 
DISC recruits multiple procaspase-8 molecules, not yet in their active forms. This process 
brings them close enough together to induce auto-cleavage by proximity (Chang et al. 
2003). From this stage, the newly activated caspase-8 can cleave procaspase-3, activating it 
in turn and signifying the initiation of the caspase cascade to apoptosis (Figure 7). This step 
can be blocked by the caspase homolog caspase-8 (FLICE)-like inhibitory protein (c-FLIP), 
which while very similar to caspase-8, lacks capability of activity in its c-terminal caspase-
like domain (Budd, Yeh, and Tschopp 2006).  
The Intrinsic Pathway 
 The intrinsic or mitochondrial pathway is often employed by cells in response to 
extracellular stimuli (despite the name), and internal deterioration like DNA damage (Fulda 
and Debatin 2006). Though there are many possible mechanisms of onset, they each 
converge at the mitochondria, typically through activation of one of the pro-apoptotic 
members of the Bcl-2 family. Pro-apoptotic signals, via proteolysis, dephosphorylation, or 
other processes, redirect and activate Bcl-2 family members like Bid, Bad, Bim, and Bax 
from the cytoplasm to the mitochondria (Czabotar et al. 2014). At the mitochondrial 
surface, anti- and pro-apoptotic Bcl-2 family members convene, competing to inactivate 
one another to regulate the mitochondrial response. If the pro-apoptotic proteins prove to be 
greater in number or effectiveness, an array of molecules is released from within the 
mitochondria (Czabotar et al. 2014). The most notable among these is cytochrome c, which, 
once free, associates with Apaf-1, a protein with a caspase recruitment domain (CARD). 
Interaction with cytochrome c allows it to form a heptamer, which binds and cleaves 
procaspase-9 (Czerski and Nuñez 2004). 
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Figure 7 : The Intrinsic and Extrinsic Pathways of Apoptosis 
Apoptosis can be triggered by death receptor activation (extrinsic) or mitochondrial stress 
(intrinsic). The binding of an osteoclast apoptosis inducer like FasL to its receptor results in the 
recruitment of the initiator caspase 8 to a trimerized receptor-ligand complex (DISC), via the 
adaptor molecule Fas-associated death domain protein (FADD). This recruitment leads to cleavage 
and activation of caspase 8. Stress-induced apoptosis is directed by release of proteins such as 
cytochrome c from the inter-mitochondrial space. The release of these proteins is partly regulated 
by Bcl2 family members, with both pro-and anti-apoptotic members participating (Bax, Bak and 
tBid, or Bcl2/Bcl-XL, respectively). These proteins inhibit or promote the release of cytochrome c, 
which once released, binds to apoptotic protease-activating factor 1 (Apaf1), leading to the 
formation of the Apaf1-caspase 9 apoptosome complex, activating initiator caspase 9. Here the 
intrinsic and extrinsic pathways converge, with caspase 9 or 8 activating the effector caspases 3, 6 
and 7, which cleave cellular substrates, and cause the classical biochemical and morphological 
changes associated with programmed cell death. 
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The Apaf-1 oligomer complete with active caspase-9 is referred to as the 
apoptosome, and following this step, the intrinsic and extrinsic pathways converge, with the 
apoptosome cleaving procaspase-3, -6, or -7. These effector caspases go on to cleave other 
vital intracellular proteins, pushing the cell through apoptosis. At this point the cell is 
effectively committed to “programmed death”. As with any step of apoptosis, there exist 
multiple controls; the activation and activity of caspase-3 can be antagonized by members 
of the inhibitor of apoptosis (IAP) family (Portt et al. 2011). However, for this inhibitor 
there is also a counterbalance, in this case regulated by the mitochondria. When the 
intrinsic pathway is activated, or with significant caspase activation post-apoptosome 
formation, the mitochondria releases the Smac/DIABLO protein, an inhibitor of IAPs 
(Adrain, Creagh, and Martin 2001).  
Regulation of Remodeling 
 Within the skeletal system, apoptosis is a key governor of development and 
maintenance, and the regulation of those molecules that moderate it is critical. While 
apoptotic signals can be induced by cytokines, hormones, and growth factors alike, 
ultimately the effect of the stimulant is dependent on the cell upon which it will be acting 
(Taylor, Cullen, and Martin 2008). TNF-α, for example can induce apoptosis via caspase -8 
and -10 activation, but can also inhibit it via NF-κB stimulation, depending on 
concentration, cell type, and other contextual factors. 
Osteoblast numbers are maintained at steady levels in part by their development to 
osteocytes and bone-lining cells, but more often, simply via apoptosis. In contrast with the 
osteoclast, while nearly 70% of bone-depositing osteoblasts will undergo this process, they 
rarely visibly exhibit chromatin clumping or nuclear fragmentation (Landry et al. 1997). 
Therefore, apoptotic osteoblasts must be identified by morphology and location, in 
combination with techniques like TUNEL in order to detect DNA breaks (Silvestrini et al. 
1998; Mutijima et al. 2014). Apoptotic osteocytes are easier to identify, as they exhibit 
condensed chromatin and degraded DNA, but given their location, are considerably more 
difficult to locate and observe. Unlike with osteoblasts (or any other bone cell, for that 
matter), apoptosis of the osteocyte is indicative of the “death” of the region of bone for 
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whose maintenance it has been responsible. New osteocytes cannot simply fill in the place 
of the old, unlike many other cell types. Therefore, osteocyte apoptosis is often 
accompanied by osteoclast recruitment signaling, allowing for resorption followed by 
renewal of the bone in that area (Al-Dujaili et al. 2011). 
Fas and its ligand, as well as TNF and TRAIL receptors have all been shown to be 
expressed in osteoblasts and osteocytes in vitro, and that stimulation of these cells with 
TNF or FasL induces apoptosis (Hock et al. 2001). Conditional knockout of FasL in 
osteoblasts lead to elevated osteoclast activity and numbers along with decreased bone 
mass, suggesting that this apoptotic pathway is required for healthy maintenance of bone 
mass (Wang et al. 2015). The importance of the balance of apoptotic receptors can be 
demonstrated by osteoblasts in bone samples from postmenopausal women. Compared with 
premenopausal women of the same age, their osteoblasts showed increased expression of 
Fas mRNA and protein levels, consistent with their increased sensitivity to FasL-induced 
cell death (García-Moreno et al. 2004). One can see how the onset of osteoporosis in these 
women may be related to the increased susceptibility to apoptosis exhibited by the cells 
responsible for bone formation. 
Osteoblasts can also be de-sensitized to apoptosis, by growth factors such as FGF, 
TGF-j8 and others (Debiais et al. 2004). IGFs upregulate calbindin-D28k, a molecule 
which then binds caspase-3, inactivating it in the process (Bobay et al. 2012). Inactivation 
of caspase-3 by this pathway blocks TNF-induced apoptosis in osteoblast-lineage cells (T 
Bellido et al. 2000). FGF activity is slightly more indirect, involving PI3K activity and the 
eventual promotion of anti-apoptotic signaling downstream of Akt (Park et al. 2009). The 
matrix metalloproteinases (MMPs) responsible for degrading collagen have also been 
associated with osteoblast survival as well, likely through the release of growth factors 
associated with the collagenous matrix as bone is processed (Karsdal et al. 2004). 
Ordinarily, this feedback helps maintain the rapid post-resorption modeling response. TNF-
induced apoptosis can be blocked or reduced by other factors like fluid shear stress or BMP 
stimulation (Tan et al. 2006). TGF-β inhibits osteoblast apoptosis by decreasing the ratio of 
Bax to Bcl-2 (Dufour, Holy, and Marie 2008). Furthermore, deletion of Smad3, a necessary 
intracellular intermediary of TGF-β, leads to decreased bone formation attributed to shorter 
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osteoblast and osteocyte lifespan (Borton et al. 2001). Highlighting the cell-specific role of 
apoptosis inducers, even within the bone microenvironment, our laboratory has shown that 
TGF-β also regulates remodeling by directly inducing apoptosis in resorbing osteoclasts via 
the Smad3 pathway (Houde et al. 2009).  
However, like TGF-β in the case of osteoclasts, some growth factors regulate 
apoptosis in a positive manner in osteoblasts. For example, while BMP-2 is a stimulator of 
bone formation, it is also capable of promoting cell death through the expression of various 
caspases as well as the release of cytochrome c from the mitochondria. This pathway has 
been shown to be PKC activation dependent (Haÿ et al. 2001). Mechanical strain, while 
generally positive for bone health and formation, also leads to induction of apoptosis in 
osteocytes (Bonewald 2006). Once these cells detect changes in bone strength and 
microdamage via their canalicular system, intrinsic apoptosis is induced, leading to the 
recruitment of resorbing osteoclasts through site-specific repair signaling, and eventually 
reinforcement of the area with more bone.  
The modulation of osteoclast apoptosis is a growing domain, with many negative and 
positive regulators already identified. PTH and Vitamin D have already been identified as 
stimulatory factors of bone resorption, and one mechanism of this is their association with 
increased osteoclast survival and activation. While they may be operating through multiple 
channels, the most likely cause of this is their mutual induction of expression of RANKL 
by osteoblasts and stromal cells, as well as decreasing expression of its regulatory partner 
OPG (Huang et al. 2004). The increase in RANKL is caused by modulating transcription of 
Runx2, the transcription factor responsible for RANKL expression. Other factors like 
RANKL associated with osteoclastogenesis and osteoclast activation also support 
osteoclast survival, as is the case of M-CSF, IL-1, and TNF (Glantschnig et al. 2003). 
Recalling that RANKL signal transduction includes TRAF6 and PI3K activity, 
phosphorylating Akt, this promotes survival via Akt phosphorylation of BAD and caspase-
9, preventing their pro-apoptotic activity (Song et al. 2005). Given that they are members of 
the same TNF family, IL-1 and TNF trigger a similar cascade, protecting against apoptosis 
(Royuela et al. 2008). Interestingly, this mechanism is not critical to M-CSF-mediated 
survival, despite the fact that M-CSF also activates PI3K, Akt, and ERK to propagate its 
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signal. One hypothesis explaining the anti-apoptotic effect of M-CSF attributes 
upregulation of Bcl-2, Bcl-xL, and XIAP to ERK activity following receptor coupling 
(Akiyama et al. 2003). M-CSF significantly augments resorption without further activating 
NF-κB or NFATc1 in RANKL-stimulated osteoclasts, but while increasing 
phosphorylation of ERK (Hodge et al. 2011). Since these anti-apoptotic genes are also 
upregulated by TNF signaling, it is possible that ERK modulates osteoclast survival via this 
gene modulation in osteoclasts as well.  
Osteoclast apoptosis is not induced by calcitonin, though it does induce their 
detachment and inhibit resorptive activity as well as differentiation, in part through TRAP 
inhibition independent of NF-κB (Granholm, Lundberg, and Lerner 2007). This adds to the 
long-standing proposition that apoptosis is not the sole method by which osteoclastic 
resorption can be halted (Kallio, Garant, and Minkin 1972). Nitric oxide is another known 
apoptosis inducer in the osteoclast, through protein kinase A and eventual caspase-3 
activation (Kanaoka et al. 2000). Interestingly, despite its potent osteoclastogenic role, 
TNF-α can induce apoptosis in mature osteoclasts in vitro under certain conditions (Abbas 
and Abu-Amer 2003).  
Over the past decade, there is increasing evidence suggesting that changes in the 
regulation of programmed osteoclast death may be an important contributing factor to bone 
diseases. Likewise, induction of osteoclast apoptosis or re-sensitizing these cells to 
apoptotic signaling represents a potential therapeutic tool (Roux and Brown 2009). One 
intriguing apoptosis inducer in osteoclasts is TRAIL, or TNF-related apoptosis-inducing 
ligand, a ligand with multiple death and decoy receptors in osteoclasts (McManus et al. 
2012). In multiple myeloma, where overactive B-cells lead to an aggressive osteoclast 
phenotype, TRAIL has been used to specifically target primary cancer cells (Lincz, Yeh, 
and Spencer 2001). Current treatments for several bone diseases involve induction of 
osteoclast apoptosis. Bisphosphonates, the most popular treatment for osteoporosis, the 
most common metabolic bone disorder, have positive effects on osteoblasts and osteocytes, 
but are perhaps best characterized by their ability to induce osteoclast death and prevent 
their function (Drake, Clarke, and Khosla 2008). Bisphosphonates attach to hydroxyapatite 
binding sites on the bone, and when osteoclasts resorb bone, the bisphosphonate released 
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impairs the ability of osteoclasts to form the ruffled border, and to produce the protons 
necessary for continued resorption (Colucci et al. 1998). In addition to preventing 
resorptive activity, current nitrogen-containing bisphosphonates then bind to and inhibit 
activity of farnesyl pyrophosphate synthase, which is a vital regulatory enzyme in the 
mevalonic acid pathway (Kavanagh et al. 2006). This limits cholesterol synthesis as well as 
post-translational modifications to proteins like Rab, Rac and Rho, who are vital in the 
regulation of core osteoclast activities, including survival (Drake, Clarke, and Khosla 
2008). Thus, modulating osteoclast apoptosis is a central part of the current treatment 
paradigm for bone diseases. 
 
Autophagy and Skeletal Maintenance 
Ubiquitin-Proteasome System 
There are two major pathways responsible for regulated protein degradation; 
autophagy and the ubiquitin-proteasome system (UPS). For many short-lived, regulatory, or 
defective proteins, the UPS is the primary pathway followed (Vilchez, Saez, and Dillin 
2014). Autophagy is traditionally associated more with degradation of long-lived proteins 
and the maintenance of amino acid reserves under stress conditions (Feng et al. 2014). 
Though once viewed as completely independent mechanisms, recent studies show that they 
may be more than just complementary, using common adaptors that are capable of 
directing ubiquitinated substrates to both pathways.  
A host of basic cellular processes are dependent on the UPS for normal function, 
from protein turnover to quality control, signal transduction, metabolism, cell death, and 
more (Tai and Schuman 2008). The post-translational modification of ubiquitination may 
serve as a degradation signal for proteins, but can also impact their activity, localization, 
and function within the cell. K48 ubiquitin chain formation is associated primarily with 
proteasomal degradation, while K63 or K11 are associated with other, non-proteolytic 
functions, such as gene transcription, cell cycle progression, and apoptosis (Welchman, 
Gordon, and Mayer 2005). Recent work has shown, however, that all types of 
ubiquitination can target substrates for autophagic degradation, representing a major 
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crossover point between the two pathways (Walinda et al. 2014). In order to covalently 
bond free ubiquitin to a target protein, an ubiquitin activating enzyme (E1) must interact 
with the carboxyl terminus of ubiquitin. The process is then dependent on a second partner, 
a ubiquitin-conjugating enzyme (E2). After this step, E2 associates with ubiquitin-ligates 
(E3s), which binds the substrate and affixes the ubiquitin molecule. In the case of some E3s 
(those possessing a RING-domain, for example), the protein does not directly bond to the 
substrate while attaching the ubiquitin, but rather acts as a scaffold, holding an E2 close and 
catalyzing ubiquitin transfer (Petroski and Deshaies 2005). 
Autophagy 
Macroautophagy (hereafter referred to as autophagy) is a process highly conserved in 
eukaryotic cells. It is crucial for nutrient homeostasis; recycling proteins and organelles. 
Proteins, aggregates, damaged organelles, invading microbes, and other materials within 
the cytoplasm are targeted for degradation, and transported to double-membraned vesicles 
initially called phagophores, which develop into autophagosomes. Then, fusion with 
lysosomes produces autolysosomes, allowing for degradation and eventual recycling of the 
vesicle's contents (Feng et al. 2014). In all cells, basal autophagy occurs at low levels, is 
necessary for maintenance of homeostasis, and can be upregulated under oxidative stress, 
hypoxia, starvation, or other stresses. Since autophagy is vital to a number of normal 
physiological processes, defective autophagy is increasingly associated with diseases, from 
Huntington’s, to cancer, and Paget’s disease of bone.  
Perhaps the main pathway regulating autophagy is that of the mammalian target of 
rapamycin (mTOR) protein, a highly conserved serine/threonine kinase that acts as a 
nutrient sensor (Jung et al. 2010). mTOR is a part of the eponymous mTORC1 complex, 
involving among other proteins Raptor and mLST8 (Dibble and Manning 2013). The 
formation of the autophagosome is a multistep process involving at least 15 known 
autophagy (ATG)-related proteins which must be recruited to the pre-autophagosomal 
structure (PAS) (Figure 8). Autophagy initiation is mediated by the UNC-51-like kinase 
(ULK) complex, which is comprised of ULK-1/2, ATG-13, -100, and FIP200 (Hosokawa 
et al. 2009). Under nutrient-rich conditions, mTORC1 is able to negatively regulate this 
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complex through the phosphorylation of ATG 13 and of ULK-1 at its Ser555 (He and 
Klionsky 2009). In contrast, in starvation conditions, proteins within the complex are 
phosphorylated as well, but in this case at activating rather than inhibitory sites (Ganley et 
al. 2009). Phosphorylation of ULK-1 at sites including Ser757 triggers the translocation of 
another multiprotein complex containing a number of proteins including Beclin-1 and PI3K 
CIII from the cytoskeleton to a pre-autophagosomal structure, initiating autophagosome 
formation. PI3P generated by PI3K CIII activity binds WD-repeat protein interacting with 
phosphoinositides (WIPI) effectors, and mediates the initial stages of autophagosome 
formation (Polson et al. 2010). Elongation and closure of the phagophore requires two 
complexes containing ubiquitin-like proteins, along with several SNARE proteins (Moreau 
et al. 2011). The first of these complexes includes ATG7 and ATG10, which conjugate 
ATG12 to ATG5, which in turn binds to ATG16. This first complex targets the second 
ubiquitin-like conjugation system to the PAS. Once at the PAS, phosphatidyl-ethanolamine 
(PE) is conjugated to the microtubule-associated light chain 3 (LC3), a yeast ATG8 
homolog. It is first processed by ATG4, activated by ATG7, and transferred to ATG3 
conjugating enzyme, where it is conjugated with PE (Rubinsztein, Shpilka, and Elazar 
2012). LC3-PE, or LC3-II, is a crucial membrane protein in autophagy, frequently used as a 
marker of autophagic activity.  
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Figure 8 : Mechanisms of Autophagy 
Initiation of macroautophagy begins with phagophore assembly site (PAS) formation. This is 
mediated by the ULK complex, consisting of ULK1, autophagy-related protein 13 (ATG13), FAK 
family kinase interacting protein 200 (FIP200), and ATG101. Nucleation relies on the class III 
PI3K complex, composed of vacuolar protein sorting 34 (VPS34) PI3K and its regulatory subunits 
ATG14L, VPS15, and beclin 1. Finally, elongation of the phagophore membrane and formation of 
the autophagosome require two conjugation pathways. One results in the conjugation of 
phosphatidyl-ethanolamine (PE) to LC3, required for expansion of autophagic membranes, their 
ability to recognize autophagic cargo, and fusion of autophagosomes with lysosomes. The other 
pathway produces an ATG5-ATG12 conjugate, which along with ATG16L promotes conjugation of 
PE to the autophagosome. The resulting autophagosome can fuse with endocytic and lysosomal 
compartments, creating the autolysosome and resulting in the degradation of its contents via 
lysosomal hydrolases. In chaperone-mediated autophagy, substrates with the pentapeptide motif 
KFERQ are recognized by the chaperone protein heat shock cognate 70 (HSC70), and translocated 
to lysosomes in a LAMP2A-dependent manner. Selective autophagy is mediated by autophagy 
cargo receptors like p62, which interact with both the autophagic substrate, and the autophagosome 
via an LC3-interacting region (LIR).  
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The activity of the autophagy machinery is regulated by upstream signals, many of 
which (growth factors, amino acids, glucose and energy status) are integrated by the kinase 
activity of mTORC1 (mammalian target of rapamycin complex 1). The induction of 
autophagy occurs by mTORC1 inhibition, resulting from starvation or exposure to 
rapamycin. The rapamycin-induced association of Raptor with mTOR, the catalytic subunit, 
inhibits mTORC1 kinase activity (Kim et al 2002).  By interacting with Raptor, p62 provides 
an alternative docking site in the modulation of mTORC1 activation (Duran et al 2011). 
Selective Autophagy 
Some autophagic cargo can be identified and directed to lysosomes. This process 
operates under both nutrient-poor and –rich conditions, and is characterized by specialized 
autophagosomes, which sequester substrates in a specific manner (Johansen and Lamark 
2014). Each category of what can be referred to as selective autophagy bears a name 
depending on its specific target. Mitophagy is the selective removal of excess or defective 
mitochondria (Dengjel and Abeliovich 2014), while pexophagy describes peroxisome 
degradation (Dunn et al. 2005). Two final selective processes are xenophagy; responsible 
for removal of pathogenic intracellular microorganisms like viruses, and aggrephagy: a 
process by which misfolded and irregular protein aggregates are cleared (Wileman 2013; 
Hyttinen et al. 2014). In each of these cases, the specificity is ensured primarily by specific 
adaptor proteins; ones with at least two functional domains. Of these domains, one must of 
course recognize the target protein, and the other must be capable of transporting said (oft 
ubiquitinated) target to the site of the autophagic operation (Lippai and Lőw 2014). In this 
way, the cargo is delivered to the inner surface of the nascent phagophore, a process which 
is typically also marked by interaction between the adaptor protein and membrane-
anchored LC3. In selective autophagy, adapter proteins such as p62, NBR1, or optineurin 
can play a key role by tethering cargo to the site of autophagosomal engulfment. 
The recognition of ubiquitinated proteins in autophagy is mediated by the interaction 
of ubiquitin-binding domains interacting non-covalently with ubiquitin. The scaffold p62, 
despite originally associated with cell growth and proliferation, was the first protein 
identified to possess this adaptor function, and can be detected in ubiquitinated protein 
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aggregates (Pankiv et al. 2007). Murine and Drosophila knockout studies showed that p62 
is necessary for formation of aggregates of ubiquitinated proteins, thereby essential for 
autophagic clearance (Lamothe, Webster, et al. 2007; W. Jin et al. 2008b). p62 levels are 
typically inversely correlated with autophagy, as the loss of autophagosome/lysosome 
fusion leads to an increase in p62-positive aggregates that have not been degraded 
(Kovalenko et al. 2003). 
The Role of p62 in Autophagosome Formation and Autophagy Regulation 
Since individual interactions between p62 and ubiquitin are relatively weak, the 
initiation of aggregate formation is dependent on p62 self-oligomerization via the PB1 
domain (Kirkin et al. 2009). In addition, recent studies have shown that p62 is not simply a 
shuttle, but that in some cases, these aggregates may serve as a nucleating scaffold from 
which autophagosomes form, through the binding of multiple Atg proteins (Zhao et al. 
2012). It has been reported that phagophores can preferentially form at these scaffold sites 
when they are located near lysosomes, in a model consistent with pre-autophagosomal 
structure formation in yeasts (Jin et al. 2009). P62 can shuttle between the nucleus and the 
cytoplasm, and has been posited to recruit proteasomes to nuclear protein aggregates. It can 
also export ubiquitinated proteins from the nucleus to the cytosol, where more thorough 
autophagic processes can take place (Pankiv et al. 2010). p62 is an interacting partner of the 
mTORC1 complex, as well (Duran et al. 2011). mTORC1 is active when bound to 
lysosomes, inhibiting autophagy through phosphorylation of ULK1/2 (Kim et al. 2011). 
Together, these results suggest that there is a direct assembly of early autophagic structures 
at the site of protein aggregates, and that this may be mediated by interactions between p62 
and upstream Atg proteins. Later in the process of autophagosome formation, LC3 is 
recruited to phagophore in development, and the formation of the double membrane will be 
made possible by interactions between p62, LC3, and other autophagy proteins (Alemu et 
al. 2012). Along with ubiquitinated proteins with which it is associated, p62 is transported 
into autophagosomes, suggesting that p62 is the receptor for these proteins, responsible for 
directing them to lysosomal degradation (Bjørkøy et al. 2005). This localization is made 
possible by the LRS (LC3 recognition sequence) (Figure 6) of p62, located between the 
zinc-finger and UBA domains, where its residues interact with the N-terminus and 
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ubiquitin domain of LC3 (Ichimura et al. 2008). However, knockout of p62 does not appear 
to significantly affect levels of ubiquitinated proteins in the cell, possibly due to 
compensatory activity by neighbor of BRCA1 gene 1 (Nbr1), a protein which interacts with 
LC3 in a manner similar to p62 (Kirkin et al. 2009). Loss of Nbr1 in a mouse model led to 
perturbation of p62 levels, and hyperactivation of the MAPK p38, favoring 
osteoblastogenesis and an osteopetrotic phenotype.  
Crosstalk Between Apoptosis and Autophagy 
The outcomes of autophagy primarily favor cell survival, though a complex crosstalk 
exists between autophagic and apoptotic pathways (Gump and Thorburn 2011). While p62 
is implicated in selective autophagic degradation of many proteins, it is also involved in 
several apoptotic and survival pathways. As noted, RANKL stimulation contributes to 
osteoclast survival through p62-driven activation of MEK/ERK and NF-κB pathways (Yip 
et al. 2006). However, similar to its dual role with TRAF6 and CYLD, p62 also interacts 
with caspase-8 following death receptor ligation, and is crucial for caspase-8 activity by 
promoting aggregation, leading to processing and full activation (Jin et al. 2009). As a 
regulatory mechanism for this pathway, p62 may be cleaved by caspases 6 and 8 in 
response to death receptor activation, and all three may be degraded by autophagy as a 
means of regulating apoptosis (Hou et al. 2010). Thus, autophagy-associated proteins affect 
the efficiency of apoptosis, and conversely, apoptotic pathways may influence p62-
dependend autophagy. 
Autophagic Defects and Bone Diseases 
In recent years, evidence has pointed to more and more cases in which defective 
autophagy is associated with bone cell dysfunction. Autophagy increases in osteoblasts 
during differentiation and mineralization (Nollet et al. 2014), and inhibition leads to 
decreased bone mineralization (Liu et al. 2013). More germane to this discussion, however, 
is the necessity of autophagy in the maintenance of normal osteoclast function. In, 2011, 
autophagy was first demonstrated to play a role in osteoclast differentiation, where 
knockdown of Atg7 inhibited expression of TRAP and CTSK on precursors (Wang et al. 
2011). Normally this expression is mediated by the induction of MCPIP (monocyte 
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chemotactic protein-induced protein), a zinc-finger protein whose activation leads to 
upregulation of Beclin-1, autophagy, and oxidative stress (Younce and Kolattukudy 2010). 
Beclin-1 has more recently been shown to have a direct role in RANKL-induced 
osteoclastogenesis through the induction of NFATc1 as well as the production of reactive 
oxygen species (Chung et al. 2014). Autophagy also mediates osteoclastogenesis under 
several other conditions including hypoxia and even microgravity (Zhao et al. 2012; 
Sambandam et al. 2014). In addition, RANKL stimulation of osteoclast precursors has been 
shown to lead to TRAF3 degradation via autophagy. As TRAF3 is a suppressor of 
RANKL-induced osteoclast formation, this is another mechanism by which autophagy is 
involved in osteoclast differentiation (Xiu et al. 2014).  
Differentiation is not the only aspect of osteoclast activity that may be regulated by 
autophagy. However, with regards to osteoclast function, the function of autophagy is not 
yet well defined compared to recent findings involving Atg-family proteins. Some 
autophagy-related proteins, including Atg5, Atg7, and LC3 perform autophagy-independent 
roles in ruffled border formation, secretory activity, and bone resorption. The presence of 
LC3-II within the membrane of the ruffled border promotes fusion with secretory 
lysosomes, which contribute to the acidic environment necessary for resorption (DeSelm et 
al. 2011). Atg5, in turn, is necessary for the recruitment of LC3-II to said membrane, and 
murine knockout of Atg5 leads to improved outlook following ovariectomy, reducing bone 
loss. In the case of LC3, it has been demonstrated that while osteoclast activity corresponds 
to LC3-I conversion to LC3-II, it is not dependent on an increase in autophagic flux (Chung 
et al. 2012). In this same article, LC3 silencing suppressed actin ring formation, the release 
of cathepsin K, and ultimately the capacity to resorb bone.  
Optineurin (Optn) is an autophagy receptor involved in the autophagic clearance of 
protein aggregates (Korac et al. 2013). In addition, its involvement in several other 
processes including the regulation of NF-κB have been reported (Kachaner et al. 2012). 
Like p62, this protein is important both to bone biology and regular autophagic activity, 
and there may be a link between these two functions.  
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As normal bone development, survival, and function have been linked to autophagy, 
likewise, a growing number of diseases are now associated with dysfunctional autophagic 
processes. The bone resorptive disorder ARO, or autosomal recessive osteopetrosis, for 
example, is characterized by osteoclasts that are unable to resorb immature bone, leading to 
abnormal marrow cavity formation as well as irregular remodeling leading to brittle bones. 
Most mutations associated with this disease are associated with impaired endosomal and 
lysosomal vesicular trafficking (Sobacchi et al. 2013). ARO osteoclasts are 
morphologically normal, yet defective formation of the ruffled border eliminates their 
capacity for resorption. Murine models have shown that defects in the a3 subunit of the V-
ATPase leading to ARO also present defects in early stage autophagy, with observed 
increases in p62 and LC3-II expression (Ochotny et al. 2013).  
The most common bone fragility syndrome is osteoporosis, affecting one out of three 
women and one out of six men over 50 years of age (Sànchez-Riera et al. 2010). Though 
loss of sex steroids are a major contributor, many of the molecular mechanisms of age-
related bone loss are not fully identified (Manolagas and Parfitt 2010). In genome-wide 
association studies, a link between autophagy genes and osteoporosis has been shown, 
suggesting a connection between the two. Additionally, oxidative stress has been identified 
in several instances as a key factor, suggesting a role for autophagy. However, to date, 
returns on research linking autophagy to aging have been mixed. Autophagic activity is 
reduced with age in varying organs, from skeletal muscle, to the kidney, pancreatic islets, 
and more (Wohlgemuth et al. 2010; Cui et al. 2012; Liu et al. 2013). In bone, recent studies 
in rats described an age-related increase in p62 expression and apoptosis in osteocytes, but 
a decreased expression in LC3-II, Beclin-1, and ULK-1, as well as decreased osteocyte 
autophagy (Chen et al. 2014). Therefore, an increase in oxidative stress associated with 
diminished autophagy may be a factor in bone loss. Yet, oxidative stress was shown to 
increase autophagy in osteocytes in a murine ovariectomy model (Yang et al. 2014). More 
studies are needed to determine if reduced autophagy contributes to bone loss following 
estrogen reduction/deprivation. To date, the majority of these studies have focused on 
osteocyte contributions, as they are by far the longest-lived cells in the bone 
microenvironment, and key regulators of bone remodeling. However, it would be prudent 
for future studies to include analysis of the effectors of the resorption step of remodeling, 
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the osteoclast, when possible. While autophagy appears to be a promising target for therapy 
in bone pathologies, mixed results from some of the studies cited may be mitigated by an 
alternate osteoclast autophagic phenotype.  
 
Paget’s Disease of Bone 
Pathophysiology and Osteoclast Phenotype 
First reported by Sir James Paget in 1876 and originally named osteitis deformans, 
Paget's disease of bone is found in approximately 3% of the population above the age of 50 
(Luis Corral-Gudino et al. 2013). In most patients, this disease manifests itself in one or 
several bones, and remains localized. The earliest radiological signs are localized areas of 
osteolytic activity, caused by an increase in the number of osteoclasts (Maldague and 
Malghem 1987). While not the only cell affected, it is primarily the osteoclast that is altered 
in Paget’s disease, and the initial phase of the disease is characterized by excessive bone 
resorption. Osteoclasts identified in pagetic lesions are both larger and more numerous 
(Hosking 1981), and have been observed with up to 100 nuclei; five to twenty times more 
than normal osteoclasts (Roodman and Windle 2005). Another characteristic feature of 
these cells are nuclear inclusions, consisting of paracrystalline arrays similar to viral 
nucleocapsids. These inclusions are not observed in other bone cells in the lesion, or in 
non-pagetic bone in patients with Paget’s disease (Rebel et al. 1980).  
 In addition to these morphological changes, the physiology of the pagetic 
osteoclast and its precursors is altered. Osteoclast precursors are hypersensitive to 
osteoclastogenic factors like 1,25-(OH)2D3 and RANKL (Neale et al. 2000), needing 10-
100 times less of these factors in order to initiate osteoclastogenesis. Additionally, 
osteoclasts isolated from pagetic patients have been shown to be more resistant to apoptotic 
stimuli, and possess a higher resorptive capacity than their normal counterparts, further 
compounding their efficiency (Chamoux et al. 2009). 
Eventually, the osteolytic lesions first seen in the disease develop into irregular 
sclerotic lesions, due to increases in the numbers of osteoblasts, responding to signals from 
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the resorbing osteoclasts (Singer 2015). Following progression from the osteolytic to the 
sclerotic phase of the disease, the bone typically becomes enlarged, deformed, and fragile. 
Diagnosis is rare under the age of 50, a product of the slow evolution of the disease, as 
onset models suggest the disease likely begins development before the age of 30, despite 
extremely rare diagnoses at this age (Renier and Audran 1997). 
Genetics 
A considerable number of patients with Paget's disease have at least one family 
member who has been diagnosed as well, estimated to be between 12-14% in the USA and 
UK (Sofaer, Holloway, and Emery 1983; Siris et al. 1991), strongly suggesting a role for 
genetic factors in the pathogenesis of the disease. The first specific gene abnormality 
associated with familial PDB was published in 2002, chronicling a mutation present in 18 
of 112 patients with Paget's disease (Laurin et al. 2002). This shared mutation was found in 
the sequestosome-1 (SQSTM1) gene, coding for the ubiquitin-binding protein p62, located 
on chromosome 5. This mutation of proline to leucine on the 392nd amino acid (P392L) is 
located in the ubiquitin-associated domain, or UBA of the protein. Since the first identified 
SQSTM1 mutation, at least 25 other mutations, (the majority of which in the UBA domain 
as well), have been identified in familial PDB. However, P392L remains by far the most 
common, represented in 20-50% of familial cases worldwide (Rea et al. 2013). The 
majority of these mutations enhance NF-κB activity in vitro, a change associated with 
increased numbers of bone lesions in affected patients (Goode et al. 2014). Haplotype 
analysis carried out in 2005 found commonality in over 90% of both familial and sporadic 
cases of Paget's disease (Lucas et al. 2005), suggesting the presence of a founder effect; a 
common ancestor between patients all over Europe and North America (Chung et al. 2008; 
Michou et al. 2011).  
Sporadic Paget's disease can generally be defined as those cases observed in a 
patient with no familial history of PDB. However, a proportion of these may in fact be 
familial, given that Paget's is often asymptomatic and undiagnosed. In Québec, 16% of 
sporadic PDB cases had germline SQSTM1 mutations (Laurin et al. 2002), and elsewhere in 
the world, rates are at roughly 5% (Rhodes et al. 2008; Falchetti et al. 2009). In one 
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transatlantic study using 376 patients, no germline P392L mutations were identified, but 
somatic mutations were found in 4.8% of the patients, and likewise in 1.4% of control 
individuals (Fecto 2011). 
Manifestation of the disease in patients with the SQSTM1 mutation has been 
reported as more severe than those who do not (Visconti et al. 2010), but the presence of 
the mutation alone does not appear to assure that an individual will develop the disorder 
(Morissette, Laurin, and Brown 2006). Since this mutation is not present in all familial 
PDB despite an established founder effect, genome-wide association and candidate gene 
analysis studies have been undertaken to identify other possible genetic links. At present 
time, 15 susceptibility loci have been identified for Paget's disease, the majority of which 
are tied closely to osteoclast differentiation and activity (Singer 2015). Of these, 67% of the 
genetic risk for Paget's is estimated to come from variants of genes coding for M-CSF, 
Optineurin, DC-STAMP, and RANK, all modulators of osteoclastogenesis (Chung et al. 
2010). Single nucleotide polymorphisms in TNFRSF11A, coding for RANK, have been 
proposed to magnify the effect of SQSTM1 mutations, increasing the severity of Paget's 
(Gianfrancesco et al. 2012).  
There are a few rare autosomal dominant skeletal disorders resembling PDB that 
develop resulting from TNFRSF11A insertion mutations (Ke et al. 2009) that lead to 
increased osteoclast activity. In addition, a disorder with overproduction of RANK 
resulting in osteopenia shows enlarged osteoclasts with nuclear inclusions like those seen in 
Paget's disease, though no cytoplasmic inclusions like with PDB have been observed 
(Dickson et al. 1991). Juvenile Paget's disease is a rare autosomal recessive disorder 
typically associated with loss-of-function mutations to TNFRSF11B, the decoy receptor of 
RANK: Osteoprotegerin (Whyte et al. 2002). From early childhood, patients are susceptible 
to fractures and deformities caused by accelerated remodeling initiated by excessive 
osteoclast numbers.  
The rare Inclusion Body Myopathy, Paget's disease and Frontotemporal Dementia 
(IBMPFD) is autosomal dominant, but with incomplete penetrance (Weihl, Pestronk, and 
Kimonis 2009). 90% of these patients have inclusion body myopathy, 50% PDB, and 30% 
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frontotemporal dementia. The syndrome appears to originate from mutations in the 
valoisin-containing protein (VCP) on chromosome 9. Also known as transitional 
endoplasmic reticulum ATPase, VCP regulates many cellular functions and is important to 
the maturation of ubiquitin-containing autophagosomes (Tresse et al. 2010). Though SNPs 
in VCP can be found in some individuals with Paget's disease, their role in the pathogenesis 
of the disease is unknown (Chung et al. 2011). Finally, though nuclear and cytoplasmic 
inclusions have been noted in muscle and brain cells of IBMPFD patients (Kimonis et al. 
2008), no studies have yet been published demonstrating this presence in osteoclasts as 
well. 
Nuclear Inclusions and Paramyxoviruses 
Nuclear inclusions in osteoclasts of patients with PDB were first observed over 40 
years ago (Rebel, Malkani, and Basle 1974), and this observation has since been 
reconfirmed in studies across the globe (Abe et al. 1995; Gherardi, Cascio, and Bonucci 
1980). These inclusions, consisting of groupings of microtubules, have been observed in 
patients with both familial and sporadic Paget's disease, and appear to be present in all 
patients with the disorder. These inclusions have been described by many groups to closely 
resemble the nucleocapsids of paramyxovirus. Interestingly, in one study, only 2 patients 
were identified in which these particles were found in the extracellular spaces of the ruffled 
border, suggesting a defect in the presumed virus (Abe et al.). One analysis of these 
microtubule structures compared samples from patients with PDB with nucleocapsids from 
two paramyxoviruses; measles virus and respiratory synctial virus (RSV) (Howatson and 
Fornasier 1982). Their results demonstrated that RSV nucleocapsids were found in the 
cytoplasm, where measles inclusions were more common in nuclei, suggesting perhaps that 
neither alone could account for the inclusions observed in PDB. Another connecting (if not 
dated) observation is that the slow viral infection of brain cells caused by measles virus 
leading to subacute sclerosing panencephalitis (SSPE) presents similar inclusion bodies, 
linking dysfunction in PDB and SSPE to measles virus through these shared inclusions 
(Baublis and Payne 1968). Inclusions have not been reported in normal bone or other 
skeletal disorders like osteoporosis.  
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In 1980 it was first reported in France that osteoclasts with patients with PDB 
reacted with measles virus and MVNP antibodies, where no reactivity was reported in 
healthy individuals (Rebel et al. 1980). Samples from 50% of patients in the USA in a 
small follow-up study were observed to stain positive for MVNP as well (Mills et al. 1984). 
These studies also found evidence of measles virus antigens in osteoclasts generated in 
vitro from pagetic bone marrow specimens (Mills et al.). However, there is no consensus 
among the scientific community regarding the potential contribution of MVNP to the 
development of Paget's disease. In three studies based in Scotland and extending to the rest 
of the UK, no evidence of measles virus RNA was found in bone specimens, cultured bone 
cells, or peripheral blood mononuclear cells, nor did immunological staining produce 
evidence of MVNP (Helfrich et al. 2000; Birch et al. 2009; Ooi et al. 2000). Neither was 
measles virus RNA detected in bone marrow or bone cell cultures isolated from Pagetic 
patients in New Zealand (Matthews et al. 2008). In a study published by perhaps the most 
vehement defenders of the MVNP hypothesis, osteoclast precursors containing MVNP and 
the P392L mutation formed osteoclasts with a Pagetic phenotype when exposed to 1,25 
dihydroxyvitamin D3 (Kurihara et al. 2011). In this model, osteoclastogenesis was blocked 
by MVNP antisense oligonucleotides, and osteoclast precursors with only the P392L 
mutation failed to respond to vitamin D3. Interestingly, precursors from both MVNP-
positive and negative PDB patients were hyper-responsive to RANKL, forming more 
osteoclasts than control cultures, but MVNP-positive osteoclasts were found to have more 
nuclei per cell. 
Animal Models of Paget’s Disease of Bone 
The Pro394Leu mutation in the mouse SQSTM1 gene is equivalent to that of 
Pro392Leu in humans. Several groups have generated these mice in an effort to determine 
its effects on osteoclasts and bone structure. In one study, mice that expressed the mutation 
had increased osteoclast numbers and progressive bone loss, but no increase in osteoblast 
numbers as seen in Paget's disease (Kurihara et al. 2007). These osteoclasts were hyper-
responsive to RANKL, exhibiting increased NF-κB signaling, but this response was not 
extended to vitamin D3, unlike PDB-derived osteoclasts. In addition, similar to the MVNP-
negative osteoclasts described in the study by Kurihara et al., these mice did not present 
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increased numbers of nuclei per osteoclast. Finally, electron microscopy did not detect 
nuclear or cytoplasmic inclusions as would be expected in Pagetic osteoclasts. These results 
suggested that while insufficient to completely generate the PDB phenotype in these mice, 
SQSTM1 mutation increases the sensitivity of osteoclast precursors and could be a 
significant predisposing factor. Similar results were obtained in a parallel knock-in study 
with the P394L mutation (Kurihara et al. 2011). Interestingly, one 2011 study in 
homozygous and heterozygous knock-in P394L mice produced differing results 
(Daroszewska et al. 2011b). Similar to previous studies, the mice presented with osteolytic 
lesions, and in this case homozygous mice had greater numbers than heterozygous mice. 
However, histological analysis showed increased bone formation in addition to the elevated 
resorption, and increased numbers of nuclei per osteoclast, both in contrast with the 
previous studies. Other experiments performed in this paper proposed a contribution of 
dysregulation of autophagy in the osteoclast precursors with the mutation, and that the 
nuclear inclusions observed may be abnormal protein aggregates as a consequence of this 
dysregulation. It is possible that the differences between these two studies may be 
explained by the localization of the bones used for the study.  
A 2006 study targeted MVNP to osteoclasts in transgenic mice, resulting in lumbar 
bone lesions in approximately 30% of these mice (Kurihara et al. 2006). The was 
performed by the same group that would later cross MVNP and P394L mice, producing 
even more pronounced lesions than either genotype alone (Kurihara et al. 2011). Osteoclast 
precursors isolated from these mice exhibited characteristics similar to PDB patients, with 
increased osteoclast size, number, and nuclei per cell, along with increased sensitivity to 
RANKL, TNF, and vitamin D3.  
The effects of the VCP mutations observed in IBMPFD have also been studied in 
transgenic mice. The model appeared to generate translatable symptoms in mice with 
respect to the brain and muscle abnormalities found in humans with IBMPFD (Custer et al. 
2010). MicroCT at 13 months showed severe osteopenia, with occasional sclerotic lesions. 
A second group also found osteolytic lesions and increased bone formation, but the mutants 
generated for this study died within 21 days of birth, making longer term analysis difficult 
(Nalbandian et al. 2012). 
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Treatment 
Initial therapies for PDB involved calcitonin administration; lowering total serum 
alkaline phosphatase and demonstrating moderate improvement of bone structure (Roth et 
al. 1996). Calcitonin inhibits osteoclast formation via an NF-κB-independent pathway 
(Granholm, Lundberg, and Lerner 2007). Various regimens of cyclic bisphosphonate 
administration have been in use for nearly 40 years, and are the mainstay of most anti-
resorptive treatment, improving turnover markers and bone histomorphometry in PDB (Tau 
et al. 2004; Cundy, Wheadon, and King 2004; Seton and Krane 2007). The gold standard 
being Zoledronic acid, a powerful bisphosphonate that induces a long-term remission of the 
pagetic process (Reid et a. 2011). Although promising new therapy, Denosumab, a 
monoclonal human antibody against RANKL (thus acting in a similar manner to OPG), 
which has been available since mid-2010 as a potent anti-resorptive agent (Schwarz et al. 
2012; Brown 2011) does not seem as effective as bisphosphonates in PDB, probably due to 
its transient effect on bone remodeling. 
 
A Potential Role for p62 in pagetic resistance to Apoptosis and autophagy defects 
In in vitro osteoclast cultures derived from PDB patients, it has been observed that 
deprivation of survival factors or treatment with death inducers such as Fas activating 
antibody or TRAIL resulted in lower rates of apoptosis versus controls (Chamoux et al. 
2009). In CBM-derived cultures transfected with wild-type or P392L forms of p62, 
overexpression of either protected against apoptosis. In addition, as it has been shown that 
p62 is overexpressed in PDB osteoclasts, this scaffold could contribute to their observed 
apoptotic resistance. One potential mechanism could be that the increased levels of p62 
may protect against cell death by preventing build-up of potentially cytotoxic proteins 
(Paine et al. 2005). Another may be that the basal NF-κB activation (and increased 
RANKL-sensitivity) associated with p62 mutants may positively regulate survival in PDB 
osteoclasts. Some genes involved in osteoclast apoptosis, notably those encoding caspase-3 
and TRAIL-R1 are downregulated in pagetic osteoclasts, while the anti-apoptotic Bcl-2 is 
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upregulated (Brandwood et al. 2003). Therefore, while we can clearly observe reduced 
osteoclast apoptosis in PDB, and that there is a role for p62 mutations, the mechanisms for 
this cytoprotection remain incomplete, and are certainly multifactorial. 
In p62 it is likely not a coincidence that the majority of PDB-associated mutations are 
located within the ubiquitin-associated domain, and further studies to investigate the role of 
defective aggregate clearance and autophagy in the context of Paget’s disease are needed. 
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Hypothesis 
In osteoclasts, early events that occur after RANKL stimulation include the 
formation of a multiprotein complex containing p62, TRAF6 and the atypical PKC. This 
complex is required for RANKL-induced NF-B activation and NFATc1 synthesis, both 
resulting in osteoclast differentiation and activation (Duran et al. 2004). We have 
previously shown that in response to RANKL stimulation, not only PKC but also its 
upstream activator PDK1 are associated with p62 in normal human OCs. Moreover, in PDB 
osteoclasts, this association is present prior to the addition of RANKL. We have also shown 
that the P392L mutation in p62 contributes to the increased activation of kinases PKC/ 
and PDK1, along with basal activation of NF-B, independently of RANKL stimulation 
(Chamoux et al. 2009). Since the kinases present in the p62 complex are activated, we must 
pose the question of the importance of complex formation as a prerequisite for kinase 
activation in the RANKL-activation cascade. Identifying this role would be consistent with 
the view of p62 as a multifunctional scaffold, charged with bringing kinases and substrates 
in contact to initiate cell activation. Since p62 is an adaptor and not an effector protein, the 
best way to understand the effects of altered p62 function is through better understanding 
its substrates in health and disease. By characterizing the relationship between p62, PDK1, 
and PKCζ, and particularly their impact on survival pathways and downstream transcription 
factor activation, we may better understand the modified osteoclast activation observed in 
PDB.  
Given our previous findings that PDK1 associates with the crucial adaptor p62 in 
osteoclasts, we surmised that PDK1 may play an important role in OC-related kinome 
regulation. Therefore, one aim of these human in vitro studies was to identify kinase 
cascades involved in the osteoclast phenotype, and to determine their impact on 
downstream processes. As the initial phase of PDB is characterized by excessive bone 
resorption, a major contributory factor are osteoclasts that are larger, more numerous, 
resistant to apoptosis, and hyperactive. As increased osteoclast survival in PDB is one of 
the major contributors to the pathology of the disease, by determining through which 
pathways it may be altered, we can better clarify the molecular basis of this resistance to 
apoptosis. We propose that PI3K/Akt activation, possibly associated with p62 signaling, 
may play a significant role in the increased survival of Pagetic osteoclasts. 
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Another anomaly associated with PDB is the presence of inclusion bodies in OCs 
within affected bone; aggregates of misfolded or ubiquitinated proteins within the cell. 
Because the inclusion bodies found in PDB osteoclasts resemble the p62-aggregates 
observed in diseases involving defective macroautophagy, dysregulation of the autophagy 
process may well be part of the pathogenesis of PDB (Helfrich and Hocking 2008). 
Activated PDK1 also leads to mTORC1 activation, and mTOR is a crucial, well-established 
regulator of autophagy. The initial induction of the autophagy process requires the activity 
of specific complexes (PI3K3 and ULK1), which are regulated by mTORc1, through 
PDK1/PI3K/Akt as well as ERK. Furthermore, while the kinase activity of mTORC1 is a 
key regulator that integrates upstream signals to inhibit autophagy induction, it has also 
been implicated in osteoclast survival (Glantschnig et al. 2003). Thus, there may be a 
significant role for kinases involved in RANKL signaling cascades in the PDB osteoclast 
phenotype, impacting the balance of autophagy and apoptotic signaling in these cells. 
Objectives 
Objective #1: To clarify the role of PKCζ-regulated signaling pathways in Pagetic 
osteoclasts, particularly in the context of the p62P392L mutation.  
To do so, we observed the impact of PKCζ inhibition on the activation of NF-κB 
subunits, as well as their regulation in conditions of altered p62 signaling. 
 
Objective #2: To identify other modulated signaling partners of p62 in Paget’s disease of 
bone.  
We identified several kinases active in PDB, and through functional assays under 
inhibition of PDK1 and ERK, we characterized their impact on survival signaling pathways 
of the pagetic osteoclast. 
 
Objective #3: Given the potential impact of altered PDK1/Akt/mTOR signaling on 
autophagy, the final objective was to identify and describe altered autophagic activity in 
PDB osteoclasts.   
This was carried out under conditions predicted to alter autophagic flux, while again 
inhibiting PDB-associated signaling pathways. 
2MATERIALS AND METHODS 
Culture of Human Umbilical Cord Blood Derived-Monocytes 
Prior to childbirth, consent is obtained from the mother. Immediately following 
delivery, the blood remaining in the umbilical cord is extracted to a sterile 50 mL heparin-
containing tube, with an average yield of 30 mL of cord blood. After removing and mixing 
the blood, it is stored at 4° Celsius until a member of the laboratory can retrieve it, typically 
within a few hours. 
The cord blood is diluted to a 1:1 volume in DMEM (Wisent), and the mononuclear 
leukocytes are separated by gradient density centrifugation using Ficoll-Paque. The 
mononuclear cells (monocytes and lymphocytes) are of lower density than the red blood 
cells, and found in suspension at the interphase between the serum and Ficoll. These 
mononuclear cells are removed and washed by centrifugation in DMEM, and resuspended 
in DMEM. The cells are again washed in DMEM, and the pellet resuspended in 3 mL of 
OPTI-MEM to be counted by hemocytometer (an 8% w/v solution of 80g of NH4Cl in PBS 
1X is used to lyse any remaining red blood cells before counting in addition to Trypan blue 
for the exclusion of non-viable cells).  
Once counted, the MNCs (multinuclear cells) are resuspended in a culture medium 
comprised of OPTI-MEM, with 2% fetal bovine serum (FBS, Gibco), and antibiotics (1% 
penicillin/streptomycin and 0.2% amphotericin B). The final volume is adjusted to produce 
a concentration of 3x106 cells/ml in suspension.  This suspension is plated and placed in an 
incubator at 37° C in a humidified atmosphere at 5% CO2 overnight.  The following day, 
the media is removed, taking with it the non-adherent cells, and is replaced with the same 
growth medium described above, with the addition of GM-CSF at 100 pg/ml.   
After 48 hours, the media is exchanged for the same growth medium, but with GM-
CSF exchanged for M-CSF at 25 ng/ml, and laboratory-produced RANKL at 100 ng/ml, in 
order to induce osteoclastogenesis. This media is renewed every three days until 21 days of 
culture is reached, at which point there is a significant population of mature osteoclasts 
(over 80%): multinucleated cells (3 or more nuclei), expressing osteoclast markers (RANK, 
CTR) and capable of bone resorption, as previously shown in our lab (Roux et al. 2005,  
McManus et al.  2012). 
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CBM cultures using Methocult Cell Amplification 
Methocult is a methylcellulose-based, semi-solid medium that aids in the 
proliferation of hematopoietic progenitor cells in which our mononuclear cells can be 
cultured following the isolation process described above. Immediately following isolation, 
the cells spend 11 days in this medium, and undergo approximately a 15-fold increase in 
numbers. This amplification presents one of the primary advantages of this system, 
providing a greater yield from a smaller initial volume of cells. Additionally, this process 
leads to an increased homogeneity prior to plating the precursors, allowing for an initial 
seeding density that is approximately eight times lower post-amplification. Therefore, 
CBM culture represents a plentiful and readily available source of in vitro osteoclasts 
(relative to precursors cultivated from adults). 
The cells are re-diluted into a suspension of 1.25x106 cells in 500 μL of OPTI-MEM 
2% FBS, 1.2% PSF following counting. Using a syringe and 16 G1½ needle, 5 mL of 
methocult is added to the suspension, at which time the tube is sealed and vortexed in order 
to evenly distribute the cells. Following this, the tube is left to sit for 10 minutes in order to 
allow bubbles formed by the vortexing process to disperse, and then with another syringe, 
1.1 mL of the methocult cell suspension is plated in a 35 mm petri dish. The petri dishes are 
placed in a humid chamber within the incubator, and left at 37° C in a humidified 
atmosphere at 5% CO2 for the aforementioned period of 11 days.   
To extract the mononuclear cells from methocult, 3 ml of PBS 1x is added to each 
petri, and mixed by pipetting in order to break up and dissolve the media. The resulting 
solution is transferred to a 50 mL tube (Falcon), and each petri dish also undergoes a 
subsequent wash of 2 mL with PBS 1x to improve yield. The tube is then centrifuged at 
1500 rpm for 10 minutes, the supernatant discarded, and the pellet resuspended in 50 mL of 
DMEM 1.2% PSF. This suspension is centrifuged for another 10 minutes at 1500 rpm, 
following which the pellet is again resuspended in 3 mL of OPTI-MEM 2% FBS, 1.2% 
PSF with M-CSF 25 ng/mL and laboratory-produced RANKL at 100ng/mL, counted 
following the same procedure outlined above, and plated at a concentration of 400,000 
cells/mL. From this point, the cells are treated the same as cells that have not undergone 
methocult amplification at the 11th day of culture, with media changes twice a week with 
the same concentration of cytokines (M-CSF 25 ng/mL, RANKL 100ng/mL).  The culture 
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contains mature, resorbing osteoclasts by the 10th day, as previously shown in our lab (Fong 
et al. 2013).  
Peripheral Blood-Derived Osteoclasts 
 Peripheral blood mononuclear cells (PBMCs) obtained intravenously from patients 
with PDB as well as from controls were also used to cultivate osteoclasts, after obtaining 
informed consent as approved by the university’s ethics committee. 
A blood sample (50 mL) was obtained from healthy donors and PDB patients. For 
every donor and patient, exons 7 and 8 of the gene encoding SQSTM1 were sequenced 
(McGill University and Génome Québec Innovation Centre, Montreal, Canada). For our 
present study, we analyzed data from 94 subjects (mean age 67 years (34 to 89)) including 
34 healthy controls (no PDB as ruled out by bone scan; no inflammatory disease; p62 gene 
sequenced and exempt from any known mutation) (CONT, mean age 59.6 years, 34 to 84); 
and 60 patients with clinical manifestations of PDB (mean age 71.4 years, 45 to 89) either 
exempt from any known mutation (PDBwt, n=43), or carrying the P392L mutation 
(PDBP392L, n=17). 
 
Table 1 : PBMC-Donors by Subgroup 
Patients- clinical 
history is presented in 
their dossier (includes 
bone scan and 
biochemical test 
results), and physical 
evaluation is repeated 
at the time of blood 
sampling
HDwt
Healthy donors: p62 gene sequenced and 
exempt from known mutations
PDBwt Patients with clinical Manifestations of 
Paget's Disease of Bone: p62 gene sequenced 
and exempt from known mutations
PDBP392L Patients with clinical manifestations of Paget's 
Disease of Bone: p62 gene carrying the P392L 
mutation
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PBMCs were isolated from heparinized blood by density-gradient centrifugation, as 
with CBMs, then washed and suspended in Opti-MEM 2% FBS, 1.2% PSF. The cells were 
plated at a density of 3 × 106/ml on 8-well chamber/slides (Lab-Tek, Biosciences, Bedford, 
MA). After incubating overnight, the cells were gently washed to remove any non-adherent 
cells, and cultured in Opti-MEM supplemented with GM-CSF (100 pg/ml) for the first 
2 days, after which point the final 18 days of culture of PBMCs are identical to the final 10 
days of culture of CBMs, as previously shown in our lab (Chamoux et al. 2009). 
Apoptosis Evaluation Via TUNEL 
For the detection and quantification of apoptosis in the osteoclasts, the TACS Blue-
Label kit from R&D Systems (Minneapolis, MN) was used.  This TUNEL-derived 
technique allows for the visualization of internucleosomal DNA degradation through 
cytochemistry. The cells are cultured following the protocol described; plated initially 
3x106 cells/mL in the chambered well slide (Lab-Tek), 0.4 mL per well.  At the end of the 
culture period, and any stimulation that may have taken place during, the media is removed 
and the cells are put into deprivation through the addition of a less rich growth medium 
(OPTI-MEM 1%FBS, 1.2% PSF) without the growth factors it had been treated with.  The 
cells are left in the incubator overnight under the same temperature and CO2 conditions 
described above.  At this time, the cells are treated with Staurosporine 1 μM for 3 hours to 
induce apoptosis. Staurosporine is a high-affinity, low-specificity ATP-competitive kinase 
inhibitor. While its mode of action for the induction of apoptosis is not well characterized, 
it does so at least in part through the inactivation of caspase-3 (Chae et al. 2000).   
Following treatment, the cells are rinsed three times with cold PBS 1X, then fixed over a 
period of 10 minutes at –20° C with a solution of 2:1 (ethanol):(glacial acetic acid), 
permeabilizing the cell membranes in the process. After fixation, the wells are washed 8 
times for 15 minutes with HBS 1x to re-hydrate the cells. Positive control wells (2 μL 
Nuclease diluted in 100 μL of Nuclease buffer) are incubated for 20 minutes at 37° C, 
during which time the other wells are filled with PBS 1X.  Following this step, the walls of 
the culture slide are removed and the slide incubated for 5 minutes at room temperature in a 
peroxidase solution (5 mL H2O2 30% in 45 mL Methanol).  The slides are washed 3 times 
in PBS 1X for 5 minutes each, then treated with the TdT Labeling solution (5 mL of TdT 
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Labeling Buffer 10X in 45 mL nanopure H2O) for five minutes.  Immediately following, 
the slide is placed in a humid chamber for a period of 2 hours at 37° C with 20 μL of the 
reaction mix (3.6 μL of TdT-dNTP, 3.6 μL of Manganese, and 3.6 μL of TdT enzyme in a 
volume of 180 μL of TdT Labeling Buffer). 
After these 2 hours of incubation, the slide is left for five minutes in the STOP TdT 
solution (5 mL of STOP TdT Buffer 10X in 45 mL of nanopure H2O). The slide is then 
dipped in water once to wash off excess solution, and excess water removed so that 
Streptavidin-HRP solution may be added (1 μL of Streptavidin-HRP in 375 μL of Blue-
Streptavidin-HRP diluent). This incubation period lasts 45 minutes at room temperature, 
and is followed by three rinses in water to remove any excess.  At this stage, the sides of 
the slide are again dried, and the nuclear blue staining is performed by addition of the TdT 
Blue-label solution for 5 minutes. The marking takes place through an enzymatic reaction 
forming an insoluble, blue precipitate with fragmented DNA.  The slide is washed once 
more and counter-stained with nuclear FAST-red for 30-45 minutes to give a pink color to 
the non-apoptotic nuclei that remain. To completely remove any traces of water before 
mounting the slide, it is dipped in a series of three solutions of ethanol at rising 
concentrations each time (75%, 95%, and 100%) and finally once in oxy-xylene. The slide 
is then mounted with the hydrophobic medium Permount (Fisher), and the cover is sealed 
with nail polish.   
The staining is observed under a light microscope, and apoptotic quantification 
obtained by manually identifying and counting the multinucleated cells. For the purposes of 
these studies, cells with 3 nuclei or more were considered to be osteoclasts, and those with 
blue nuclei were considered apoptotic. While the culture is heterogenous in terms of 
composition, this allows to select almost exclusively for osteoclasts in evaluating cell by 
cell.  
Western Blot Protein Analysis 
To recover the total protein content of the cells in culture, the cells are washed once 
with cold PBS 1x, and each well treated with 50 μl of lysis buffer (1% NP-40, 50 mM Tris 
HCl, 0.25% Sodium Deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM PMSF, 1 µg/ml 
Protease Inhibitors (Roche), 1 mM NaVO4, 1 mM NaF, pH 7.4). After 10 minutes of on-ice 
incubation, the wells are scraped with the anterior end of a 200 μl tip, and the suspension is 
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transferred to a 1.5 mL microcentrifuge tube. The tubes of lysate are then centrifuged at 
13000 rpm at 4ο C, and the supernatant conserved and transferred to a new tube. 
Dosage of the proteins obtained is performed in a 96 well plate, in which a standard 
curve from 0 to 10 μg of protein (using BSA) is established. This is done so with 1 mg/mL 
BSA being added at 0-1-2-3-4-6-8-10 μl per well in triplicate, and 2μl of each protein 
lysate added in triplicate to other wells on the plate. Using the DC protein assay kit (Bio-
Rad, Saint-Laurent, QC), 20 μL of Reagent A (20 μL of solution S and 1 mL of Reagent A) 
is added to each well, followed by 200 μL of Reagent B. The plate is left to develop for 5-
15 minutes, then placed in a microplate reader, measuring absorbency of light at 595 nm 
(Titertek Multiskan MCC/330). From the standard curve produced, the concentration of 
each protein sample can be calculated. 
A quantity of 20-50 μg of the proteins, depending on the target, is placed in a tube 
completed to 40 μL with water, and 10 μL of Sample buffer 5X is added (20% Glycerol, 
140 mM SDS, 2% β-mercaptoethanol, 150 mM bromophenol blue, 25% Concentrator 
buffer [35 mM SDS, 100 mM Trizma Hydrochloride (Sigma), pH 6.8]). This solution is 
heated at 100° C in a water bath for five minutes, and immediately transferred to ice and 
spun down. The samples are then loaded into an SDS-PAGE gel in an electrophoresis 
machine with electrophoresis buffer (250 mM Trizma Base (Sigma), 2000 mM Glycine, 35 
mM SDS), and run at 135 V for 60-90 minutes. Following this migration, the gels are 
transferred from the machine to a bath of Transfer buffer (25 mM Trizma Base (Sigma), 
200 mM Glycine, 3.5 mM SDS, Methanol 20%) for ten minutes. An appropriately-sized 
PVDF membrane (Roche) is activated for 30 seconds in methanol, and placed in water for 
2 minutes, then transfer buffer. At the end of the ten minute incubation period, the 
membrane and gel are sandwiched between six sheets of 3mm chromatography paper 
(Whatman), and loaded into a cassette. This cassette is lowered into a transfer machine, set 
to 100 volts for 60 minutes.  At this time, the proteins have been transferred to the surface 
of the membrane, where detection via immuno-labeling will be possible.   
Now that the transfer is completed, the membrane is placed immediately into 
blocking solution comprised of TBS-Tween 1X(2.42g/l Tris base, 8 g/L NaCl, 0.1% Tween 
20 (Amersham Biosciences), pH 7.5) and 5% of either powdered skim milk, or BSA, 
depending on the antibody used. After 30 minutes of blocking to prevent background 
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binding, the primary antibody directed towards the protein of interest is introduced at a 
specific dilution in the particular blocking solution.  The concentrations of antibodies 
(primary and secondary) used are provided on Table 2.  The primary antibody is left to 
incubate at 4° C overnight in a sealed pouch on a rotisserie shaker (Thermolyne). The 
following day, the membrane is washed 3 times with TBS-Tween 1X at room temperature 
for 5 minutes on a rocking machine (Stovall).  At this time the secondary antibody in a 
solution of blocking buffer is added to the membrane in a second pouch, and the membrane 
is rocked on the same machine for a period of 3 hours at room temperature.  Now the 
membrane is removed and washed again 3 times following the same protocol.  At this 
point, the protein-specific antibody binding is visualized by chemiluminescence (ECL, 
Amersham Bioscience).  Enhanced Luminol and Oxidizing reagent are mixed in equal 
quantities to put 500 μL on the surface of the membrane, which are placed in a cassette and 
exposed to film. This measures light intensity produced by the binding of the reagents to 
secondary antibody bound to the membrane, indicating presence of the target protein.  The 
intensity of the bands is then quantified via ImageJ.   
For the re-use of these membranes so that we might observe different protein 
expression through use of another antibody, the membrane may be stripped. The membrane 
is first re-washed in TBS-Tween 1x, and then rinsed in water, and subjected to two washes 
of 8 minutes in 0.5M NaOH. Following this, the membrane is rinsed twice in water, and 
subject to two washes of 5 minutes in TBS-Tween 1x. After the final washing, a new 
Western blot can be performed starting at the blocking step.  
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(Table 3). All samples were run in triplicate. Relative expression levels were normalized 
with respect to a set of reference primer pairs and the quantification analysis was performed 
relying on the qBase method as described in (Hellemans et al. 2007).  
 
 
Table 3 : List of Primer Sets Used 
 
Resorption Assay 
After Ficoll-Paque isolation as described above, PBMCs and CBMs were settled on 
devitalized bone slices, and cultured under the same conditions described above. The cells 
were treated with PDK1 and ERK inhibitors for the last 48 hours in culture, and the bone 
slices were removed, washed with sodium hydroxide and distilled water, sonicated to 
remove cell debris, and stained with 1% toluidine blue containing 1% sodium borate. Bone 
slices were then observed under light microscopy with epi-illumination (Zeiss Stemi 2000-c 
stereomicroscope, magnification 45x), and images were quantified via ImageJ software. 
Kinase Assay 
The PDK1 kinase assay was performed following a published method (McDonald et 
al.  2007). OCs cultured in medium supplemented with M-CSF and RANKL were 
incubated in the presence of a PDK1-specific inhibitor at 10μM or a diluent control for 
30 min. Cells were disrupted by NP-40 lysis as previously described, and lysates were 
immunoprecipitated with anti-PKCζ or anti-PDK1 antibodies. Immunoprecipitates were 
Supplemental Table 2 - List of primer sets used
Gene
GenBank accession 
number
Forward Primer Reverse Primer
Encoded 
protein Symbol
AKT1 NM_005163.2 5'-CGCTGAGATTGTGTCAGCCCT-3' 5'-GATCTTAATGTGCCCGTCCTTGTCC-3' Akt
SRC NM_005417.4 5'-TGGGAGAGAACCTGGTGTGCAA-3' 5'-CCGACTTGATGGTGAAGCGGC-3' c-Src
PDPK1 NM_002613.4 5'-ACACGGCTGAGATTGTGTCTGC-3' 5'-TGCTGTTCCAAAATCTGTGATCTGGA-3' PDK1
ATG5 NM_004849.3 5'-GAGCCGGAAGGAGGAGCCATAG-3' 5'-AATTCGTCCAAACCACACATCTCGA-3' ATG5
ATG12 NM_004707.3 5'-TGTGAATCAGTCCTTTGCTCCTTCC-3' 5'-TCTTTGTGGTTCATCCCCACGC-3' ATG12
ATG13 NM_001142673.2 5'-CTCAATTCCCAGGACAGAAAGGACC-3' 5'-GTTGGAGAAGATGATGAACGAGTGCA-3' ATG13
BECN1 NM_003766.4 5'-TGCCCAGTGTTCCCGTGGAAT-3' 5'-AGAGACTCCAGATATGAATGGTTTCCGT-3' Beclin1
MTOR NM_004958.3 5'-ATTTTGGACGGTGTGGAACTTGG-3' 5'-GAATAGATTCTGGCACTGTGGTCC-3' mTOR
LAMP2 NM_002294.2 5'-TGGCAATGATACTTGTCTGCTGGC-3' 5'-AGTAGAGCAGTGTGAGAACGGCA-3' LAMP-2
MAP1LC3A NM_032514.3 5'-GCGACCAGCACCCCAGCAAA-3' 5'-TGATCTTGACCAACTCGCTCATGTT-3' LC3A
MAP1LC3B NM_022818.4 5'-CCGCCGCCCAGATCCCTG-3' 5'-GATTTTGGTTGGATGCTGCTCTCG-3' LC3B
PIK3C3 NM_002647.3 5'-GCCAGTGAGAACATCCTACAAAGCA-3' 5'-CCGGGACCATACACATCCCATATG-3' PI3K3
RAB7A NM_004637.5 5'-CTCTAGGAAGAAAGTGTTGCTGAAGGT-3' 5'-CAGCTCCTATTGTGGCTTTGTACTGA-3' Rab7
WIPI1 NM_017983.5 5'-TGACTTCAGGGGAGATTGTGCTTTATG-3' 5'-CTGAGGCATTGAAGGTGATGGCA-3' WIPI-1
ULK1 NM_003565.2 5'-CCGAGCTACTGTCCTCCGGC-3' 5'-ACACCACGCTGGCCTTGTACA-3' ULK1
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washed in lysis buffer (with NP-40 and NaCl) and resuspended in 20 μl kinase buffer 
(20 mM HEPES, pH 7.2, 10 mM MgCl2, 5 mM DTT, 20 nM ATP, 0.05% NP-40) 
containing dephosphorylated myelin basic protein (MBP), a PDK1 substrate, and 0.5 μl [γ-
32P]ATP (10 mCi/ml). After 15 min, reactions were stopped by adding boiling Laemmli 
sample buffer 2 μl, and samples were migrated on SDS-PAGE gel prior to autoradiography 
at -80οC. 
Immunofluorescence 
Cells were treated with PDK1, MEKK, and protease inhibitors at the described 
concentrations, washed quickly with cold PBS, and then fixed for 10 minutes with ice-cold 
100% methanol. Non-specific binding sites were blocked with protein block solution 
(DAKO, Mississauga, ON). Specific antibodies directed against p62 and LC3 (Table 2 : 
Antibodies) were incubated at a concentration of 1/500 in antibody diluent (DAKO) 
overnight at 4 °C. Alexa-546 (red) anti-rabbit antibodies, and Alexa-488 (green) anti-mouse 
antibodies (Life Technologies, Mississauga, ON) were incubated for 2 h at room 
temperature at 1/1000 in antibody diluent. DAPI counter-staining was performed 
(fluorescent at 405nm, visualized as blue), so that osteoclasts containing three or more 
nuclei could be identified. Sequences of pictures were taken with appropriate filters to 
show all three colors, and superimposed using Simple PCI software. Quantification of 
puncta number and size was performed by manually outlining the cells, and establishing an 
intensity threshold to exclude background using ImageJ software. 
Autophagy study 
 Autophagosome formation requires the activation of LC3-I conjugated to 
phosphatidyl-ethanolamine (PE) to generate LC3-II (Ravikumar et al 2010). LC3B-II 
correlates with increased levels of autophagic vesicles, and to date is the only reliable 
marker associated with autophagic structures throughout the process from phagophore 
assembly to lysosomal degradation (Barth el al. 2010). To study autophagy we evaluated 
the expression of LC3B and p62 using both immunoblotting and immunofluorescence. OC 
cultures were either subjected to starvation (incubation for 6 hours in DMEM 2% FBS, no 
RANKL or 4 hours in HBSS) to induce autophagy, or to an enriched medium (DMEM/F12 
10% FBS) to reduce it. The autophagic flux was evaluated in conditions that promote 
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autophagy in the presence or absence of lysosomal protease inhibitors (E64d and pepstatin, 
10 g/ml each for ) (Klionsky et al. 2012).  
 
Statistical Analysis 
Results were expressed as the mean ± standard deviation (SD), and the significance 
was determined by paired or unpaired Student's t-tests, or analysis of variance (ANOVA) 
with Tukey's post-test where appropriate. Results within P<0.05 are considered significant.  
All of these statistics have been calculated on the GraphPad Prism program (v6).   
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3RESULTS 
PART I : The p62P392L Mutation and PKCζ Activation in PDB 
PKCζ and p62 Interaction in NF-κB Activation 
In a 2009 publication our laboratory first identified PKCζ as a potential role-player 
in Paget’s disease (Chamoux et al. 2009). In PBMC-derived osteoclasts from healthy 
donors, only low levels of PKCζ were detected in p62 precipitates. However, much greater 
amounts were found following RANKL stimulation of these cells. What’s more, in 
osteoclast extracts cultivated from Pagetic patients (p62wt), levels of PKCζ co-precipitated 
with p62 were significantly higher than those of healthy donors (HDwt, no mutation). 
Additionally, this increase was observed in both healthy carriers (HDP392L) and PDB 
patients carrying the p62P392L mutation, suggesting that this mutation contributes to PDB-
associated aPKC activation. Since the function of RANK-mediated PKCζ activation 
remains unknown, the follow-up to this study was intended to clarify the impact of 
RANKL/PKCζ signaling in a Pagetic context, deconstructing the role of the p62P392L 
mutation in PKCζ activation and downstream signaling. 
 First, to determine the relationship between the two, we analyzed the interactions 
between active (phosphorylated) PKCζ and p62 in normal osteoclasts. In CBM-derived 
osteoclast cultures, time-course stimulation with RANKL followed by p62 
immunoprecipitation was performed. This showed that RANKL stimulation induced a 
time-dependent association peaking from 10 to 60 minutes (Figure 9). Upon visual 
examination by immunofluorescence, both p62 and p-PKCζ were shown to undergo nuclear 
and perinuclear colocalization.  
 To determine the necessity of PKCζ to RANKL-induced activation of NF-κB in 
osteoclasts, we used a myristoylated pseudosubstrate for PKCζ in a series of NF-κB 
activation assays. In order to confirm the specificity of this inhibitor, we performed a 
kinase assay ( 
Figure 10-a). Osteoclasts were cultured in the presence of this inhibitor for 30 minutes prior 
to RANKL stimulation, and protein extracts were separated into nuclear and cytosolic 
fractions. Stimulation with RANKL more than doubled nuclear p50 levels, while inhibition 
of PKCζ prevented this effect ( 
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Figure 10-b). This indicated an involvement of PKCζ in RANK-induced NF-κB activation.  
 
 
 
 
Figure 9 : PKCζ and p62 Interactions in Human Osteoclasts 
At the end of CBM cultures, the cells were either stimulated with RANKL (100 ng/ml) for the time 
indicated or left untreated. a) Immunoprecipitations (IPs) were conducted with an anti-p62 antibody 
in cell lysates. Western blots (WBs) with anti-p-PKCζ/λ and anti-p62 antibodies are shown. 
Optical densities (ODs) for bands corresponding to p-PKCζ/λ were corrected with the OD 
obtained for bands corresponding to p62, and computed in graphical representations (3 independent 
experiments). Analyses are reported as mean ratio ± SD. *p<0.05; **p<0.01; ***p<0.001 vs. 
nonstimulated cells. b) Immunofluorescence studies were performed using antibodies directed 
against p62, PKCζ, p-PKCζ/λ, p-PKCλ/ι. Actin filaments were stained with Alexa Fluor 
633-conjugated phalloidin. Images taken with appropriate filters reveal p62 (Alexa-488, green), 
PKCζ and p-PKCζ/λ, p-PKCλ/ι (Alexa-594, red) and nuclei (DAPI, blue). Typical cells are 
shown and represent about 75% of MNCs observed in 2 experiments. (Chamoux, McManus et al. 
2013) 
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Having previously reported that the p62P392L mutation enhanced NF-κB activation 
as well as p62/PKCζ association (Chamoux et al. 2009), we investigated the role of this 
mutation in PKCζ activation using CBMs transfected with p62 variants or an empty vector 
(EV). While overexpression of wild-type (WT) p62 produced an increasing trend of the p50 
NF-κB subunit’s translocation, it was not significant. However, overexpression of p62P392L 
in these osteoclasts induced a significant basal increase in nuclear/cytoplasmic p50, and 
still retained their sensitivity to RANKL stimulation. Interestingly, inhibition of PKCζ in 
these cells reduced p50 translocation levels to those equivalent to those of the EV (Figure 
10-c). This result, in turn, indicated that PKCζ plays a crucial role in basal as well as 
RANKL-induced over-activation of NF-κB in the context of the P392L mutation.  
 
 
 
 
 
 
 
 
 
  
88 
88 
 
 
Figure 10 : Effect of a PKCζ Inhibitor on NF-κB Nuclear Translocation 
OC cultures supplemented with M-CSF and RANKL were incubated in the presence of a 
myristoylated pseudosubstrate (Myr-SIYRRGARRWRKL-OH) at 10 μM or diluent control for 30 
min. PKCζ or PKCλ/ι immunoprecipitates were analyzed in a kinase assay using myelin basic 
protein (MBP) as substrate. The relative ratios are indicated (vs absence of PKCζ inhibitor). The 
data shown are representative of 2 independent experiments (a). At the end of CBM cultures, the 
cells were transfected with a pEGFP-C2 plasmid containing p62wt, p62P392L, or an empty pEGFP 
vector (EV), or were not transfected. Non-transfected cells (b), or cells transfected with vectors 
containing p62 variants (c) were preincubated with a myristoylated PKCζ pseudo-substrate at 10 
μM for 30 min, and then stimulated with RANKL (RL) 100 ng/ml for 30 min or left untreated (no 
RL). Lysates were separated into fractions enriched with nuclear or cytoplasmic proteins. Western 
blots were performed with an anti-p50 (NF-κB) subunit antibody, and after membrane stripping, 
with anti-actin or anti-lamin antibodies for the cytoplasmic or nuclear fractions respectively. 
Western blots (WB) of the cytoplasmic and nuclear fractions are shown. ODs were measured with 
ImageJ software, and the ratios of p50 to lamin (nuclear fraction) over p50 to actin (cytoplasmic 
fraction) were computed. Analyses are reported as the mean ratio±SD. *p<0.05, **p<0.01 vs 
untreated, #p<0.05, ##p<0.01 absence vs presence of PKCζ inhibitor, °p<0.05 vs EV. The data are 
representative of 3 independent experiments. (Chamoux, McManus et al. 2013) 
 
 
  
89 
89 
 Having identified this, we analyzed the possible mechanisms of this activation, 
starting with canonical NF-κB signaling. As activation via this pathway relies on 
degradation of IκB, liberating other NF-κB subunits, the expression of IκBα following 
RANKL stimulation was observed via western blot (Figure 11-a). IκBα/Actin ratios were 
reduced by 50% in control cells treated with RANKL. As p62 may contribute to 
proteasome-mediated degradation of IκB via its polyubiquitin chain binding capabilities as 
well as through facilitating kinase pathway activation, these experiments were repeated in 
the presence of MG132, a potent proteasome inhibitor. Under these conditions, no 
degradation of IκBα was observed by western blot following RANKL addition (Figure 11-
a). When p62WT was overexpressed in osteoclasts, lower levels of IκBα were present, but 
were increased following proteasome inhibition, suggesting accelerated degradation of 
IκBα, but higher basal levels. Curiously, expression of the p62P392L mutation increased 
IκBα, and these levels were insensitive to MG132 pretreatment (Figure 11-b). This increase 
was in sharp contrast to the increased basal activation of NF-κB observed in osteoclasts 
carrying p62P392L, and though it did not explain the NF-κB status, this result suggested a 
defect in the IκBα degradation process. 
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Figure 11 : Study of IkB Expression 
At the end of CBM cultures, the cells were transfected with a pEGFP-C2 plasmid containing p62wt, 
p62P392L, or an empty pEGFP vector (EV), or were not transfected. Non-transfected cells (a) or 
cells transfected with vectors containing p62 variants (b) were preincubated with MG-132 
(proteasome inhibitor) at 10 nM for 1 h before the experimentation where appropriate. The cells 
were then treated with RANKL (100 ng/ml) for the length of time indicated (a), or for 45 min (b), 
or left untreated (no RANKL).Whole cell lysates were subjected to Western blotting using an anti-I
κBα antibody. After stripping, the membranes were reblotted using anti-actin antibodies. After 
quantification, the ODs obtained for each band were computed, and subjected to a two-way analysis 
of variance. The ratios of IκBα to actin were reported (n=3 independent experiments). **p<0.01, 
***p<0.001 RANKL vs no stimulation; #p<0.05, ##p<0.01, ### p<0.001 MG132 vs no pre-
treatment; §§p<0.01, §§§p<0.001, p62WT or p62P392L vs EV; ¤¤¤p<0.001 p62P392L vs p62wt. 
(Chamoux, McManus et al. 2013) 
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 Since p62 is associated with proteasomal degradation, and its P392L mutation is 
located in the UBA domain, which binds polyubiquitin chains (Seibenhener et al. 2004), 
the mutation could potentially interfere with ubiquitinated IκBα interactions with said UBA 
domain. Therefore, we next then investigated the potential associated of p62 and IκBα, and 
the possible changes induced by P392L mutation. Via immunoprecipitation of IκBα 
followed by western blot directed towards p62, it was determined that the two proteins 
were associated in a time-dependent manner in non-transfected cells stimulated with 
RANKL, increasing linearly through 60 minutes post-induction (Chamoux et al. 2009). 
Following this, CBMs overexpressing p62WT showed high levels of interaction between p62 
and IκBα after RANKL stimulation, but cells expressing the P392L variant did not 
significantly differ from EV extracts. This may indicate that this p62 mutation alters NF-κB 
signaling by altering or decreasing its ability to bind IκBα, preventing it from being 
shuttled to the proteasome (therefore increasing IκBα levels) , but still did not explain the 
basal activation of NFB in presence of p62P392L. 
  
92 
92 
 
 
Figure 12 : Interactions between p62 and IB 
At the end of the CBM cultures, the cells were transfected with a pEGFP-C2 plasmid containing 
p62wt, p62P392L, or an empty pEGFP vector (EV), or were not transfected. Non-transfected cells (a) or 
cells transfected with vectors containing p62 variants (b) were stimulated with RANKL (100 ng/ml) 
for 0, 10, 15, 30 and 60 min. as described above, and then lysed. Immunoprecipitations were 
conducted on the lysates with an anti-p62 antibody. Agarose-bead precipitates were then loaded onto 
SDS-PAGE, and Western blots were performed with an anti-IB antibody. After visualization, the 
membranes were stripped and probed again with an anti-p62 antibody. The reverse experiment, 
consisting of precipitating IB and revealing p62 was performed to confirm the specificity. Optical 
densities were measured with ImageJ software, and the ratios of IB to p62 were reported. Analyses 
are reported as the mean ratio ± SD. *p<0.05, **p<0.01, ***p<0.001 vs non-treated. The data shown 
are representative of 3 independent experiments. (Chamoux, McManus, 2013) 
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PKCζ May Act as an IKK Kinase in Osteoclasts 
  
 Since PKCζ has previously been demonstrated to act as an IKK kinase, upstream of 
IκB phosphorylation and ubiquitination (Duran et al. 2008), we proposed that altered PKCζ 
and p62 interaction in PDB may contribute to an activation of IKK regulating NF-κB over-
activation. In order to evaluate this possibility, we examined phosphorylation of IKKβ, the 
regulatory subunit of the IKK complex, under RANKL stimulation at 3 and 30 minutes, 
and following with the same conditions after PKCζ inhibitor pretreatment of osteoclasts. 
 No significant changes were observed in phosphorylation levels of p-IKKβ or p-
IκBα after short term (3 min) RANKL stimulation (not shown). However, at 30 minutes 
post-RANKL stimulation, EV-transfected osteoclasts showed significantly increased IKKβ 
phosphorylation (Figure 13), which was prevented by the presence of the PKCζ inhibitor. 
No significant modulation of p-IKKβ in the p62WT-overexpressing osteoclasts was 
observed. In the p62P392L transfected cells, basal phosphorylation levels exhibited a 
tendency towards an increase, albeit a non-statistically significant one. Once treated with 
PKCζ inhibitor, these osteoclasts saw significantly reduced levels of p-IKKβ that were not 
re-established by RANKL stimulation. These results demonstrate a possible role of PKCζ 
as an IKK kinase in RANKL-induced activation of NF-κB in osteoclasts, but the changes 
observed do not appear to account for the major activation of NF-κB observed in the 
presence of the p62P392L mutation.  
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Figure 13 : Expression of p-IKKβ in Osteoclasts Following 30-min RANKL 
Stimulation, With or Without PKCζ Inhibition 
At the end of culture, CBM-derived osteoclasts were transfected with a pEGFP-C2 plasmid 
containing an empty vector (EV), p62wt, or P62P392L. Following, the cells were pre-incubated with a 
myristoylated PKCζ pseudosubstrate at 10 μM for 30 minutes, then stimulated with RANKL at 100 
ng/ml for 30 minutes. A) Whole lysates were visualized via Western blotting using an anti-pIKKβ 
and anti-actin antibodies. Western blots (WB) are shown. B) Optical density was measured with 
ImageJ software, and protein expression normalized to respective actin intensity, and these results 
are expressed as relative to the untreated EV-transfected cells (mean ± SD). * p<005, ** p<0.01 v/s 
untreated, # p<0.05 v/s the presence of PKCζ inhibitor. The data shown is representative of 5 
independent experiments. 
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PKCζ May Act as a p65 Kinase Independently of IκBα 
 We thus established that IκBα expression increases in the presence of p62P392L, even 
without RANKL stimulation, and that altered IκBα degradation through modified p62-
UBA interaction may be partially responsible. However, the increase observed in IκBα 
expression in P62P392L osteoclasts appears to contrast with the increased activation of NF-
κB observed in these same cells. Since PKCζ is critical to their NF-κB activation, we 
considered that PKCζ could be activating NF-κB through another mechanism. In this case, 
we hypothesized that PKCζ may be directly phosphorylating p65 (RelA), activating NF-κB 
independently of IκB, and evaluated two targets (Ser536 and Ser311) for phosphorylation 
(direct or indirect) by PKCζ. In non-transfected osteoclasts, RANKL stimulation did not 
modify phosphorylation of p65 at Ser311, but significantly increased p-Ser536 p65 levels 
(Figure 14-a). Inhibition of PKCζ ablated this increase.  
 In the transfected model, the same results were observed in EV osteoclasts, and 
p62WT-overexpressing cells also showed a sensitivity to RANKL, but no significant 
response to PKCζ inhibition. Similar to the effects seen in the NF-κB translocation 
described previously, p62P392L-expressing osteoclasts exhibited higher basal p-Ser536 p65, 
which still responded further to RANKL stimulation, but which were reduced to values not 
statistically different from the EV osteoclasts upon PKCζ inhibition (Figure 14-b). These 
results suggest that while PKCζ is involved in the p62-regulated activation of NF-κB seen 
induced by RANKL, the aPKC is also implicated in the basal NF-κB activation observed in 
the presence of the p62P392L mutation, via its regulation of RelA phosphorylation. This may 
explain NF-κB activation despite the IκBα levels seen in the transfected osteoclasts. 
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Figure 14 : p65 Phosphorylation and the Effects of PKCζ Inhibition 
At the end of culture, CBM-derived osteoclasts were transfected with a pEGFP-C2 plasmid 
containing an empty vector (EV), p62wt, or P62P392L. Following, non-transfected A), or transfected 
cells B), were pre-incubated with a myristoylated PKCζ pseudosubstrate at 10 μM for 30 minutes, 
then stimulated with RANKL (RL) at 100 ng/ml for 30 minutes. Western blots were performed 
using an anti-p-p65 (RelA) antibody detecting NF-κB p65 when phosphorylated either at Ser536 or 
Ser311, and subsequently with anti-actin antibodies as a loading control. Optical density was 
measured with ImageJ software, and protein expression normalized to respective actin intensity, and 
these results are expressed as relative to the untreated EV-transfected cells (mean ± SD). * p<0.05, 
** p<0.01 v/s untreated, # p<0.05 v/s the presence of PKCζ inhibitor, O p<0.05 v/s EV. The data 
shown is representative of 3 to 4 independent experiments. 
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PART II: Kinase Cascades in Survival and Autophagy in Paget’s Disease of Bone 
Kinome Activation in Normal Osteoclasts 
PDK1, Akt, and RANKL Signaling in normal Osteoclasts 
 Our laboratory demonstrated that like PKCζ, the serine/threonine kinase PDK1 is 
associated with p62 in response to RANKL stimulation in normal human osteoclasts 
(Chamoux et al. 2009). Similarly to PKCζ, this association can be found prior to RANKL 
stimulation in PDB-derived osteoclast cultures. Given that PDK1 is also a major AGC kinase 
affecting multiple regulatory pathways, we hypothesized that it may play a role in the 
phenotype of these pagetic osteoclasts, most probably through survival and autophagic 
signaling secondaries. 
 Therefore our first action was to establish the role of PDK1 in RANKL signaling in 
human CBM-derived osteoclasts. A potent cell-permeable, ATP site-targeting inhibitor of 
PDK1 was purchased, and its specificity at varying concentrations assured in osteoclasts via 
kinase assay (Figure 15-a). Here we demonstrate that while effective at suppressing PDK1 
signaling at low concentrations, other AGC kinases like PKCζ are not affected. The best 
characterized target of PDK1 is Akt. PDK1 phosphorylates Akt on its activation loop at 
Thr308, and Akt is also phosphorylated within its carboxyl terminus at Ser473, typically by 
mTOR. Via immunoblotting, we examined phosphorylation at both of these sites under non-
treated and RANKL stimulation at 30 minutes. Osteoclasts responded to stimulation via 
RANKL only at p-Ser473 Akt, with no significant change in PDK1-regulated Thr308 
phosphorylation. Additionally, inhibition of PDK1 virtually eliminated p-Thr308 Akt, and 
while it did not affect baseline p-Ser473, it prevented significant response to RANKL (Figure 
15-b). Both responded significantly to TNF-α stimulation, which was equally dependent on 
PDK1 signaling. This confirms the necessity of PDK1 to Akt activation in the osteoclast 
model.  
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Figure 15 : PDK1 and Akt Signaling in Osteoclasts 
At the end of CBM-derived OC cultures, cells were treated with a PDK1-specific inhibitor at 10 μM 
for 1 hour or left untreated (NT). A) PKCζ (as control) or PDK1 immunoprecipitates were analyzed 
in a kinase assay using myelin basic protein (MBP) as substrate. B) Whole cell lysates were subjected 
to IB for the indicated proteins using antibodies for Thr308pAkt, Ser473pAkt, and total Akt. Optical 
density was measured with ImageJ software, and protein expression normalized to total akt levels, 
and these results are expressed as relative to the untreated cells (mean ± SD). ** p<0.01, **** 
p<0.0001 v/s untreated, # p<0.05 v/s untreated. The data shown is representative of 3 to 4 independent 
experiments. 
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Kinome Regulation of Resorption 
 As both PI3K/PDK1 and ERK pathways play major roles in OC functions and 
survival and interact to regulate each other (Gingery et al. 2003; Kwak et al. 2006; Mendoza 
et al.  2011), both pathways were investigated in functional assays. The best functional 
evaluation of osteoclast activity is its resorptive capability. In order to determine the impact 
of PDK1 and ERK inhibition on bone resorption, CBMs were cultivated on bone slices and 
treated with PDK1 or MEK1/2 inhibitors upon reaching maturity, then left in culture for 96 
more hours of activity (Figure 16). Osteoclasts cultured under normal conditions (Opti-MEM 
and 2% FBS), and enriched conditions (DMEM-F12 and 10% FBS) were active, resorbing 
approximately 9 and 14% of total bone surface, respectively. Their serum and cytokine-
deprived counterparts recorded only about 2% bone surface resorption. Inhibition of MEK1/2 
or PDK1, regardless of serum composition, resulted in a similar phenotype, with significant 
loss of bone-resorbing activity (Figure 16). This confirms that both kinases likely play an 
important part in maintaining normal levels of resorption. 
 
Kinome Activation in Pagetic Osteoclasts 
Survival Pathways in Pagetic Osteoclasts 
 A characteristic phenotype of osteoclasts in PDB is their resistance to apoptosis 
(Chamoux et al, 2009), so the first signaling cascades we examined were those involved in 
osteoclast survival. In osteoclast cultures from Pagetic patients and controls, we performed 
western blotting for the phosphorylated (and thus active) forms of p38, ERK, Akt, and PDK1 
(Figure 17). Phosphorylation of both Thr308 and Ser473 of Akt were observed to be higher 
in PDB osteoclasts than in controls, and following RANKL stimulation, p-Ser473 Akt/ΔAkt 
increased significantly and proportionally in Pagetic and control osteoclasts (Figure 17-A). 
As with CBM-derived osteoclasts, phosphorylation of Akt at Thr308 in PBMC-derived 
osteoclasts was not responsive to RANKL signaling under these conditions. ERK1/2 
phosphorylation at Thr202/Tyr204 was significantly higher in PDB osteoclasts, while p38 
Thr180/Tyr182 remained unchanged. Interestingly, despite the increase in p-Thr308 Akt, no 
difference in phosphorylation of PDK1 at Ser241 in its activation loop was observed between 
the two study groups (Figure 17-B).  
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Figure 16 : Resorption by CBMs Under PDK1 Inhibition 
At the end of the CBM-derived OC cultures on bone slices, the cells were either subjected to a 48-
hour medium deprivation (1% FBS), cultured in enriched medium (5% FBS), or in standard 
conditions, in the presence or absence of a PDK1 (10 μM) or a MEK1/2 inhibitor (25 μM) for 48 
hours. A) Images of bone resorption were obtained under light microscopy with epi-illumination 
(Zeiss Stemi 2000-c stereomicroscope, magnification 45x). B) Results are presented as the percentage 
of the total bone area that has been resorbed. * p<0.05, ** p<0.01 v/s untreated, # p<0.05, # p<0.01 
v/s serum enriched, $$ p<0.01 v/s inhibitor PDK1 treated. The data shown is representative of 3 
independent experiments. 
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Figure 17 : Kinase Activation in Pagetic Osteoclasts 
At the end of the OC cultures (PDB n=14 including 3 carrying p62P392L, controls n=10), whole cell 
lysates were subjected to immunoblotting using for the indicated phosphorylated (p) or total protein 
using antibodies for Akt, Thr308 and Ser473p-Akt, PDK1, Ser241p-PDK1, p38, Thr180/Tyr182p-p38, ERK, 
and Thr202/Tyr204p-ERK. A) Phosphorylation of Akt upon RANKL stimulation: At the end of the 
cultures, mature OCs were treated with RANKL (150 ng/ml) for 30 min or left untreated. Protein 
extracts were analyzed by immunoblotting for the phosphorylated (p) or total proteins. We analyzed 
the band intensities using NIH ImageJ Software, the phosphorylation results are normalized for the 
total protein intensity (mean ± SD), and the results are presented on graphs corresponding to Thr308p-
Akt /Akt, and Ser473p-Akt /Akt. B) Phosphorylation of ERK, p38 and PDK1. Protein extracts were 
analyzed by immunoblotting for the phosphorylated (p) or total proteins. The results are presented on 
graphs corresponding to p-p38/p38, p-ERK/ERK, and p-PDK1/PDK1 (mean ± SD). *p<0.05; 
***p<0.001 vs controls same conditions; °°p<0.01, °°°p<0.001 RANKL vs no RANKL. 
  
A
controls PDB
Thr308 p-Akt
Ser473 p-Akt
Akt
Ser241p-PDK1
PDK1
ERK
Thr180/Tyr182p-p38
p38
β-Actin
IB
B
C
0.0
0.2
0.4
0.6
0.8
1.0
Thr308p-Akt
***
*
controls PDB
0         RANKL 0         RANKL
Thr202/Tyr204
p-ERK1/2 
0
1
2
3
controls PDB
Ser241p-PDK1
0.0
0.2
0.4
0.6
0.8
**
controls PDB
Thr202/Tyr204p-ERK1/2
p
h
o
sp
h
o
/t
o
ta
l p
ro
te
in
0.0
0.2
0.4
0.6
0.8
1.0
Ser473p-Akt
°°
°°°*
*
controls PDB
0         RANKL 0         RANKL
p
h
o
sp
h
o
/t
o
ta
l p
ro
te
in
controls PDB
0.0
0.2
0.4
0.6
0.8
Thr180/Tyr182p-p38
  
102 
102 
Impact of PDK1 Inhibition on Downstream Targets in Pagetic Osteoclasts 
 Given the increased basal activity of PDK1 substrate Akt in pagetic osteoclasts, we 
wished to determine the impact of PDK1 inhibition on phosphorylation levels of this target, 
as well as of glycogen synthase kinase 3β (GSK3β), an inhibitory kinase regulated 
negatively by phosphorylation of its Ser9 by Akt (Figure 18-A). 
 Upon treatment with the specific inhibitor, phosphorylation of Akt at Thr308 was 
significantly reduced from non-treated levels in both PDB and control patients, and levels 
of p-Ser473 Akt were reduced to control-comparable levels in PDB patients (Figure 18-B). 
Concordantly, while levels of p-GSK3β were significantly increased in PDB, levels of 
phosphorylation in both control and pagetic osteoclasts were reduced to significantly below 
control untreated conditions. This suggests a regulatory role for PDK1 signaling in PDB 
osteoclasts which normally display overactive Akt. Along with increased levels of 
phosphorylated ERK, the kinome profile observed may contribute to the higher survival 
rates observed in PDB osteoclasts. 
 These regulated factors are also well-identified in other tissues as regulators of 
autophagy through activation/repression of mTORC1, and we thus wondered if these 
factors may reflect an impaired autophagic balance in PDB osteoclasts. 
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Figure 18 : Effects of PDK1 Inhibition on Survival Kinases in PDB 
(A) Immunoblot (IB): At the end of the OC cultures (PDB n=4 no p62P392L, controls n=4) 
performed in the presence of a PDK1 inhibitor (10 μM for 1 hour) or left untreated (NT), 
whole cell lysates were subjected to immunoblotting for the indicated phosphorylated (p) or 
total protein using antibodies for Akt, Thr308 and Ser473p-Akt, GSK3β and Ser9p-GSK3β. (B) 
IB quantification: The band intensities were analyzed using NIH ImageJ Software, the 
phosphorylation results are normalized for the total protein intensity (mean ± SD) and the 
results are presented on graphs corresponding to Thr308pAkt/Akt, Ser473pAkt/Akt and 
Ser9pGSK3β/GSK3β. *p<0.05; ***p<0.001. 
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Autophagy in Pagetic Osteoclasts 
Evaluation of Autophagy in Osteoclasts via LC3 Immunoblot 
 Autophagosome formation requires the activation of LC3-I conjugated to PE to 
generate LC3-II. Levels of LC3-II correlate to numbers of autophagic vesicles, and it is 
considered the only reliable marker associated with autophagic structures throughout the 
autophagic process (from phagophore to lysosomal degradation). In order to investigate 
autophagy in osteoclast cultures from pagetic patients, we first examined the levels of LC3B 
in basal and autophagy-induced conditions by western blot analysis (Figure 19-A). 
 In PDB, the basal ratio of LC3B-II over LC3B-I was higher than that of controls. 
When submitted to starvation in order to induce autophagy, these levels increased, both in 
controls and PDB, remaining at a proportionally higher rate in pagetic osteoclasts (Figure 
19B). 
 As p62 is a major adaptor involved in selective autophagy, this experiment was 
performed with cells derived from patients both with and without the p62P392L mutation. 
Studying global autophagy (and not specifically p62-related selective autophagy), an 
identical LC3B-II phenotype was produced, suggesting that the mutation is contributing no 
additional autophagy-based effect to the osteoclast phenotype. More significantly, these 
results indicate that the autophagic process is indeed dysregulated in PDB osteoclasts. 
 However, with this information alone we cannot pinpoint the type of dysfunction. 
Since LC3B-II itself is subject to autophagic degradation at the lysosome, increased LC3B-
II/LC3B-I ratios may be associated with increased autophagosome synthesis, or reduced 
autophagosome turnover due to delayed trafficking, reduced fusion, or impaired lysosomal 
proteolytic activity.  
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Figure 20 : Autophagy-Related Gene Expression Analysis 
We selected 12 candidate genes related to autophagy encoding Atg12, Atg13, Atg5, Beclin 1, 
mTOR, LAMP2, LC3A, LC3B, PI3K class III, Rab7, WIPI-1, and ULK1, as well as 3 genes 
encoding upstream kinases involved in the regulation of mTORC1 activity: Src, Akt, and PDK1. 
Total RNA extraction was performed on cultures from PBMC-derived OCs (PDB n=29 including 
12 carrying p62P392L, controls n=14), followed by real-time PCR experiments. Relative expression 
quantification analysis relied on the qBase method, relative levels being normalized with respect to 
a set of reference primer pairs for 3 housekeeping genes. We compared the mean, normalized, 
relative expression between groups (all PDB vs controls, PDBwt vs PDBP392L) using Student’s t-test. 
Differential expression is reported as the log2 ratio (**p<0.01, ***p<0.001 PDB vs controls). 
 
The Dynamics of Autophagy in PDB as Observed by Immunofluorescence 
 Since the basal autophagy-related gene expression profile did not indicate an 
increase in autophagy, the high basal LC3B-II ratio we observed earlier may instead be 
attributable to defective autophagosome processing. To investigate this process, we 
measured the autophagic flux in the presence of lysosomal protease inhibitors, using single-
cell based immunofluorescence in order to determine the number of LC3B punctas per area 
in the osteoclasts (Figure 21-A). In comparison to cultures in standard conditions, the 
number of LC3B punctas/area were decreased in control osteoclasts that were exposed to 
the richer growth medium DMEM-F12 with 10% FBS. 
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The Regulation of Akt/mTORC1 Signaling in Pagetic Osteoclasts by PDK1 
 As we showed that PDK1 appears to play a regulatory role in PDB osteoclast 
signaling, and these osteoclasts demonstrated autophagic defects, we were interested in 
evaluating the impact of PDK1 on mTOR signaling in these cells. The activation of mTOR 
was thus investigated through the phosphorylation of its targets 4EBP1 (eukaryotic 
initiation factor 4E-binding protein 1), the serine/threonine kinase p70S6K, as well as 
phosphorylation of Raptor (regulatory-associated protein of mTORC1), which is required 
for mTOR kinase activity. 
 Phosphorylation of Raptor and 4EBP1 were slightly but significantly increased in 
pagetic osteoclasts, and this phosphorylation was significantly reduced in both populations 
following PDK1 inhibition (Figure 23). 
 p70S6K is activated by mTOR via phosphorylation at residue Thr389, which allows 
a subsequent phosphorylation at Thr229 by PDK1. Higher basal levels of p-Thr229p70S6K 
were observed in PDB osteoclasts, while p-Thr389 levels were curiously equivalent with 
those of controls. In this case again, inhibition of PDK1 resulted in significant reduction in 
p70S6K phosphorylation at both sites and across both populations (Figure 23). 
 Here the results appear to indicate that mTORC1 is activated in pagetic osteoclasts, 
with increased levels of phosphorylated Raptor, p70S6K, and 4EBP1 in these cells, and the 
impact of its inhibition on these processes suggests a requirement of PDK1 for this 
activation. 
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Figure 24 : ULK Regulation by PDK1 and in PDB 
At the end of the OC cultures, cells were treated with a PDK1-specific inhibitor at 10 μM 
for 1 hour or left untreated (NT). Following this, the cells were treated with RANKL or 
TNF-α for 30 min at 150 ng/ml and 100 ng/ml, respectively. 
A) ULK activation in Paget’s Disease. Whole cell lysates from patients (n=4) and 
controls (n=4) were subjected to IB for total ULK1. 
B) ULK regulation by PDK1. Whole cell lysates from CBM-derived osteoclasts were 
subjected to IB for the indicated phosphorylated (p) or total protein using antibodies for 
ULK1, and Ser555p-ULK1.  The phosphorylation results are normalized for the total protein 
intensity (mean± SD). Representative photographs of IB are shown under each graph. 
*p<0.05, **p<0.01 vs NT. (n=4 experiments) 
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This may indicate that while ULK1 phosphorylation and total protein levels are not 
modulated in PDB, its activation (and thus autophagy initiation) is dependent on normal 
PDK1 activity. 
 
The Impact of Kinase Inhibition on Osteoclast Apoptosis, Autophagy, and Activity 
 Having found that ERK and Akt pathways contribute to osteoclast signaling in 
PDB, and further, that Akt activation was regulated by PDK1 activity, we wished to 
confirm the functional impact of these over-activated kinases on the osteoclast phenotype 
in PDB. To do so, experiments to modulate osteoclast autophagy, survival, and ultimately 
resorptive capability were carried out via upstream modulation of these kinases.  
PDK1 Inhibition of Osteoclast Autophagy 
 In comparison with untreated cultures LC3B-II/LC3B-1 ratios evaluated by western 
blot exhibited similar increases under deprivation conditions in both pagetic and control 
osteoclasts. While inhibition of MEK1/2 had no significant impact on either population, 
inhibition of PDK1 resulted in a significant increase of LC3B-II/LC3B-I in PDB osteoclasts 
only (Figure 25A). Analysis of LC3 and p62 punctas was carried out via immunofluorescent 
marking and confocal microscopy, and again control osteoclasts exhibited increases in the 
number of LC3 punctas per osteoclast following deprivation conditions, while PDK1 and 
MEK1/2 inhibition produced no statistical change. However, in pagetic osteoclasts, a 
significant increase in the number of LC3B puncta/area was observed following PDK1 
inhibition (Figure 25-B,C). This same pattern was observed in p62-positive puncta counted 
in PDB versus control osteoclasts (Figure 25-D), demonstrating that there is a Paget’s-
specific alteration in these cells regulated by PDK1. 
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Pagetic Osteoclast Apoptotic Response to Kinase Inhibition 
 In order to determine whether the observed changes in resorption were due primarily 
to cell survival levels or changes in activation, viability assays were performed under similar 
conditions to the resorption tests. PDB osteoclasts do exhibit higher basal resistance to 
apoptosis under deprivation and “normal” conditions, responding equally well to 
staurosporine as a positive control for apoptosis (Figure 27). Inhibition of PDK1 and MEK1/2 
renders both populations equally susceptible to apoptosis, and at higher rates than observed 
in control osteoclasts under mild apoptotic stimuli (deprivation). This accounts for a roughly 
10-15% increase in apoptosis in control osteoclasts, and approximately 30% difference in 
PDB in order to bring them to control levels. 
 
    
Figure 27 : Pagetic Osteoclast Apoptosis and Kinase Inhibition 
At the end of the 3-week culture period, the medium was changed to either standard medium (no 
Dep), or deprived conditions (Dep) by removing M-CSF and RANKL, as well as reducing FBS to 
1% in the Opti-MEM for 24 h. In deprived conditions, OCs were incubated with PDK1 or MEK1/2 
inhibitors, with staurosporine (ST; 1 M for 3 hours) or left untreated (Dep). Results of the TACS 
Blue labeling are expressed as the percentage of apoptotic MNCs over the total population of 
MNCs (mean ± SD; n= 4 PDB and 3 controls). *p<0.05 PDB vs controls, ° p<0.05, °°p<0.01 vs no 
inhibitor. 
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4DISCUSSION 
 
Pagetic osteoclasts exhibit basally altered signaling pathways, leading to their 
overactive phenotype. One aim of these studies was to identify the kinase cascades and 
signaling partners involved in this osteoclast phenotype, and determine their downstream 
impact. The first of these was PKCζ, a protein kinase we showed to be implicated in Paget’s 
disease, particularly under condition of the p62P392L mutation. We have shown that this 
mutation contributes to increased activation of PKCζ /λ and PDK1, along with basal NF-κB 
activation (Chamoux et al. 2009). We were able to further link the p62P392L mutation to PKCζ 
and NF-κB activation, and inhibition of PKCζ was sufficient to cancel out this activity even 
in the case of p62 mutation. This suggests a unique role for this kinase in at least some forms 
of the disease.  
 Given the association of PDK1 to PKCζ and p62, we also found it pertinent to 
examine the potential role for PDK1 in pagetic osteoclast regulation. Gene analysis allowed 
us to identify PDK1 and ERK as possible effectors of altered signaling in these cells, and 
functional assays following inhibition of each determined that both are vital to both osteoclast 
activity and survival, in disease as in health. Given that increased resistance to apoptosis is a 
major characteristic of pagetic osteoclasts, this suggests an important regulatory role for the 
two, particularly PDK1, whose substrates and downstream targets were more active in 
Paget’s than in control osteoclasts.  
 As altered PDK1/Akt/mTOR signaling may logically lead to a change in autophagic 
flux, and pagetic osteoclasts are traditionally associated with nuclear inclusion bodies 
resembling those found in some diseases involving defective autophagy, we investigated a 
potential role for dysregulation of this process in Paget’s disease. Indeed, both induction and 
termination of autophagy appear to be hampered in these osteoclasts. These cells appear to 
accumulate non-degradative autophagosomes, as observed by higher numbers of p62 and 
LC3B puncta per osteoclast. Furthermore, the inhibition of PDK1 reversed the induction 
defect, possibly through mTORC1 regulation. These results suggest a strong potential role 
for PDK1 in both stimulatory and autophagic pathways in osteoclasts, likely contributing to 
the pagetic phenotype. 
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PKCζ and Osteoclast Activation Via NF-κB Pathways 
 In murine osteoclasts, the formation of a ternary complex between TRAF6, p62, and 
aPKCs in response to RANKL stimulation has been reported (Durán et al. 2004), and in 
human osteoclasts RANKL stimulation also forms a multiprotein complex containing 
TRAF6, PKCζ, p62, and PDK1 (Chamoux et al. 2009). In pagetic osteoclasts as well as 
CBM-derived osteoclasts overexpressing wild-type and mutant p62, the formation of 
activated kinase/p62 complexes is constitutive, and p62P392L expression is associated with 
increased basal NF-κB activation (Chamoux et al. 2009). This data thus identifies p62 as an 
important osteoclastogenesis mediator, and links the p62P392L mutation to the formation of 
overactive osteoclasts through signaling pathways involving PDK1, PKCζ, and NF-κB 
activation. PKCζ was shown to be involved in RANKL-induced activation of NF-κB as well 
as in the basal over-activation of NF-κB observed in p62P392L-transfected osteoclasts 
(Chamoux et al. 2013).  
 Activation of NF-κB typically involves IKK-mediated phosphorylation of IκB, 
leading to its release from NF-κB subunits p50/p65. This allows these subunits to translocate 
to the nucleus, while IκB phosphorylation targets it for ubiquitination and eventual 
proteasomal degradation. IκBα expression was shown to be greater in the presence of the 
p62P392L mutation, and given the shuttling role of p62 (Seibenhener et al. 2004), this may be 
related to defective UBA domain activity, preventing it from binding polyubiquitinated 
proteins directly (Cavey et al. 2006). Our results suggest that p62 contributes to IκBα 
degradation by direct association, and thus high levels of IκBα detected in the case of p62 
mutation are likely related to defective IκBα clearance, in addition to NF-κB-induced IκB 
gene expression (Perkins 2007). This finding was consistent with other studies that conclude 
that a functional UBA domain is required for p62-dependent proteasomal functions (Wooten 
et al. 2005).  
 However, one would expect impaired IκBα degradation to lead to a decrease in the 
liberation/activation of NF-κB subunits remaining in the cytoplasm (Mitchell 2003). This has 
in fact been reported in a murine osteoclast model, where proteasomal inhibitors suppressed 
RANKL-induced osteoclastogenesis by preventing IκBα degradation (Ang et al. 2009). This 
apparent incongruity may be due to a relatively larger impact of other mechanisms 
stimulating NF-κB activation, or through IκB sequestration but no accompanying 
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degradation. Depending on the system, PKCζ has been shown to activate NF-κB by acting 
as an IKK kinase, or downstream of IKK by controlling the transcriptional activity of the 
NF-κB complex (Moscat, Diaz-Meco, and Wooten 2007). In a non-osteoclastic model, it has 
been proposed that IKKΒ could be recruited to the multiprotein complex including TRAF6, 
p62, and PKCζ following activation signaling (Wooten et al. 2005). IKKβ over-activity has 
been shown to induce osteoclastogenesis even in the absence of RANKL (Otero et al. 2010). 
The results we obtained suggest that PKCζ can act as an IKK kinase in RANKL-induced 
activation of NF-κB in osteoclasts, but did not suggest that this kinase activity is sufficient 
to account for the activation of NF-κB associated with the p62P392L mutation.  
 There are other mechanisms besides cytosolic degradation of IκB that may account 
for NF-κB activation, like the phosphorylation of the NF-κB subunit p65 (Neumann and 
Naumann 2007). This phosphorylation may occur at specific serine residues, and take place 
in the nucleus or cytoplasm, all dependent on kinase, stimuli, and cell type (Viatour et al. 
2005). Direct phosphorylation of p65 not only enhances its transactivation potential, but 
reduces its affinity for the regulatory IκB, allowing for nuclear translocation independent of 
canonical signaling (Perkins 2007). Of the kinases known to phosphorylate p65 are included 
MAP3K NF-κB-inducing kinase (NIK) (Jiang et al. 2003), IKKs at Ser536 (Sakurai et al. 
1999), and PKCζ at Ser311 (Duran, Diaz-Meco, and Moscat 2003). In a human osteosarcoma 
cell line (SAOS), ribosomal S6 kinase-1 (RSK1) has been shown to phosphorylate nuclear 
p65 at Ser536, reducing its IκBα affinity, and reducing IκBα-mediated nuclear export of the 
p-p65/p50 complex (Bohuslav et al. 2004). Another pathway identified in osteoclast 
precursors from mice demonstrated that RANKL induces phosphorylation at this same serine 
residue via the TGFB-activated kinase 1 (TAK1)-MKK6-p38 pathway, independently of IκB 
degradation (Huang et al. 2006). In our human osteoclast model, we evaluated the 
phosphorylation of targets of IKK and PKCζ, Ser536 and Ser311, and found that RANKL-
induced p-Ser536 p65 levels were altered by PKCζ inhibition. Despite PKCζ’s previous 
association as a Ser311 kinase, phosphorylation of this site was not significantly modified 
under the conditions tested. However, the PKCζ-regulated Ser536 phosphorylation was 
further augmented (and equally reduced following inhibition) in osteoclasts carrying the 
p62P392L mutation, indicating that the PKCζ/p65 pathway is a potential contributor to the 
basal over-activation of NF-κB observed in these cells. This alternative pathway could be 
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used preferentially in the presence of the p62P392L mutation, which may hinder the ubiquitin-
proteasome pathway. 
Transcriptional Control of NF-κB by PKCζ Through p65 Phosphorylation 
 Under basal conditions, dimers of NF-κB subunits are bound to gene regulatory 
elements in the chromatin. This prevents undesired, uncontrolled activity through the 
recruitment of histone deacetylase (HDAC), which keeps the expression of kB-dependent 
genes inhibited by deacetylation of histones (as the name implies) (Zhong et al. 2002). p65 
has 12 potential phosphoacceptor sites. RelA can be phosphorylated by PKA and/or MSK1 
on its Ser276 once p50/RelA heterodimers are released from IκB. This phosphorylation 
promotes RelA interaction with the transcriptional co-activator CREB-binding protein 
(CBP), resulting in increased CBP-mediated histone acetylation, producing a more 
permissive chromatin structure for NF-κB transcriptional activity. In addition to Ser276, 
RelA has also been shown to be phosphorylated on Ser311 in response to TNF-α (Duran, 
Diaz-Meco, and Moscat 2003). This serine residue is specifically targeted by PKCζ, and 
has been shown to be required for full NF-κB transcriptional activity, both in vivo and in 
vitro (Leitges et al. 2001). Both phosphorylation residues in this Rel homology 
dimerization domain (RHD) are necessary for the recruitment of CBP (Duran, Diaz-Meco, 
and Moscat 2003). Phosphorylation of Ser311 is important as it takes place in a region 
proximal to other post-translational modifications that modulate the strength and duration 
of NF-κB nuclear activity (Yang, Tajkhorshid, and Chen 2010) (Figure 28). The acetylation 
of Lys310 is required for full transcriptional potential of NF-κB, and Lys314 and 315 are 
methylated to terminate the NF-κB signal (Yang et al. 2009). It has been reported that both 
acetylation and methylation are in a functional regulatory balance with phosphorylation in 
order to control transcriptional activation. The acetylation of Lys310 is blocked in the 
absence of Ser276 phosphorylation (Brasier et al. 2011), and this acetylation, in turn, 
impairs methylation of the other adjacent lysines, delaying ubiquitination and degradation 
of RelA (Yang, Tajkhorshid, and Chen 2010).  
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osteoclasts with a pX330 plasmid carrying the Cas9 nuclease and 100-150bp single-
stranded DNA guide with homology to p65, a point mutation can be induced by replacing 
the active serine with an alanine via the guide nucleotides. As this would inactivate the site 
in question without altering the other 11 known phosphorylation sites directly, it would 
allow us to further examine the PKCζ-driven NF-κB signaling pathways in the osteoclast. 
PKCζ and Non-Canonical NF-κB Signaling Pathways 
 These observations of PKCζ and IκBα expression and degradation promote a striking 
distinction between osteoclasts expressing wild-type or P392L mutant p62. While NF-κB 
activity is further activated when the UBA domain is affected, it does not appear to do so via 
the traditional pathway, and PKCζ may be one preferential pathway to the observed NF-κB 
activation, in part through regulating phosphorylation of p65. The mechanisms involved in 
over-activation of PKCζ in the presence of mutant p62 have not yet been fully investigated, 
though one hypothesis is that modification of the UBA domain could alter protein-protein 
interactions involving p62, promoting PB1 domain interaction between PKCζ and p62, or 
other activating kinases like PDK1 in the multiprotein complex (Seibenhener, Geetha, and 
Wooten 2007). TRK-fused gene (TFG), the only other protein yet identified with a PB1 
domain besides PKCζ and p62, has also been implicated in aggregate-related disease. In 
Charcot-Marie-Tooth disease, TFG mutations were identified as a genetic predispository 
factor, as well as associated with aggregate formation and faulty protein secretion in neurons 
(Tsai et al. 2014). It is important to note that PKCζ is not the only aPKC involved in 
osteoclastogenic signaling. PKCλ may also have an important role, as it has been shown to 
interact with p62 (Moscat et al. 2006), and interestingly, one study demonstrated that loss of 
PKCζ does not appear to impair RANKL-induced osteoclastogenesis (Durán et al. 2004). 
This suggests perhaps an alternative aPKC pathway necessary for NF-κB activation. In the 
2012 study, our laboratory showed that phosphorylation levels of PKCζ/λ were increased in 
PDB-like osteoclasts, and that p-PKCζ/λ colocalized with p62 following RANKL 
stimulation, while p-PKCλ/ι did not, indicating PKCζ specificity to this action (Chamoux et 
al. 2013). 
 Here we analyzed the impact of the p62P392L mutation on mature human osteoclasts, 
but effects of this mutation on osteoclastogenesis and differentiation merit further 
examination. For example, studies of murine precursors demonstrate an increased NF-κB, 
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p38 MAPK and NFATc1 activation in p62P394L mutants (Kurihara et al. 2007). While the 
presence of the p62P392L likely cannot account for all aspects of the pagetic osteoclast 
phenotype, we show that it clearly affects osteoclast activity and signaling pathways.  
 
The Role of P392L in Pagetic Osteoclast Activation 
Paget's disease of bone is characterized by focal and disorganized increases in bone 
turnover, and the pathology of the disease may be principally associated with increased and 
aberrant osteoclast function (Roodman and Windle 2005). The role of p62 as an important 
modulator of bone turnover in PDB (as well as healthy patients), was first highlighted by 
the discovery of mutations to the SQSTM1 gene in pagetic patients. Mutations to the UBA 
domain of p62 lead to a reduction in CYLD activity, and thus an increase in osteoclast 
development and resorption (Sundaram et al. 2011). However, the p62P392L substitution, 
first identified in 2002, is the most frequently recurring mutation associated with PDB 
(Hocking et al. 2002). 
The significance of this P392L mutation has made it a popular target for study, and 
it has been examined extensively in both human and murine models since its discovery. 
Osteoclast precursors transfected to over-express p62P392L are hyper-responsive to 
osteoclastogenic factors, such as RANKL and TNF-α, and also show an increased 
capability for bone resorption (Kurihara et al. 2007). As previously mentioned, transgenic 
mice that express the murine-equivalent mutation (P394L) develop an incomplete pagetic 
phenotype, but PDB-like bone lesions (Daroszewska et al. 2011a). Transgenic mice with 
the measles virus nucleocapsid (MVNP) under the tartrate-resistant acid phosphatase 
(TRAP, an osteoclast marker) promoter develop a PDB phenotype which is dramatically 
worsened under coexpression with the P394L mutation (Kurihara et al. 2011). 
Previous findings in our laboratory demonstrated that in human osteoclasts, even 
prior to RANK activation, p62 is associated with phosphorylated PDK1 and PKCζ in PDB 
osteoclasts (Chamoux et al. 2009). This association is also observed in healthy donors 
harboring the p62P392L gene, as well as P392L transfected osteoclasts. Although the 
overexpression of both wild-type and mutant p62 was shown to favor the formation of 
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activated aPKC complexes, only that of the p62P392L led to an increased basal level of NF-
κB activation in osteoclasts (Chamoux et al. 2009). Similarly, the overexpression of 
p62P392L in HEK293 or Cos-1 cells increases basal and RANKL-induced NF-κB activation, 
more so than overexpression simply of wild-type p62 (Rea et al. 2006)(Rea et al. 2009). 
Additional studies have also shown that this mutation upregulates NFATc1 expression in 
osteoclast precursors, favoring increased osteoclastogenesis, and the increased osteoclast 
activity associated with metabolic bone disease (Sundaram et al. 2011). Together, these 
findings suggest that p62P392L contributes to the induction of osteoclast activation in PDB 
by contributing to stimulation of signaling.  
 Changes in p62 activity or production have been shown to lead to impaired 
signaling and deficient autophagy in other cell and receptor models (Komatsu et al. 2007a). 
It is probable that the build-up of p62 or faulty UBA activity responsible for increased p62 
substrate activity is also responsible for reduced shuttling/ubiquitin-related activity, and 
ultimately any number of p62-associated feedback and signaling loops. Since studies 
support the theory that p62 acts as a conformational adaptor, not simply shuttling substrates 
to the proteasome, but linking substrates from one domain to those bound to another, its 
role in the osteoclast may be extremely complex (Seibenhener, Geetha, and Wooten 2007). 
Regardless, given the number of mechanisms thus regulated directly or indirectly by p62, 
its importance to osteoclast activation is unquestionable; critical to signaling, 
polyubiquitination, autophagy, and trafficking. Therefore this RANKL regulator and its 
substrates provide a number of targets of interest in order to better understand osteoclast 
activation and survival signaling. Overall, our findings provide new insights into the p62-
linked pathways leading to NF-κB activation in human OCs, and highlight the crucial role 
of PKCζ in the uncontrolled activation of PDB OCs, which may contribute to the increased 
resistance to OC apoptosis and to the excessive bone resorption observed in pagetic lesions. 
Osteoclast Apoptosis and Survival Pathways 
 The RANK-p62-TRAF6 signaling complex activates a host of kinases and cascades 
essential to survival and activity in osteoclasts. In PDB osteoclasts, there are major shifts in 
the pathways activated by RANKL, with an upregulation of activity and survival, regardless 
of the presence of the PDB-associated p62P392L mutation. Gene expression studies have also 
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indicated that genes involved in osteoclast apoptosis, such as CASP3, TGFBR1, 
TNFRSF10B, and others were downregulated in PDB, whereas expression of anti-apoptotic 
BCL2 and AKT1 were upregulated (Michou et al. 2010). While the prevention of apoptosis 
has been well-established in PDB, the underlying mechanisms have yet to be fully 
characterized beyond conjecture. It is known that the RANKL-induced p62-TRAF6 complex 
promotes NF-κB transcription, as well as activating c-Src, a tyrosine kinase that signals 
through both PI3K/Akt and MEK/ERK pathways, both shown to be essential to osteoclast 
survival. It is thus logical to presume that the increased phosphorylation levels of Akt and 
ERK observed here encourage PDB osteoclast survival.  
 Differentiated, mature osteoclasts have a short lifespan. In addition, they are 
extremely sensitive to growth factor signaling pathways, with one in vitro study reporting 
less than 24% survival in the absence of cytokines and growth factors following a 24 hour 
incubation (Lee et al. 2001). This same study reported that stimulation with TNF-α was 
sufficient to increase survival rate to ~80%, via reduction of apoptosis through suppression 
of caspase activation.  This pathway increased Akt phosphorylation in osteoclasts, while the 
effect was attenuated by PI3K (LY294002) or Src (PP1) inhibition. TNF-α stimulation also 
led to an increase in ERK phosphorylation, increasing survival (Lee et al. 2001). These results 
are not unlike those we observed in the pagetic model, where phosphorylation of ERK, Akt, 
and Akt targets were increased, leading to apoptosis resistance. Later studies showed that 
supplementing in vitro osteoclasts with RANKL and/or M-CSF did not impact survival, 
blocking MEK, Akt, or NF-κB pathways led to high apoptosis levels. Inhibition of MEK and 
Akt simultaneously resulted in near total cell death, simulating loss of PI3K signaling 
(Gingery et al. 2003). In vitro, PDB osteoclasts thus appear to follow a basal TNF-like 
stimulation pattern of PI3K, in which we demonstrated the Akt-regulated survival pathway 
to be PDK1-dependent.  
 As RANKL is a TNF family member, TNF-α and RANKL stimulate activity of NF-
κB, c-Fos, and NFATc1 sequentially in vitro in osteoclast precursors in a very similar manner 
(Boyce and Xing 2007). However, TNF induces significantly less osteoclasts in vitro than 
RANKL (Yamashita et al. 2007). TNF induces osteoclastogenesis in RANK-/- precursors, 
but fails to induce osteoclast formation in RANK-/- mice in vivo, suggesting that it may also 
induce inhibitors of osteoclastogenesis (Li et al. 2000). Both TNF and RANKL induce 
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expression of the inhibitory NF-κB p100 protein, but differ in that RANKL processes it to 
p52 while TNF does not (Chaisson et al. 2004). Indeed, p100/RANKL dKO mice were able 
to form osteoclasts following TNF stimulation (Yamashita et al. 2007), illuminating a 
mechanism by which TNF-induced osteoclastogenesis is regulated. As TNF depends on other 
TRAFs than RANK, the introduction of a catalytically inactive TRAF2 would provide an 
interesting point of study in the osteoclast. As demonstrated in other models, the RING 
domain of TRAF2 is necessary for NF-κB reporter activity (Hupalowska, Pyrzynska, and 
Miaczynska 2012), and is vital for TNF-associated ubiquitination processes. Defective 
TRAF6 signaling (as mediated by p62) is already associated with the pagetic phenotype 
(Sundaram et al. 2011), and negative regulation of TRAF2 could lead to a switch from 
canonical to non-canonical NF-κB signaling (Grech et al. 2004).  
PKC and Akt Regulatory Pathways in Survival 
 There exists potential for crosstalk between the aPKCs and Akt signaling as well. 
One such pathway is through the pro-apoptotic protein Par-4 (prostate apoptosis response 
4). This protein drives trafficking and activation of Fas and Fas ligand to induce apoptosis, 
while also inhibiting NF-κB transcriptional activity in prostate cell models. Par-4 carries 
out this second action in part through interaction with the zinc-finger domain of aPKCs, 
which results in the repression of their enzymatic activity, reducing NF-κB activation 
(Díaz-Meco et al. 1996). One example of Par-4 regulation of aPKC activity was 
demonstrated in a murine model, where PKCζ knockout mice demonstrated impaired B- 
and T-cell proliferation and function (Martin et al. 2002), and Par-4 deficient mice saw 
increases in proliferation and activity of these cells (Lafuente et al. 2003). Other studies in 
knockout mice have suggested Par-4 as a tumor suppressor through its ability to modulate 
cell survival through the aPKC-NF-κB cassette (Joshi et al. 2008; Diaz-Meco and Moscat 
2012). Recent in vivo results, however, have demonstrated crosstalk with Akt in a PTEN-
deficiency-driven prostate cancer model (Fernandez-Marcos et al. 2009). Par-4 inactivation 
in PTEN heterozygous mice led to invasive carcinoma formation. It was also demonstrated 
that inactivation of NF-κB dramatically reduced Par-4/PTEN deficiency-driven 
tumerogenicity (Fernandez-Marcos et al. 2009). PTEN is a negative regulator of Akt 
activation, suppressing the PI3K pathway through its lipid phosphatase activity of PIP3 
(Song, Salmena, and Pandolfi 2012). Enhanced Akt activity was observed in both PTEN 
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mutant and Par-4 KO prostates, and this activation was additive in double Par-4/PTEN 
mutant prostates (Fernandez-Marcos et al. 2009), suggesting that Akt is a downstream 
target of Par-4. Similarly, it has been shown that PKCζ has been shown to be able to 
phosphorylate Ser473 and Ser124 of Akt, and these phosphorylations are antagonized by 
Par-4 (Joshi et al. 2008). While PKCζ can target Ser473, the principal kinase of this Akt site 
is the TORC2 complex, and studies employing Rictor (rapamycin-insensitive companion of 
mammalian target of rapamycin) knockdown strategies demonstrated that PKCζ is not a 
major contributor to activation of Ser473, yet is vital to Ser124 phosphorylation (Sarbassov 
et al. 2005b). The phosphorylation of this residue, along with that of Thr450, plays an 
important role in facilitating Thr308 and Ser473 phosphorylation by PDK1 and mTOR, 
respectively (Manning et al. 2002). Therefore, Par-4/PKCζ interaction may be at least 
partly responsible for Akt and NF-κB activation in Paget's disease, as they have shown to 
be in several neoplasias. Interestingly, it has also been reported that Akt is, in turn, a 
regulator of Par-4 activity (Goswami et al. 2005) Figure 29. Akt physically binds to Par-4 
via the latter's leucine zipper domain, and phosphorylates it, marking it for sequestration by 
14-3-3, and thus preventing its pro-apoptotic signaling. In cancer cells, apoptosis caused by 
inhibition of Akt was blocked by concurrent inhibition of Par-4 expression, but not by 
inhibition of other Akt substrates that are apoptosis agonists, suggesting that PI3K-Akt 
inhibition-induced apoptosis is Par-4 dependent (Goswami, Ranganathan, and Rangnekar 
2006). 
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Figure 29 : Regulatory Elements in Akt and aPKC Signaling Pathways 
Following RTK activation, PI3K phosphorylates PIP2 to generate PIP3, leading to the 
activation of many downstream kinases. PTEN is a lipid phosphatase that antagonizes this 
pathway by hydrolyzing PIP3. Loss or reduction of PTEN leads to increased recruitment of 
PH domain containing proteins to the membrane and their subsequent activation. Par-4 
directly binds the zinc-finger domain of aPKC isoforms, inhibiting their enzymatic activity, 
impairing NFκB activation. As Akt is a direct substrate of PKCζ, this reduces Akt activation 
as well. Conversely, Akt can inhibit Par-4 by phosphorylation, marking it for sequestration, 
increasing pro-survival and activation signaling in the process. 
 
 
 Via Akt, GSK3β plays an important role in RANKL-induced osteoclastogenesis 
through the NFATc1 signaling cascade. In addition to increasing osteoclast formation and 
NFATc1 expression in bone marrow-derived macrophages (BMMs), overexpression of Akt 
was also shown to enhance phosphorylation of GSK3β, thus inactivating it and allowing for 
the increased nuclear localization of NFATc1 (Moon et al. 2012). Conversely, 
overexpression of constitutively active GSK3β downregulates NFATc1 and reduces 
osteoclast formation. Recently, a signaling link between GSK3β and PTEN in RANKL 
signaling has been identified, as down-regulation of PTEN by RNAi increased Akt and 
GSK3β phosphorylation levels by RANKL, promoting osteoclast formation (Jang et al. 
2013). In this study, phosphorylation of PTEN at Thr366 decreased during RANKL-
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induced osteoclastogenesis, and a Thr366 defective mutant presented increased 
osteoclastogenesis, consistent with lower phosphatase activity and a less-regulated PI3K 
axis. Additionally, GSK3β inhibitor treatment enhanced Akt phosphorylation through 
PTEN phosphorylation suppression, suggesting that inhibited GSK3β further activates Akt 
through PTEN regulation (Jang et al. 2013). Differential phosphorylation of the PI3K-
regulating PTEN is therefore one potential mechanism by which pagetic osteoclast 
signaling is dysregulated. 
 Another major physiological function of Akt relating to survival and tied to GSK3β 
is the regulation of cell metabolism. When high levels of insulin are present, Akt 
phosphorylates and inhibits GSK3β, promoting the storage of glucose as glycogen (Cross et 
al. 1995). GSK3β is also involved in regulating many other signaling pathways besides 
glycogen storage and NFATc1 transcription, like the β-catenin transcriptional pathway 
(Doble and Woodgett 2003). The inhibition of GSK3β has been demonstrated as pro-
survival, and one mechanism for this has been proposed to be cell metabolism-linked (Pap 
and Cooper 1998). The deprivation of cells through the withdrawal of growth factors leads 
to a reduced ability to use nutrients in the medium, leading to depleted ATP and glucose-
derived metabolites in the cell (Rathmell et al. 2000). Akt activation allows cells to 
continue importing glucose and amino acids (Song et al. 2005). In fact, Akt-directed 
glucose metabolism has been shown to prevent Bax conformational change to an active 
state, promoting growth factor-independent survival (Rathmell et al. 2003). It may be by 
such a mechanism that the osteoclasts observed in PDB enjoy a measure of protection 
against apoptosis under deprivation conditions when compared to control cells. 
The Role of PDK1 in Osteoclast Signaling 
 PDK1, as a kinase for the activation loop of many protein kinases of the AGC 
superfamily (cAMP-dependent, cGMP-dependent, and PKC, as well as Akt isoforms). Many 
proteins in the PI3K signaling pathway, like PI3K, Akt, and the phosphatase and tensin 
homolog on chromosome 10 (PTEN) are mediated by PDK1 activity (Cohen, Alessi, and 
Cross 1997). In addition, PDK1 activation is responsible for a number of downstream kinases 
associated with mTOR including p70S6K and 4EBP1, promoting cell growth and survival. 
Though it has previously gone unstudied in osteoclasts, the involvement of PDK1 in the 
regulation of such diverse kinases indicates a probable central role in osteoclast signaling. 
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Activation of PDK1 is dependent on PI3K, which while generally activated by tyrosine 
kinase receptors, is also regulated by TRAF6, signaling partner of RANK (Moon et al. 
2015a). PDK1 is known to be constitutively active via autophosphorylation on its T-loop at 
Ser241, but can be further activated by tyrosine phosphorylation (Tyr9 and Tyr373/376) 
(Park et al. 2001). The phosphorylation of PDK1 on Tyr9 is important for PDK1/Src complex 
formation (Yang et al. 2008), and this may be made possible by TRAF6-associated Src 
activation. While we did not observe any differences between PDB and control osteoclasts 
in terms of Ser241 phosphorylation, we did not specifically study tyrosine phosphorylation 
and activation of the kinase, which may contribute to the over-activation we observed of its 
substrates. Another target of interest may be phosphorylation of Ser396; the regulatory step 
necessary for nuclear shuttling of PDK1, possibly through its influence on the nearby nuclear 
export sequence (Figure 6) (Scheid, Parsons, and Woodgett 2005). By examining its nuclear 
localization as well as Ser396 phosphorylation, we may be able to determine if this residue 
(and by extension, any of its kinases), may be influential in the activation of the numerous 
downstream targets of PDK1 we observed in PDB.  
In addition, the position and protein-interactions of PDK1 within the cell may inform 
its activity beyond its role as a kinase (Kikani, Dong, and Liu 2005). Given the role of PDK1, 
a serine/threonine kinase, as a master protein kinase in the regulation of many cell signaling 
pathways, it may also play a role in other TRAF6-p62 associated cascades. In addition, 
overexpression of PDK1 has been associated with toxicity in some cell types, despite the 
numerous pro-survival pathways maintained by its target kinases. For example, biochemical 
studies have revealed that PDK1 interacts with TAK1, inhibiting its association with TAB2, 
reducing TRAF6 ubiquitination, and ultimately downstream signaling including that of NF-
κB (Moon et al. 2015b). Finally, PDK1 activity against specific substrates requires that those 
targets be primed, an activity that is mainly mTOR dependent (Yang and Guan 2007), before 
PDK1 phosphorylation can take place. Through this mechanism is represented another 
possible source of regulation of PDK1 that may explain in part the Pagetic phenotype 
observed. We observed increased Ser473 phosphorylation of Akt, and Thr389 p70S6K, for 
example, but there are numerous other targets like PKCα, SGK1, and others that could further 
indicate mTOR priming of PDK1 substrates.  
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Survival and Resorptive Capacity Following PDK1 and MEK Inhibition 
We found that inhibition of MEK1/2 or PDK1 was sufficient to induce apoptosis at 
levels equivalent in PDB and control osteoclasts, eliminating the initial apoptotic resistance 
of PDB osteoclasts. While Akt has surprisingly been shown to be dispensable for survival in 
osteoclast precursors (Sugatani and Hruska 2005), many molecules targeting the PI3K/Akt 
pathway, both indirectly and directly, have been demonstrated to be effective in inhibiting 
OC differentiation and thus ultimately resorption (Cao et al. 2013). The significant reduction 
of resorption observed by both control and PDB osteoclasts following inhibition suggest that 
PDK1 is indeed pivotal in controlling pathways responsible for osteoclast activity. Indeed, 
the observed increases up to 60% apoptosis under PDK1 inhibition represent a change of 0.5 
to 3 fold, while the concomitant decreases in resorption observed were from 5 to 20 fold. 
This change suggests that while PDK1 directly regulates survival, it also likely impacts 
osteoclast activity beyond the apoptotic pathway as well. 
ERK Activation and Targeting in Osteoclasts 
 It has also been reported in vitro that MEK/ERK inhibitor PD98059 reduces 
osteoclast development and belt formation (Yan et al. 2008), though effects on mature 
osteoclasts were not published. As with Akt, it appears that one mechanism by which ERK 
promotes cell survival is through inactivation of pro-apoptotic proteins. ERK has been 
shown to be involved in the Ser112 phosphorylation of BAD, member of the Bcl-2 family 
(Fang et al. 1999). Ordinarily, non-phosphorylated BAD translocates from the cytosol to 
the mitochondria, heterodimerizing with Bcl-xL to induce apoptosis (Zha et al. 1996)). 
However, ERK cannot directly phosphorylate BAD at Ser112, and this phosphorylation has 
been suggested to be carried out by a downstream kinase of ERK, such as RSK (Bonni et 
al. 1999). While our results showed no change in phosphorylation of RSK2 between PDB 
and control osteoclasts, despite increased ERK phosphorylation (data not shown), ERK 
activity was still clearly necessary to survival in the cells observed. The PI3K/Akt pathway 
and crosstalk with Raf/MEK/ERK have also been identified as controlling osteoclast 
apoptosis (Bradley et al. 2008). Ras but not Raf inhibition decreases PI3K activation, and 
inhibition of PI3K or Raf blocks MEK/ERK activation and promotion of osteoclast 
survival, suggesting that Raf is separate from Ras/PI3K signaling, and likewise, PI3K is 
separate from Ras/Raf, but that there is some interplay between the two, promoting 
  
131 
131 
MEK/ERK-mediated osteoclast survival. Considerable crosstalk between these pathways 
has been observed in other cell types as well, with Ras identified as the common mediator 
in osteoclasts (Bradley et al. 2008). Ras mutations are strongly correlated with cancers and 
hyper-proliferation (Prior, Lewis, and Mattos 2012), and while such mutations have not 
been identified in PDB, this does not preclude altered functionality of Ras contributing to 
Paget’s disease, given the pathways augmented are regulated by this GTPase. 
 Another effect of ERK inhibition through PD98059, as mentioned, was inhibition of 
ruffled border formation in osteoclasts. A similar phenomenon has been reported following 
wortmannin treatment (a PI3K inhibitor) (Hall, Jeker, and Schaueblin 1995). These 
structures essential for bone resorption are believed to be formed by the fusion of 
lysosomes. In one study, vacuoles were visible in osteoclasts after incubation with 
PD98059, possibly due to prevention of lysosome transport, leading to accumulation of 
vacuoles. There are substrates of ERK like stathmin, a microtubule-associated protein 
(Filbert et al. 2012), that regulate cell-organelle transport, that may mediate this process. 
ERK has also been associated with cell polarity (Nakamura et al. 2003), as well as studies 
that have demonstrated that activation of ERK and subsequent regulation of its targets leads 
to enhanced cell migration (Huang, Jacobson, and Schaller 2004). Therefore ERK in 
osteoclasts may be involved in survival, motility, and cell polarity, at the very least. 
While PD98059 inhibits phosphorylation of both ERK1 and 2, this makes it difficult 
identifying which (or if both) are participating in osteoclast differentiation. In addition, the 
antibody we used was not specific to either form. However, the previously mentioned study 
showed that genetic disruption of ERK1 versus ERK2 preferentially impairs osteoclast 
formation and function, suggesting that ERK1 is more actively involved in 
osteoclastogenesis (He et al. 2011). As our antibodies recognized both ERK1 and ERK2, 
we can only therefore hypothesize that ERK1 may be the form driving the increase in 
phosphorylation that we observed in PDB osteoclasts.  
Pending confirmation, isoform-specific chemical inhibition may prove a promising 
avenue to targeted therapy. Though osteoclast treatment has focused on bisphosphonates, 
more selective compounds like those targeting Ras have been considered. Yet, results from 
Ras targeting methods like farnesyl transferase inhibitors have not been rewarding, as the 
isoforms present in myeloid lineages, like K-ras and N-ras are not farnesylation dependent 
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(Baines, Xu, and Der 2011). Therefore, given that ERK1 disruption is sufficient to dampen 
osteoclast function in vivo to the point that bone mineral density is increased (He et al. 
2011), ERK1-targeted chemical kinase inhibitors may be effective in treating the 
diminished bone mineral density found in skeletal pathologies. In the case of PDB, the 
augmentation of mRNA and phosphorylation levels we observed make it an even more 
appealing target, and this strategy may selectively modulate osteoclast function while 
reducing off-target effects of other MEK or ERK2 substrates. Of course, the interaction 
between individual cell lineages within the bone microenvironment under ERK isoform 
inhibition would first require further study. 
Treatment of Invasive Cells Via PDK1 Targeting 
 PDK1 was first identified as a possible cancer target when transgenic mice 
hypomorphic for PDK1 were crossed with tumorigenic heterozygous PTEN+/- mice 
(Bayascas et al. 2005). Those mice with deficient PDK1 levels were then shown to have 
reduced tumor burden. Identified as a potential target in several cancers since then, results 
from a colorectal cancer model demonstrated that PDK1 induced resistance to rapamycin 
inhibition, through Myc activation (Tan et al. 2010). While this study showed that this Myc 
activation is PDK1-dependent, it also proposed that said activation is PI3K/Akt 
independent, suggesting that in dysregulation, PDK1 can act independently of Akt. Another 
study fitting with this hypothesis, this time in breast cancer, observed that some cell lines 
exhibited reduced dependence on Akt signaling for tumerogenicity, but instead rely more 
heavily on PDK-1 activity (Vasudevan et al. 2009). Recent studies have also shown that 
Akt can facilitate cell death under certain conditions; increasing reactive oxygen species 
and suppressing antioxidant enzymes, representing a weakness of heavily Akt-active cells 
(Los et al. 2009). 
 While the necessity of PDK1 to cell growth, often through Akt, has been well 
characterized, it has also been increasingly linked to cell motility. For example, it has been 
demonstrated to regulate Rho-associated coiled-coil containing protein kinase 1 (ROCK1)-
dependent contraction of actin-myosin (Pinner and Sahai 2008). ROCK1 activation in these 
cells was not dependent on PDK1 kinase activity, but required direct binding of PDK1 to 
ROCK1 at the plasma membrane. This result suggests that PDK1 may have regulatory 
functions distinct both from its kinase activity as well as from Akt, relying instead on 
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allosteric interactions. Another study has linked PDK1 to PLCγ1 activation, in a 
mechanism requiring association of the two proteins (Raimondi et al. 2012). As with 
ROCK1, this pathway was also shown to regulate invasive capabilities of cancerous cells. 
 Phosphorylation of PDK1 at Ser241 is frequently elevated in breast cancers, with 
matching increases in phosphorylation of downstream kinases in a profile similar to that 
that we observed in PDB (Maurer et al. 2009). Among the elevated kinases in one study 
were Akt, mTOR, p70S6K, S6, and STAT3. Also similar to our results, in this particular 
study, PDK1 mRNA was found to be overexpressed in a majority of human breast cancers 
(Maurer et al. 2009). Here, copy number variation in the PDPK1 gene was attributed to 
PIK3CA, ERBB2, or PTEN alteration, suggesting targets that may perhaps also be linked to 
over-activation of PDK1 pathways in Paget’s disease, given the common downstream 
effects observed. 
 The first concern when considering clinical potential of PDK1-directed therapy is 
safety and specificity. There are now a number of highly selective compounds that bind 
PDK1 can target the active and inactive forms of the kinase (Medina 2013). These 
compounds have been shown to potently inhibit Akt Thr308 phosphorylation (Falasca et al. 
2010), and S6K and SGK activation in vivo (Najafov et al. 2011). However, only a small 
amount of in vivo data is currently available. One difficulty in the bone microenvironment 
is the ubiquity of PI3K/Akt survival signaling, as osteoblasts are also dependent on this 
pathway, and a murine osteoporosis model shows a reduction in PI3K family 
phosphorylation (Xi et al. 2015). Therefore, targeting PDK1 at effective doses may prove to 
be a difficult proposition. 
 PDK1 inhibition may prove most effective in combinatory treatment with other 
targeted therapies. Crosstalk between mTOR and Akt signaling pathways has been 
identified in some cancers (Lauring, Park, and Wolff 2013), and this has led to the 
combination of mTOR and PI3K inhibitors. Clinical success with mTOR inhibitors in 
combination with PI3K and Akt inhibition has been reported early on in breast cancer trials 
(Yardley 2013). One mechanism described is through Ser473 phosphorylation of Akt using 
mTOR inhibitors, further sensitizing Akt to PDK1 inhibitors (Najafov, Shpiro, and Alessi 
2012). The following combination of the two reduced Akt activation to below basal levels 
and markedly inhibited proliferation. We have observed, at the very least, an overlap in our 
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pagetic model between mTOR and PDK1 regulation of the autophagic process. Combining 
inhibition of the two in vivo may also represent a potential therapeutic avenue in PDB. 
However, it should be noted that toxicity of mTOR inhibitors has presented a major 
obstacle for some of the breast cancer patients treated.  
Autophagic Defects in Paget’s Disease of Bone 
 The detection of inclusion bodies that contain p62 and ubiquitin in PDB osteoclasts 
within affected bone suggests altered regulation of autophagy in these cells, as seen by 
aggregate accumulation. In concordance with this theory, we observed increases in LC3B-
II/LC3B-I ratios as well as LC3B puncta numbers per osteoclast in pagetic cells as compared 
to controls, in both basal and autophagy-induced conditions. As the expression of autophagy-
related genes in PDB osteoclasts was not seen to be upregulated in basal conditions 
(excluding ULK1), and also as LC3B levels did not further increase in the presence of 
lysosomal protease inhibitors, these findings suggest that there is an accumulation of non-
degradative autophagosomes in PDB osteoclasts. What’s more, the autophagy flux analysis 
indicates that PDB osteoclasts were less sensitive to induction of autophagy under weaker 
stimulatory conditions when compared with control cells, suggesting a defect in 
autophagosome formation as well. The increase in expression of the autophagy-initiating 
kinase ULK1 gene did not rely on autophagy induction, as the expression profile of a number 
of other autophagy-related genes, including LC3, were unchanged. However, ULK1 may be 
dependent on other modulators, which may not necessarily be associated with induction of 
autophagy, such as transcription factor ATF4, a downstream target of PI3K/Akt that is 
involved in osteoclast differentiation and RANKL signaling (Cao et al. 2010). In addition, 
no significant change in protein level was observed in pagetic osteoclasts. This could be due 
to a number of factors, with regulation at the post-transcriptional, translational, and 
degradation levels all influencing protein expression. Recent studies have demonstrated that 
mRNA concentrations can correlate to as little as 40% of observed protein levels (Vogel and 
Marcotte 2012). In short, a lack of production or activation of ULK1 suggests that it is not 
through this pathway that autophagy is altered in PDB osteoclasts, though we do show that 
its activity can be regulated by inhibition of PDK1. This may be regulated by PDK1 and c-
Src-mediated activation of AMP-activated kinase (AMPK), a nutrient-sensing enzyme that 
balances autophagy and ULK1 regulation along with mTOR.   
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 Indeed, in addition to being overactive and resistant to apoptosis, the PDB-derived 
osteoclasts that we observed also exhibit defects in autophagy. As crosstalk exists between 
autophagy and apoptosis pathways, we speculated as to whether common signaling pathways 
may generate the apoptosis and autophagy characteristics of PDB osteoclasts. Inhibition of 
autophagy through mTOR activation promotes osteoclast survival, and the Akt/mTOR 
pathway has been shown to be involved in RANKL-induced osteoclast formation and 
activation. We observed an augmentation in basal phosphorylation levels of mTORc1 subunit 
Raptor, which may relate to the observed increase in mTOR-mediated effects. Like most 
other mTOR and PDK1 substrates we tested, this phosphorylation was also sensitive to PDK1 
inhibition. There may be a second effector of Raptor activation, as p62 is an interacting 
partner, necessary to mediate S6K and 4EBP1 activation in an amino acid dependent manner 
(Duran et al. 2011). We observed basal activation of these two pathways, which were also 
shown to be dependent on PDK1 phosphorylation, suggesting that p62’s regulatory function 
of mTOR in PDB may rely on PDK1 kinase activity.  
Rapamycin, a potent mTORC1 inhibitor, decreases osteolysis in an in vivo model of 
bone metastasis, and decreases RANKL-induced osteoclast formation in vitro (Hussein et al. 
2012). The activation of Akt also results in phosphorylation and inactivation of the FoxO3 
transcription factor, responsible for regulation of autophagy-related genes like LC3B and 
BNIP3 (Bcl-2 interacting protein 3) (Mammucari, Schiaffino, and Sandri 2014). 
Furthermore, Akt-mediated phosphorylation of Beclin1 has recently been shown to inhibit 
autophagy (Wang et al. 2012). Accordingly, we observed that inhibition of PDK1 not only 
induced apoptosis as noted, but also reduced signaling in both mTOR and PI3K/Akt 
pathways in osteoclasts, negating the increases in basal activation shown in PDB. 
Autophagy-associated Osteoclast Dysfunction 
 Autophagy was long viewed as a non-selective process, but increasing studies 
demonstrate varying forms of selective autophagy (Reggiori et al. 2012). Unwanted 
structures are sequestered by autophagosomes through the action of specific receptors and 
adaptors, connecting the cargo to be degraded with the core autophagy machinery. Typically 
these receptors present a ubiquitin-binding domain, allowing their interaction with 
ubiquitinated structures targeted for destruction, and a specific amino acid sequence referred 
to as the LIR motif, or LC3-interacting region, which binds to ATG8 protein family members 
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in the PAS (Shaid et al. 2013). The best characterized autophagy receptors to date include 
p62, NBR1, and Optineurin (Optn).  
P62 has been detailed elsewhere here as a key regulator of selective autophagy, and 
its presence in inclusion bodies has been reported. As virtually all the mutations identified to 
date in PDB are clustered within or near the UBA domain of p62, there may well be a 
connection between the shuttling of ubiquitinated substrates. An impaired autophagosomal 
degradation of p62 has been observed in HEK293 cells transfected with p62-expressing 
plasmids (Zhou et al. 2013), and introducing the PDB-related p62P394L in transgenic mice led 
to RANKL-dependent increases in LC3B-II/Actin in osteoclasts (Daroszewska et al. 2011a). 
However, in our study, we did not find any impact of p62P392L on autophagy-related gene 
expression, nor on LC3BII/LC3B-I ratios, and thus we did not further attempt to characterize 
the impact of the p62P392L mutation on the kinome profile or the autophagic process as a 
whole. We did not specifically investigate p62-related selective autophagy, which may 
further elucidate its role in the pagetic phenotype. 
Of the selective autophagy receptors, Optineurin has also been associated with PDB, 
as one common variant has been found at its locus, resulting in reduced levels of mRNA 
(Obaid et al. 2011). Loss of Optn function in a murine model leads to enhanced osteoclast 
differentiation, as unlike p62, Optn was shown to be a negative regulator of osteoclast 
differentiation (Obaid et al. 2015). Osteoclasts derived from these mice had increased NF-
κB activation and reduced interferon beta expression in response to RANKL. These effects 
appear to be dependent on expression level and the ability of Optn variants to bind 
polyubiquitin.  
Nbr1 is a ubiquitous kinase scaffold protein which has been linked to bone mass 
regulation. Like p62, it contains PB1 and UBA domains, and targets LC3 as well as 
polyubiquitin-positive bodies in a p62-independent manner (Waters et al. 2009). This is 
perhaps the most intriguing aspect of the protein as it relates to PDB, as it may explain 
somewhat the partial phenotypes of p62 mutants. Nbr1 may provide a redundant pathway, 
taking over some of the autophagy-related functions of p62 in the osteoclast (Komatsu et al. 
2007b). It has been shown to bind a number of other targets as well, proteins associated with 
ubiquitin-mediated turnover and vesicle trafficking whose disruption is implicated in several 
hereditary human diseases (Lange et al. 2005). Genetic truncation of murine Nbr1 leads to 
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age-dependent increase in bone mass and bone mineral density, a process driven by increases 
in osteoblast differentiation and activity (Whitehouse et al. 2010). Truncated Nbr1 co-
localizes with p62 and LC3 in osteoblasts, but unlike the full-length version of the protein, 
fails to complex with activated p38. Both osteoblasts and osteoclasts show increased 
activation of p38 MAPK, but in this model the increase in bone formation outweighs any 
added osteoclast contribution. Nbr1 truncation also led to increased p62 protein expression 
(Whitehouse et al. 2010), further suggesting that p62 and Nbr1 may play compensatory roles 
for one another. 
Autophagy and Non-Canonical NF-κB Signaling 
 CD40L-mediated degradation of TRAF3 by TRAF2/cIAP1, thus regulating non-
canonical NF-κB signaling occurs in osteoclast precursors in response to RANKL 
(Zarnegar et al. 2008). This results in NIK-mediated proteasomal degradation of p100 and 
p52/RelB nuclear translocation. In cells like B-cells, TRAF3 is degraded through the 
ubiquitin-proteasome pathway by E3 ligases, while deubiquitinases inhibit TRAF3 
proteolysis, limiting non-canonical NF-κB activation (Criollo et al. 2010). However, in 
osteoclast precursors, the degradation of TRAF3 is mediated by an autophagosomal rather 
than proteasomal pathway (Xiu et al. 2014). This degradation can be prevented in vitro by 
treatment with autophagy inhibitor chloroquine, which raises the pH of lysosomes, thus 
inhibiting lysosomal enzymes than function in acidic conditions, and preventing 
degradation (Zarnegar et al. 2008).  
 By preventing TRAF3 degradation, chloroquine dose-dependently inhibited 
RANKL-induced osteoclast formation, and prevented bone resorption (Zarnegar et al. 
2008). The TRAF3-/- genotype is lethal within 2 weeks of birth, due to multi-organ 
inflammation associated with uncontrolled NIK activity, a phenotype that is rescued by 
crossing these mice with p100-/- mice (Lee et al. 2004), confirming the role of p100 as a 
negative regulator of non-canonical NF-κB signaling. However, osteoclast-lineage-specific 
deletion of TRAF3 increased osteoclastogenesis, leading to osteoporosis, demonstrating 
that TRAF3 is a major negative regulator of osteoclast formation (Xiu et al. 2014). 
Therefore in addition to the contribution we attributed to PKCζ, the non-canonical NF-κB 
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activity accounting for nuclear localization of NF-κB subunits in PDB may also come 
partly from autophagic dysfunction. It is possible that sequestering of TRAF3 or p100 by 
p62 aggregates could lead to increased osteoclast activity as well. 
p62 and Autophagic Regulation 
The role of p62 as an autophagic regulator is controversial or at the very least, 
varied. As noted, it has been suggested to aid in mTORC1 activation by promoting its 
translocation to the lysosome. Stimulation of mature osteoclasts with RANKL increases the 
size and number of lysosomes, via transcriptional activation of lysosomal genes implicated 
in bone resorption (Lacombe, Karsenty, and Ferron 2013). This occurs without affecting 
osteoclast numbers (Ferron et al. 2013), inferring a differentiation-independent mechanism. 
Reducing p62 may be expected to activate autophagy by way of mTORC1 inactivity 
(Duran et al. 2011). In carcinoma cells, the silencing of p62 suppressed proliferation and 
induced autophagy, consistent with mTOR inactivation, but abnormal autophagosomes 
were identified, and continued inhibition lead to autophagic cell death (Nihira et al. 2014). 
Additionally, in multiple cancerous cell lines, p62 has been demonstrated to disrupt the 
association of Bcl-2 and Beclin1, liberating the latter, and thus may positively regulate 
autophagy induction (Zhou et al. 2013). Autophagy has been involved in hypoxia-induced 
osteoclastogenesis (Zhao et al. 2012), and p62 has been linked to starvation-induced 
autophagy in human osteoclasts (Hocking et al. 2010). The role of p62 in autophagy is 
nuanced and often context-dependent. 
Another pathway tied to autophagy and impacted by p62 activity is the oxidative 
stress response, regulated by the Keap1-Nrf2 system (Wardyn, Ponsford, and Sanderson 
2015). Via its KIR motif, p62 can bind Keap1, an E3 ligase adaptor protein. Keap1 
promotes polyubiquitination of the transcription factor Nrf2, leading to proteasomal 
degradation under normal circumstances, but p62 binding inhibits this activity. Interaction 
with p62 also leads to selective autophagy of Keap1, removing it from the cytosol (Taguchi 
et al. 2012).Consequently, expression of antioxidant and cytoprotective target genes of 
Nrf2 are increased (Komatsu et al. 2010). As part of a positive feedback loop, the p62 gene 
itself is one such target for Nrf2 under certain conditions of oxidative stress (Jain et al. 
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2010). The antioxidant effect provided by sestrins is due in part to the induction of p62-
dependent autophagy of Keap1 (Bae et al. 2013). The development of some liver 
carcinomas has been associated with autophagic impairment and subsequent accumulation 
of p62, resulting in over-activation of Nrf2 (Komatsu et al. 2010). In this same model, p62 
has been shown to be phosphorylated by mTORC1 to increase its affinity for Keap1, 
demonstrating that via p62, mTORC1 may promote selective autophagy, despite its role as 
a negative regulator of the autophagic process in general (Ichimura et al. 2013). 
Autophagy Inhibition and the Bone Microenvironment 
Several compounds known to induce autophagy have been shown to benefit bone 
balance (Rubinsztein, Codogno, and Levine 2012). Rapamycin is a potent mTOR inhibitor, 
and therefore an autophagy inducer. In vitro, a rapamycin analog has been shown to inhibit 
osteoclast formation and activity, and prevented ovarectomy-induced bone loss by 60% in 
mice (Kneissel et al. 2004). The mood-stabilizer Lithium induces autophagy through several 
mechanisms, including inhibition of inositol monophosphatase (IMPase), leading to reduced 
IP3 levels, reducing signaling downstream of ULK (Motoi et al. 2014). Lithium also activates 
canonical Wnt signaling in mice, leading to bone formation (Clément-Lacroix et al. 2005), 
and reduces turnover in humans (Zamani, Omrani, and Nasab 2009).  
Two potent inhibitors of bone resorption are also associated with autophagy 
regulation. Estradiol stimulates bone matrix synthesis and osteoblast proliferation, in addition 
to its inhibitory effects on resorption (Galea et al. 2013; Y. Matsumoto et al. 2013). 
Commonly used to prevent bone loss and osteoporotic fractures in postmenopausal women, 
it has recently been shown to enhance osteoblast autophagy through the Ers-ERKmTOR 
signaling axis (Yang et al. 2013). Under these same conditions, increased autophagy rescued 
osteoblasts from apoptosis. The most commonly prescribed treatment for osteoporosis and 
various other disease associated with increased bone resorption are bisphosphonates (Bolland 
and Cundy 2013). It has been shown that bisphosphonates induce autophagy in some cancer 
cells which leads to apoptosis (Wasko, Dudakovic, and Hohl 2011). This bisphosphonate-
induced autophagy has more recently been shown to be mediated via oxidative stress increase 
in cancer cells (Khandelwal et al. 2014). 
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PDK1 as an Autophagy Regulator in Osteoclasts 
 The inhibition of PDK1 produced a more potent effect in PDB osteoclasts than in 
controls, with a significant impact on the formation of LC3B and p62-positive punctas. This 
may be due to a sustained activation of this pathway in pagetic osteoclasts, slowing the 
induction of autophagy, and these results suggest that PDK1/Akt represent a critical 
checkpoint for autophagic dysfunction in Paget’s disease. Concurrently, inhibition of 
MEK1/2 did not significantly alter puncta formation between PDB and control osteoclasts, 
despite being an equally effective inducer of apoptosis as PDK1. Inhibition of the MEK/ERK 
pathway has been shown to selectively impact late autophagosomal maturation, but did not 
seem to impact autophagosomal clearance in PDB (or control) osteoclasts, implying that this 
is regulated by another mechanism to be determined. The modulation of cell survival was 
insufficient to change autophagic flux, confirming that these are independent pathways for 
the osteoclast. 
MAPK Regulation of Autophagy 
 Despite MEK inhibition alone being insufficient to change the PDB autophagic 
phenotype in vitro, another means of dysregulation of autophagy in PDB may be through 
JNKs. RANKL stimulation induces significant c-Jun phosphorylation at low doses in 
pagetic osteoclasts (Menaa et al. 2000). Once activated, JNKs translocate from the 
cytoplasm to the nucleus (Mizukami et al. 1997). c-Jun is best characterized as a regulator 
of pro- and anti-apoptotic genes Bax and Bcl-2 (Kops et al. 2002). It is through this 
regulation of Bcl-2 activity that c-Jun may regulate autophagic processes. Bcl-2 is capable 
of forming complexes with several different proteins, one of which is Beclin1, and this 
complex has been theorized to act as a rheostat, maintaining the proteins responsible for 
autophagy activation, ensuring rapid response to cellular stressors (Pattingre et al. 2005).  
 Beclin1 is the first identified mammalian autophagy protein (Oberstein, Jeffrey, and 
Shi 2007). Autophagy in tumor cells correlates with Beclin1 expression (Zhou et al. 2015), 
and it has since been described as a core element in membrane formation; recruiting and 
activating the hVpw34 protein, forming a complex of Beclin1-hVps34-Vps15. This 
complex is vital to development of the pro-autophagosomal protein structure/phagophore 
assembly site (PAS) (Furuya et al. 2005). Beclin1 is a BH3-only domain protein, interacting 
with Bcl-2 family anti-apoptosis proteins through said domain, thus inhibiting its activity. 
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Other BH3 proteins can induce autophagy through competitive inhibition of this interaction 
with Bcl-2 (He and Levine 2010; Maiuri et al.). It has been shown that in addition to Bcl-2, 
viruses can inhibit Beclin1-dependent autophagy in mammalian cells (Pattingre et al. 
2005), and transgenic expression of Bcl-2 in murine myocardial cells reduced starvation-
induced autophagy, demonstrating in vivo and in vitro regulation though this complex. 
Research has since demonstrated that regulation of Beclin1/Bcl-2 interactions governs the 
autophagic response to different cell stresses (Levine, Sinha, and Kroemer 2008), and post-
translational modifications of one or both alter this interaction, and thus autophagic balance 
(He and Levine 2010). Additionally, it has been reported that phytoalexin resversatrol 
(RSV) can induce caspase-independent apoptosis of myeloid leukemia cells through 
autophagy, via JNK-dependent p62 accumulation, as well as overexpression of JNK-
mediated p62 and activation of AMP kinase (Puissant et al. 2010). This response has been 
hypothesized to be mediated not just by JNK, but also by the pro-survival signals regulated 
by Akt/mTOR (Rodríguez-Blanco et al. 2012). Therefore, MAPK/JNK regulation of 
autophagy in pagetic osteoclasts may be complicated by the over-activation of Akt/PI3K 
pathways we observe. 
Other Contributory Factors 
 One additional factor to consider when regarding the results presented here are that 
the patients with PDB in our cohort were significantly older than the controls. Autophagy is 
known to be impaired with age, with associated declines in classical and selective autophagy, 
and both autophagy induction and autophagosomal degradation are impacted (Levine and 
Kroemer 2008). This may therefore have weighted the results with an even greater natural 
variance in autophagic processes between PDB osteoclasts and controls. Conversely, the 
prevalence of Paget’s disease steadily increases with age, affecting up to 5% of adults over 
55 years of age, but nearly 10% of the population over 70, and a continuous trend (Galson 
and Roodman 2014). This suggests that autophagic defects associated with aging may very 
well be a part of the pagetic process itself. If we consider the correlation between aging and 
the rise of autophagic deregulation (Kroemer 2015), and apply Occam’s razor, this possible 
contribution seems ever more probable. 
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Environmental Factors and Paget’s Disease of Bone 
 Despite still affecting between 1.5-8% of the population, depending on age and 
country of residence, the prevalence of PDB has seemed to decrease in recent decades (Luis 
Corral-Gudino et al. 2013). The number of new referrals has sharply declined over the past 
two decades, to one half the rate seen in the early nineties (Cundy 2006). In addition to this 
observed decrease in prevalence, the severity of the disease is substantially reduced in more 
recently presenting subjects, and the mean age of onset has steadily been increasing as well 
(L Corral-Gudino et al. 2013; Cundy 2006). Therefore, there is a strong likelihood of some 
environmental factor contributing to the pathology of the disease. 
 One such factor proposed to play a role in the aetiology of PDB are toxins such as 
arsenic or lead. Arsenic has been suggested, as the highest incidence of PDB in the UK are 
in town situated on estuaries where significant quantities of wastewater were dumped from 
cotton mills (Lever 2002). In the USA, a decline in Paget’s disease starting in 1974 was 
hypothesized to be connected to the halt of the use of Calcium arsenate as a pesticide in 
1945. However, no direct evidence supporting these suppositions have been produced. One 
occupational and environmental exposure study to lead of persons with PDB showed that 
virtually the entire test group had considerable exposure to lead (Spencer, O’Sullivan, and 
Sontag 1992), but follow-up studies of bone biopsies did not conclusively connect the two 
(Adachi et al. 1998).  
 Vaccination has been proposed as a mechanism leading to Paget’s reduction, 
particularly by proponents of the MVNP model of PDB. In 1963, the USA first made the 
measles vaccine available, and there may be some correlation between the effective end of 
measles in the states and the decline of Paget’s disease. Interestingly, Italy has not enjoyed 
the same decrease as most of the rest of the world in PDB incidence (Gennari et al. 2006), 
and their vaccination program began in 1976 (Filia et al. 2013). However, trends that 
already had begun years ago in the USA would be due even by now in Italy, suggesting 
again that perhaps contributions from viral inclusions tell only part of the Paget’s story. 
Similarly to the measles virus, canine distemper virus (CDV) transcripts have been reported 
in osteoclasts of PDB patients (Mee et al. 1998), and CDV induced osteoclastogenesis in 
human osteoclast precursors through p62 and NF-κB activation (Selby, Davies, and Mee 
2006). This induction is the same response produced by MVNP in these precursors, which 
  
143 
143 
may be unsurprising given structural similarities between the two viruses. However, other 
studies have reported no evidence of CDV transcripts (Birch et al. 2009; Ralston et al. 
2007), or differences in circulating antibody levels in patients with the disease (Gordon et 
al. 1993). Finally, RSV nucleocapsids have been described to be morphologically very 
similar to microfilaments observed in pagetic osteoclasts (Singer 2015), but while some 
studies have observed RSV and measles virus antigens in  Paget’s patients, its contribution 
remains controversial (Helfrich et al. 2000). 
 In short, there is an abundance studies indicating that germline SQSTM1 mutations 
increase the probability of developing PDB. However, not all patients with a SQSTM1 
mutation develop this disease, and the incidence is declining globally. Controversy about 
the role of measles virus inclusions in the aetiology of Paget’s disease continues, but there 
is significant evidence suggesting it could at least play a role in development of the disease. 
Besides the murine models, the decline of rate of incidence accompanying measles 
vaccination onset strengthens this hypothesis. This evidence together suggests an 
assumption which is now generally accepted; that multiple factors are likely required for 
the development and manifestation of the disease. Regardless, if there are several roads to 
Paget’s disease, determining the common end-point of these “roads” (like defective 
autophagy, for example), may help to identify causative factors.  
Alternative Splice Variants in Paget’s Disease of Bone 
 Our laboratory hypothesized that given the insufficiency of p62 mutations alone to 
drive the pagetic phenotype, specific RNA isoforms of osteoclast-related genes may 
contribute to the over-activity of these cells, along with other predisposing factors. 
Alternative splicing (AS) is a key source of protein diversity and post-transcriptional gene 
regulation. Disruption of AS variants has been associated with tumorigenesis as well as 
muscular dystrophies and premature-aging disorders (Tazi, Bakkour, and Stamm 2009). 
Splicing site SQSTM1 (p62) mutations have twice been reported in Paget’s disease of bone 
(Cavey et al. 2006; Beyens et al. 2006). Using a screening strategy, our lab identified six 
osteoclast-related genes with AS events that were significantly associated with PDB 
(Klinck et al. 2014). Several of these genes were associated with apoptosis resistance, such 
as CASC4, linked to cell proliferation and survival pathways (Gutierrez and Schiff 2011), 
and LGALS8, which encodes Galectin-8, which induces RANKL expression, 
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osteoclastogenesis, and bone mass reduction in mice (Vinik et al. 2015). One other target 
produced by this study was the de-ubiquitinating enzyme (DUB) USP4 (Ubiquitin-specific 
peptidase 4). CYLD, another DUB, has already been well characterized as important to 
TRAF6 activity and osteoclast signaling (Kovalenko et al. 2003; Sundaram et al. 2011). 
USP4 de-ubiquitinates TAK1 (Fan et al. 2011), and has been shown in HEK293 cells to 
associate with TRAF6 and inhibit its ubiquitination and subsequent NF-κB activation (Xiao 
et al. 2012). This could therefore represent one potential means of RANKL-pathway 
modulation in PDB. Finally, one protein associated with autophagy was also identified; 
TBC1D25 (OATL1), a Rab-GTPase-activating protein (Rab-GAP). There exist two spliced 
isoforms of this binding partner of LC3, and it has been shown to be involved in late-stage 
autophagosome maturation in MEFs and COS-7 cells (Itoh et al. 2011). Splice variation in 
pagetic osteoclasts may be linked to the changes causing the autophagic defects we 
observed at this stage. In total, while these results do not confirm causation, they identify 
common altered pathways that may be associated with altered osteoclast survival, 
autophagy, and activation signaling, through modulation of AS events. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
145 
145 
Conclusions  
 
In human osteoclasts, a multiprotein complex containing p62, PKCζ, PDK1, and 
others forms in response to RANKL stimulation. Overexpression of the p62P392L mutant 
generates at least a partial pagetic phenotype in the osteoclast, and these other kinases may 
be involved in regulation of that pathway. We observed that PKCζ appears to be involved 
not only in RANKL-induced activation of NF-κB, but also in the basal activation observed 
in p62P392L-transfected cells. We also found that RANKL-induced p-Ser536p65 levels were 
altered by inhibiting PKCζ, exaggerated further in the presence of the P392L mutation. 
This suggests that the PKC/p65 pathway contributes to basal NF-κB activation observed in 
Pagetic osteoclasts.  
 The difference between non-mutated and mutant p62 IκBα expression/degradation 
as regulated by PKCζ suggested that when the p62 UBA domain is affected, PKCζ may 
become a preferential pathway to NF-κB activation through p65 phosphorylation. While 
the p62P392L substitution does not account for all aspects of the pagetic phenotype, it does 
affect osteoclast behavior and signaling pathways. The findings regarding this mutation 
identify downstream targets of p62 in human osteoclasts, and highlight the role of PKCζ in 
the increased activation of pagetic osteoclasts, which may contribute to the increased bone 
resorption and resistance to apoptosis that characterize these cells.  
 We also demonstrated that in PDB osteoclasts, Akt and ERK survival pathways are 
activated. We found that inhibition of PDK1 not only induced apoptosis, in both pagetic 
and control osteoclasts, but reduced signaling in both PI3K/Akt and mTOR pathways in 
osteoclasts.  Therefore, in addition to (and perhaps contributing to) hyperresorption and 
apoptotic resistance, defective autophagy may be part of the pagetic phenotype. Through 
observation of autophagic flux, we noted that PDB osteoclasts indeed demonstrate defects 
in the process of autophagy. Since this modification was irrespective of p62 mutation, this 
may explain a common pathway to Paget’s disease, shared by the autophagy-regulating 
protein.  
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Figure 30 : PDK1-Regulated Pathways Altered in the Pagetic Osteoclast 
PDB-PBMC-derived osteoclasts presented higher basal Akt, ERK, and mTOR signaling. 
This manifested functionally as increased survival and activation, accompanied by a 
decrease in autophagy. There is a great deal of inter-regulation in these pathways, as 
indicated by the arrows between mTOR, Akt, and PDK1, and we observe that inhibition of 
PDK1 lead to reduced signaling of all of these pathways, and removal of the pagetic 
phenotype. The exact mechanism for increase in pathways regulated by PDK1 is as-yet 
undetermined, and the decrease in autophagic flux may be as much a cause as a symptom.  
 
 
 PDK1 inhibition was more potent in pagetic osteoclasts than in controls, suggesting 
that PDK1/Akt activation is a critical checkpoint for autophagic dysfunction in Paget’s 
disease. This also possibly reflects a sustained activation of the autophagic pathway in 
these cells, slowing the induction of autophagy. Thus PDK1 appears to play a pivotal 
regulatory role, associated with deregulation of both autophagy and apoptosis. (Figure 30) 
By inhibiting PDK1 (as well as ERK), in addition to altering several associated signaling 
cascades, there was the functional impact of reduced survival and resorption by the 
osteoclasts in culture. Together, these findings characterize the impact of several kinases 
associated with defective p62 signaling, and ultimately, Paget’s disease of bone. They 
provide novel approaches to osteoclastogenic, apoptotic, and autophagic pathways relevant 
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to the pathogeny of this disease, and hopefully this greater understanding can one day lead 
to more effective treatment and prevention. 
 
Perspectives 
NF-κB Activation in Paget’s Disease of Bone 
While we observed phosphorylation of p65, and nuclear translocation of p50 
following RANKL stimulation or with mutant p62, the ultimate marker of NF-κB activity 
remains transcription. As early as 2001, the treatment with RANKL of osteoclast precursors 
transfected with a plasmid containing NF-kB consensus elements linked to luciferase 
produced greatly enhanced reporter activity (Wei et al. 2001). Using the same system, the 
p62P392L mutation has been linked to increased RANKL and TNF-α sensitivity (Kurihara et 
al. 2007). A 2011 study with reporters for NFAT and AP-1 also associated increased 
transcriptional activity in osteoclast precursors (Sundaram et al. 2011). Therefore, it would 
be of interest to confirm via transfection of luciferase constructs in CBM-derived osteoclasts 
that the reduction of phosphorylation and translocation of NF-κB subunits equates to a 
functional decrease in transcription. Concurrently, the same system could be used to 
determine the transcriptional impact of PDK1 inhibition in these osteoclasts, allowing 
analysis of the functional impact on NF-κB.  
 As proposed in the discussion on page 120, point mutations to p65, both phospho-
mimetic and inactivating could be induced in order to identify which sites are crucial to 
osteoclast activity, particularly in the context of the p62P392L mutation and PKCζ signaling. 
Again, the ultimate effects on transcription of these modifications could be observed via 
transfection of these cells with a luciferase reporter for NF-κB. 
PDK1 Impact on Differentiation and Signaling 
 The specificity of our inhibitor used for PDK1 was confirmed via kinase assay, but it 
would be pertinent to be able to work with a complete knockout model of PDK1, either by 
CRISPR gene editing, shRNA, or another method. This would allow us to exclude potential 
toxic effects of the inhibitor, non-specific binding, incomplete inhibition, and any issues with 
the half-life of the product. By disabling PDK1 early in osteoclast precursors we could 
observe effects on osteoclast differentiation, in addition to the effects on resorption and 
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apoptosis of mature cells already quantified. As loss of Akt in osteoclast precursors resulted 
in lack of differentiation due to down-regulation of NF-κB activity (Sugatani and Hruska 
2005), we might expect similar results, or an even greater reduction, given the number of 
PDK1 targets.  
 In fact, the number of PDK1 targets leave several kinases still ripe for analysis in 
PDB. For example, S6K and SGK possess residues that are equivalent to Thr308 and Ser473 
in Akt (Thr252 and 412 for S6K, and Thr246 and Ser422 for SGK) (Frödin et al. 2002). The 
phosphorylation of both these kinases at their T-loop and hydrophobic motifs is necessary 
for their activation and dependent on PI3-kinase activation, but unlike Akt, they do not 
possess a PH domain, and do not interact with PtdIns(3,4,5)P3 (Mora et al. 2004). However, 
like PKCζ, they do share a PDK1 interacting fragment (PIF) region, the presence of which is 
necessary for their phosphorylation (Collins et al. 2003). Substrates of S6K include mTOR, 
BAD, elF4B, and many others, regulating protein synthesis, cell survival, size, and 
proliferation, to name a few (Ruvinsky et al. 2006). SGK participates in the regulation of 
transport, proliferation, and apoptosis, as well as increasing activity of ion channels, carriers, 
and Na+/K+-ATPase (Lang et al. 2010). By determining which substrates of PDK1 and their 
respective pathways are activated in PDB, we may better characterize the mechanism of 
action of the disease. 
p62 Mutations and Autophagic Flux 
 While we successfully characterized some of the impacts of the p62P392L mutation, 
and associated it in osteoclasts with at least a partial pagetic phenotype in vitro, we did not 
determine its effects, if any, on autophagic flux. As p62 participates in the process of 
autophagy and appears to accumulate in pagetic osteoclasts, it would be of interest to 
determine if mutation to this scaffold protein can lead to some of the autophagic defects we 
linked to pagetic osteoclasts. This may take place either by altering the activity of p62 itself, 
or through the increased signaling of the proteins with which it interacts. Following 
transfection of CBM-derived osteoclasts with p62P392L, we could compare LC3B western 
blots and immunofluorescence with control cells as described previously. In 2011, 
osteoclasts derived from both heterozygous and homozygous p62P394L mice were 
demonstrated to have significantly higher LC3-II protein levels following Bafilomycin A 
treatment than their wild-type counterparts as observed by western blot (Daroszewska et al. 
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2011a). Though we observed no difference between PDB p62wt and p62P392L patients in our 
study, we did not have a sufficient patient base to compare HDwt and HDP392L. Therefore we 
cannot yet exclude the possibility that the p62 mutation is sufficient to at least partially confer 
the altered autophagic phenotype seen in PDB osteoclasts. 
The measles virus nucleocapsid protein induces activation of TBK1 (Sun et al. 2014), 
a protein which, in addition to activating IL-6 production, is involved in regulation of 
autophagosome maturation, and phosphorylates p62Ser403 (in the UBA), enhancing binding 
and clearance (Pilli et al. 2012). If MVNP+ osteoclasts, p62P394L mice, non-mutant PDB 
osteoclasts, and p62P392L transfected CBMs all exhibit potentially altered autophagy, this 
could represent a major common element linking causes of this multifactorial disease. 
Paget’s Disease and Pinpointing the Impact of Autophagy 
 An increase in the accumulation of autophagosomes was observed in pagetic 
osteoclasts when compared to those derived from healthy donors. Given that these cells 
respond poorly to autophagy induction, our initial conclusion was that the osteoclasts suffer 
from impaired clearance of the autophagosomes. It should be possible to measure GFP-
tagged LC3 and fluorescent red lysotracker (a dye for labeling acidic organelles) via 
microscopy in PDB and normal osteoclasts, as has previously been performed in rat 
hepatocytes, and numerous studies since (Köchl et al. 2006). By comparing localization, this 
model allows for differentiation between autophagosomes that have fused with endosomes 
and those that have not, and should show if pagetic osteoclasts exhibit impaired fusion or 
acidification.  
We identified an association between PDB and altered autophagy, and it would be of 
interest to determine if this autophagic imbalance contributes to the pagetic phenotype. By 
inhibiting the autophagic process at different points it should be possible to establish which 
steps may be involved in PDB. As we observed both an accumulation of autophagosomes 
and a reduction in capability to initiate autophagosome formation, there may be multiple 
checkpoints. For comparing early stage defects in PDB versus control osteoclasts, 
Wortmannin inhibition has been demonstrated to inhibit autophagic sequestration, preventing 
Atg5 from localizing to isolation membranes along with Atg16 and Atg12 (Suzuki and 
Ohsumi 2010). Later in the development of the autophagosome, treatment with Bafilomycin 
A1 inhibits autophagosome-lysosome fusion (Mauvezin et al. 2015), while Chloroquine 
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selectively accumulates in lysosomes and prevents acidification, ultimately preventing 
proteolysis (Misinzo, Delputte, and Nauwynck 2008). In addition, since impaired clearance 
of autophagosomes was observed, we could determine if restoring lysosome acidity through 
photoactive nanoparticles as recently described (Trudeau et al. 2016) would in turn restore 
autophagic flux and potentially alter the activity of the pagetic osteoclasts. Each of these 
treatments, along with rapamycin (blocking mTOR activity), could help to characterize the 
impact on the osteoclast of defects in differing stages of autophagy, and ultimately even 
determine to what degree these defects may contribute to the phenotype observed in PDB. 
By further demystifying the autophagic dysfunction associated with this disease, we may 
better be able to move closer to a therapy targeting this pathway. Indeed, if autophagy 
provides a common link across PDB cases of potentially differing origins, it remains a prime 
target for study. 
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